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1  Abbrevations  
 
 
APC Antigen-presenting cell 
 
BM-DC Bone marrow-derived dendritic cell 
 
BN Brown Norway 
 
CD Cluster of differentiation 
 
cpm Counts per minute 
 
CTL Cytotoxic T cell 
 
DC Dendritic cell 
 
FACS Fluorescence activated cell sorting 
 
FCS Fetal calf serum 
 
FITC Fluorescein Isothiocyanate 
 
FSC Forward scatter 
 
IFN-γ Interferon-gamma 
 
IL-2 Interleukine-2 
 
IL-12 Interleukine-12 
 
LCs 
 
Langerhans cells 
LEW Lewis 
 
LN Lymph node 
 
MDC Myeloid-derived DC  
 
MF Mean fluorescence 
 
MHC Major histocompatibility complex 
 
MLC Mixed leukocyte culture 
 
MLR Mixed leukocyte reaction 
 
NK cell Natural killer cell 
 
NMMA NG-methyl-L-arginine acetate 
 
NO Nitric oxide 
 
PAMPs Pathogen-associated molecular patterns 
 
PBS Phosphate-buffered saline 
 
PDC 
 
Plasmacytoid-derived DC  
PD-L1 Programmed cell death 1 
 
PD-L2 Programmed cell death 2 
 
PRRs  Pattern recognition receptors  
 
RBCs Red Blood Cells 
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rGM-CSF Rat granulocyte-macrophage colony stimulating factor 
 
rIL-4 Rat Interleukine-4 
 
SSC Side scatter 
 
TCR T-cell receptor  
 
TGF-β Transforming growth factor-beta  
 
TH cell T-helper cell 
 
TLRs Toll-like receptors  
 
TNF Tumor necrosis factor 
 
Treg cell Regulatory T cell 
 
RPE R-Phycoerythrin 
 
S.D. Standard deviation 
 
S-DC Spleen dendritic cells 
 
S.E.M. Standard errow of the mean 
 
WF Wistar Furth 
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2 Summary 
 
Tolerogenic dendritic cells (DC) and regulatory T (Treg) cells are able to prevent 
destructive immune responses. There is reason to hope that it may soon be possible 
to use DC and Treg cells to suppress immune responses antigen-specific, not only 
after transplantation, but also in the case of autoimmunity and allergy. At the 
moment, the generation of such cell types is very time-consuming and not suitable 
for clinical routine. In addition, it is not yet fully understood how these cells elicit a 
desired protective immune response in vivo and how the risks of an excessive 
immune suppression can be managed. 
 
The rat is one of the most important animal models in biomedical research. It is 
therefore surprising that tolerogenic DC and Treg cells in particular have not been 
more thoroughly investigated in this model. Thus, the aim of the present study was to 
systematically characterize these immune cells and investigate their impact on the 
immune system. 
 
Tolerogenic DC were generated from bone marrow precursors cultured with GM-CSF 
and IL-4 (= IL-4 DC). The proportion of naturally occurring Treg cells with a 
CD4posCD25posFoxp3pos phenotype comprises approximately 5-8% of the peripheral 
CD4pos T cells.  
 
The characterization of IL-4 DC revealed an up to 26-fold reduced expression of 
surface molecules such as MHC class II molecules, CD80, CD86, ICAM-1 and CD25 
in comparison to mature splenic DC (S-DC). This low expression did not change 
when the cells where stimulated with different maturation-inducing signals such as 
replating, LPS, TNF- α and CD40L. Thus, these cells possess a robust phenotype 
resistant to maturation-inducing stimuli. 
 
IL-4 DC take up antigen via endocytosis and are not able to activate naïve T cells or 
to restimulate antigen-specific T cells. Furthermore, they are able to inhibit and 
prolongate mature S-DC induced T cell proliferation as well as mature S-DC induced 
restimulation of antigen-specific T cells, respectively. Thereby, the T cell proliferation 
was reduced up to 95%. This strong inhibitory effect was mediated within 24 hours in 
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association with a reduced cytokine production (IL-2 about 49% and IFN-γ about 
92%). 
 
The inhibitory properties of IL-4 DC don´t seem to be caused exclusively by the 
reduced expression of co-stimulatory molecules. In this study, the detection of the 
inhibitory molecules PD-L1 and PD-L2 on IL-4 DC suggests they have an impact on 
mediating inhibitory signals to the T cells. 
 
In addition, a suppressive effect of soluble factors was shown. The supernatant of 
one million IL-4 DC, collected after a 24 hour culture, suppressed mature S-DC 
induced proliferation of naïve T cells by about 90%. TGF-β, which was detected in 
the supernatant (up to 300 pg/ml), appears to be the causing soluble factor for this 
immune inhibition. By contrast, the supernatants of mature S-DC, which did not 
inhibit the activation of T cells, showed a TGF-β concentration of only about 100 
pg/ml. The cytotoxic nitric oxide does not contribute to the IL-4 DC-mediated 
inhibition of T cell proliferation. The NO synthase inhibitor NMMA reduced the 
amount of NO by about 50%, but the decreased NO levels did not influence T cell 
proliferation. 
 
Indeed, IL-4 DC are not able to induce T cell proliferation, but this doesn´t mean that 
there is no change on the molecular level. For instance, T cells co-cultured with IL-4 
DC during a first culture are not able to proliferate in the presence of mature S-DC 
during a second culture. This anergic-like state, however, could be abolished by 
adding exogenous IL-2. In addition, T cells co-cultured with IL-4 DC are able to inhibit 
the activation of naïve T cells. Naïve and activated T cells were not able to inhibit the 
mature S-DC induced T cell proliferation. This observation suggests the induction of 
Treg cells and was investigated in more detail. Indeed, flow cytometric analysis 
showed a 1.6-fold expansion of CD4posCD25posFoxp3pos T cells from naturally 
occurring Treg cells in the presence of IL-4 DC. Thereby, the expansion of 
CD4posCD25posFoxp3pos T cells occurs independently of the maturation state of DC. 
Both immature IL-4 DC as well as mature S-DC were able to expand the percentage 
of naturally occurring Treg cells. However, Treg cells pre-incubated with mature S-DC 
demonstrated a diminished inhibitory effect compared to Treg cells pre-incubated with 
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IL-4 DC. Treg cells pre-incubated with IL-4 DC were able to inhibit the activation of 
naïve T cells. 
 
In this study it was shown that the regulatory potential of DC cannot be deduced 
solely by their phenotype or maturation state. Other factors, such as functional 
properties, need to taken into consideration, too. The induction of Treg cells with 
suppressive properties induced by in vitro generated tolerogenic IL-4 DC might 
provide an important mechanism for the maintenance of peripheral tolerance. 
However, for clinical application further investigation is necessary, not only to 
understand the interactions between tolerogenic DC and Treg cells, but also to 
investigate the impact of the transfer of a larger quantity of regulatory cells on the 
immune system of the recipient. 
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3 Zusammenfassung 
 
Tolerogene Dendritische Zellen (DZ) und regulatorische T-Lymphozyten (Treg) 
verfügen über die Fähigkeit, destruktive Immunantworten zu verhindern. Die 
Hoffnung besteht, solche Zellen in naher Zukunft für therapeutische Zwecke 
einzusetzen, um z. B. Immunantworten nach Transplantation, aber auch bei 
Autoimmunität und Allergie antigenspezifisch zu supprimieren. Zum jetzigen 
Zeitpunkt ist die Generierung solcher Zellen aufwendig und noch nicht für die 
klinische Routine geeignet. Zudem sind die Mechanismen noch wenig verstanden, 
wie diese Zellen eine gewünschte Immunhemmung in vivo auszulösen und wie der 
möglichen Gefahr einer zu starken Immunhemmung zu begegnen ist.  
 
Das Kleinnagermodell Ratte ist für die biomedizinische Forschung noch immer von 
großer Bedeutung, umso überraschender ist es, dass insbesondere tolerogene DZ 
und Treg in diesem Modell bisher nur unzureichend untersucht wurden. Das Ziel der 
Arbeit war deshalb, diese Immunzellen umfassend zu charakterisieren und ihre 
Funktion auf das Immunsystem zu untersuchen.  
 
Tolerogene DZ wurden mit GM-CSF und IL-4 aus Knochenmarkvorläuferzellen 
generiert (= IL-4 DC). Der Anteil an natürlich vorkommenden Treg mit einem Phänotyp 
CD4posCD25posFoxp3pos umfasst ca. 5-8% der peripheren naiven CD4pos T-
Lymphozyten.  
 
Die Charakterisierung der IL-4 DC zeigte im Vergleich zu reifen DZ der Milz eine bis 
zu 26-fach geringere Expression von Oberflächenmolekülen wie MHC-Klasse II 
Molekül, CD80, CD86, ICAM-1 und CD25. Diese geringe Expression änderte sich 
auch nicht, wenn die Zellen verschiedensten Reifungssignalen wie das Replattieren, 
LPS, TNF-α und CD40L ausgesetzt wurden. IL-4 DC verfügen somit über einen 
robusten und gegenüber Reifungssignalen überaus resistenten Phänotyp.  
 
IL-4 DC nehmen Antigene durch Endozytose auf und sind unfähig, sowohl naive T-
Lymphozyten zu aktivieren, als auch antigenspezifische T-Lymphozyten zu 
restimulieren. Zudem sind sie in der Lage, die Aktivierung naiver T-Lymphozyten und 
die Restimulierung antigenspezifischer T-Lymphozyten durch reife Milz-DZ zu 
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verhindern bzw. zu verzögern. Dabei verringerte sich die Proliferation der T-
Lymphozyten um bis zu 95%. Diese Beeinflussung der Proliferation ist nach Zugabe 
der IL-4 DC bereits innerhalb von 24 Stunden zu messen. Die verringerte Aktivierung 
geht zu dem mit einer verringerten Zytokinausschüttung (IL-2 um 49% und IFN-γ um 
92%) einher.  
 
Die inhibitorischen Eigenschaften der IL-4 DC scheinen aber nicht ausschließlich auf 
der verringerten Expression kostimulatorischer Moleküle zu beruhen. Der Nachweis 
der beiden inhibitorischen Oberflächenmoleküle PD-L1 und PD-L2 auf IL-4 DC lässt 
ebenfalls eine Bedeutung dieser Moleküle bei der Vermittlung inhibierender Signale 
vermuten.  
 
Auch die suppressive Wirkung löslicher Faktoren wurde in der vorliegenden Arbeit 
gezeigt. Überstände einer 24-stündigen Kultur mit einer Million IL-4 DC hemmten die 
Aktivierung naiver T-Lymphozyten durch reife Milz-DZ um etwa 90%. Für diese 
Immunhemmung scheint das in diesen Überständen nachgewiesene Zytokin TGF-β 
(bis 300 pg/ml) verantwortlich zu sein. Im Vergleich dazu wiesen Überstände reifer 
Milz-DZ, die nicht die Aktivierung von T-Lymphozyten hemmten, eine TGF-β 
Konzentrationen von bis 100 pg/ml auf. Im Gegensatz dazu scheint zelltoxisches 
Stickstoffmonoxid nur eine geringe Rolle bei der Inhibierung der T-Zellproliferation zu 
spielen. Die Zugabe des NO Synthase-Inhibitors NMMA verringerte zwar den Anteil 
an NO um ca. 50%, doch führte dies nicht zu einer Steigerung der Proliferation von 
T-Lymphozyten. 
 
IL-4 DC sind zwar nicht in der Lage, T-Lymphozyten zur Proliferation zu bringen, 
doch bedeutet dies nicht, dass keinerlei Veränderungen auf molekularer Ebene 
festzustellen wären. So sind T-Lymphozyten nach ihrer Inkubation mit IL-4 DC nicht 
in der Lage, in Gegenwart von reifen Milz-DZ zu proliferieren. Dieser anergische 
Zustand wurde nach Zugabe von IL-2 aufgehoben. Zudem können diese T-
Lymphozyten nach ihrer Inkubation mit IL-4 DC die Aktivierung naïver T-
Lymphozyten hemmen. Naïve und aktivierte T-Lymphozyten können dies nicht. 
Diese Beobachtung, die auf eine Induktion von Treg schließen lässt, wurde genauer 
untersucht. In der Tat zeigten durchflusszytometrische Analysen eine 1,6-fach 
verstärkte Expansion von CD4posCD25posFoxp3pos T-Lymphozyten aus natürlich 
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vorkommenden Treg in Gegenwart von IL-4 DC. Dabei erfolgte die Expansion von 
CD4posCD25posFoxp3pos T-Lymphozyten unabhängig vom Reifegrad der DZ. So 
waren auch reife Milz-DZ dazu in der Lage, die Zahl der natürlich vorkommenden Treg 
zu erhöhen. Doch wiesen diese mit Milz-DZ inkubierten Treg einen verminderten 
inhibitorischen Effekt auf. Im Gegensatz dazu waren die mit IL-4 DC inkubierten Treg 
in der Lage die Aktivierung naiver T-Lymphozyten zu hemmen.  
 
In dieser Arbeit wurde gezeigt, dass sich das regulatorische Potential von DZ nicht 
ausschließlich vom Phänotyp bzw. ihrem Reifegrad ableiten lässt, sondern dass 
hierzu auch ihre funktionellen Eigenschaften zu untersuchen sind. Die Induktion von 
Treg mit suppressiven Eigenschaften durch in vitro generierte tolerogene IL-4 DC 
könnte ein wichtiger Mechanismus zur Aufrechterhaltung der peripheren Toleranz 
darstellen. Vor einer klinischen Umsetzung sind aber noch weitergehende 
Untersuchungen notwendig, um das Zusammenspiel zwischen tolerogenen DZ und 
Treg zu verstehen, aber auch um die Auswirkungen eines Transfers großer Mengen 
regulatorischer Zellen auf das Immunsystem des Empfängers zu untersuchen.  
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4  Introduction 
 
4.1  The immune system 
 
The immune system, that is divided into the innate immune system and the adaptive 
immune system, is a complex network of many interdependent cell types that protect 
the body against foreign substances such as bacteria, parasites, fungi, viruses, tumor 
cells and even transplanted organs and tissues. Thereby, one of the most important 
functions of the immune system is the discrimination between self and non-self. The 
distinction between self and non-self is considered to involve a series of interactions 
between various cells of the immune system, most notably the extensive bidirectional 
interactions between dendritic cells (DC) and T cells. DC serve as a link between the 
innate and adaptive immune system, as they present antigen to T cells, one type of 
key cell of the adaptive immune system (Guermonprez P et al., 2002). Recent 
evidence has shown that DC and also a certain type of T cells or regulatory T cells 
(Treg), play a key role in the maintenance of central and peripheral tolerance which is 
critical to prevent autoimmunity, allergy and allograft rejection (Fadilah SA et al., 
2007; Oh JW et al., 2002; Sakaguchi S et al., 2005; Shevach EM et al., 2002; 
Steinman RM and Nussenzweig MC, 2002; Suciu-Foca N et al., 2009). A major 
challenge in immunology and medicine is to determine how immunological self-
tolerance is established, maintained and controlled to avoid damage to the host. An 
understanding of the mechanisms of immunological self-tolerance and therefore, an 
understanding of the biology of tolerogenic DC and Treg cells is important as a basis 
for new therapeutic tools to prevent autoimmune diseases and transplant rejection. 
 
This study is focussing on the characterization of tolerogenic bone marrow-derived 
dendritic cells (BM-DC) and Treg cells from rat. The following chapters of this 
introduction will provide some background information on the importance of DC and 
T cells in general. Additional information is given on potential roles of different DC 
subsets in tolerance, their interaction with Treg cells and their roles in health and 
disease. Finally, the aims and the experimental approach of this study are explained.  
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4.1.1  The innate immune system 
 
The innate or “non-specific” immune system, which presents the first line of defence 
against any pathogenic agent, is capable of responding immediately or within several 
hours to pathogenic agents. Innate immunity comprises four types of defensive 
barriers: anatomic (skin, mucous membrane), physiologic (chemical mediators, low 
pH), phagocytic (e.g. eosinophils, neutrophils, monocytes and macrophages), and 
inflammatory (acute phase proteins, cytokines and complement proteins). Most of the 
cells of the innate immune system are able to identify specific components of 
microbial organisms, the so called pathogen-associated molecular patterns (PAMPs) 
such as lipopolysaccharide (LPS) peptidoglycan, lipoteichoic, and other components 
of microbial cell walls (Janeway CA Jr and Medzhitov R, 2002) via pattern-
recognition receptors (PRRs) on their surface, which can bind PAMPs on bacteria, 
fungi, and viruses. The most important PRRs are the Toll-like receptors (TLR) that 
are expressed on the surface of various effector cells (Medzhitov R and Janeway CA 
Jr, 2000). The engagement of TLRs elicits a significant cytokine release, which in 
turn leads to the recruitment and activation of cells of the innate immune defence 
system, thus activating the adaptive immune response (Pasare C et al., 2004). 
 
However, innate immunity is not antigen specific in its response and does not exhibit 
a memory response, meaning that this system does not confer long-lasting immunity 
against a pathogen. Therefore, if innate immunity was not able to clear the infection 
and to initiate long-term protection, cellular mediators of the adaptive immunity move 
into action. 
 
 
4.1.2 The adaptive immune system 
 
While the innate immune system is the first line of defense against invading 
microbes, the adaptive or “specific” immune system acts as a second line of defense 
against any "foreign" substance. The four characteristic attributes of adaptive 
immunity are antigen specificity, diversity, immunologic memory and discrimination 
between “self and non-self” (Jiang H and Chess L, 2009). The adaptive immune 
response involves three major groups of cells: B cells (humoral immunity), T cells 
(cell-mediated immunity) and antigen-presenting cells (APC). The adaptive immune 
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system is based on the total repertoire of lymphocytes bearing clonally diverse 
antigen-specific receptors facilitating the recognition of almost any foreign antigen 
(diversity). In contrast to the innate immune system, the adaptive immune system 
uses somatically generated antigen receptors which are clonally distributed on T and 
B cells. B and T cell specificity is created by random recombination of gene 
segments that encode the antigen-binding receptor (antibody on B cells and T-cell 
receptor on T cells) with a single specificity on the cell surface on B cells. Once 
antigen receptor gene rearrangement occurs, lymphocytes are sorted for “self/non-
self” distinction within the thymus. This includes the elimination of lymphocytes 
whose receptors are specific for self antigens in order to prevent autoimmunity 
(Eason DD et al., 2004). 
 
The induction of adaptive immunity requires antigens that can be captured, 
processed and presented to specific lymphocytes by APC. Among APC, dendritic 
cells are the most highly specialized. They are able to encounter microbial agents 
from the external environment and transport them to the lymphoid organs where they 
present antigens on either MHC class I or MHC class II major histocompatibility 
complex (MHC) molecules to naïve T cells. This in turn leads to the activation, 
proliferation and differentiation of naïve T cells into effector T cells and memory T 
cells. Effector T cells function to eliminate the antigen. Memory cells show enhanced 
potential of activation allowing a more rapid and effective secondary response upon 
repetitive exposure to the antigen (Cellular and Molecular Immunology, Lichtman, 5th 
edition). 
 
 
4.2  Dendritic cells  
 
Dendritic cells are highly specialized APC that provide a direct link between innate 
and adaptive immunity (Steinman RM et al., 2003). They were first described as 
dendritically shaped cells of the epidermis by Paul Langerhans, a medical student in 
Berlin, in 1868 (Langerhans P et al., 1868; Wolff K et al., 1991). Today we know that 
Langerhans cells (LC) are a subpopulation of epithelial-tissue-specific non-lymphoid 
DC (Steinman RM et al., 1991). One century later, in 1973, the term “dendritic cell” 
was coined by Ralph Steinman and Zanvil Cohn, for a novel cell type they identified 
in adherent cell populations prepared from mouse peripheral lymphoid organs 
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(spleen, lymph node, Peyer's patch) on the basis of morphological criteria such as a 
large nucleus, long and cytoplasmic processes after adherence and spreading on 
glass or plastic surfaces (Figure 4.1; Steinman and Cohn, 1973).  
In the following years mouse dendritic cell 
research with respect to DC isolation, in vitro 
culture, as well as functional properties in vitro, 
started to emerge (Steinman RM and Cohn ZA, 
1974; Steinman et al., 1974, Steinman RM et 
al., 1975). Steinman’s group demonstrated for 
the first time their unique capacity to induce 
activation of naïve T cells in response to 
antigen presentation (Steinman and Witmer 
MD, 1978; Romani N et al., 1989). 
 
 
 
 
 
4.2.1  Dendritic cells: differentiation from precursor populations 
 
Dendritic cells develop from bone-marrow derived CD34pos hematopoietic precursors 
(Banchereau J et al., 2000; de Heer HJ et al., 2004). Although they share many 
common features, DC can be subdivided into a number of sub-populations based on 
their expression of cell surface markers and functional properties under the influence 
of different cytokines and growth-factors (Quah BJ and O'Neill HC, 2005). Two major 
subsets of DC have been described: myeloid-derived DC (MDC) and plasmacytoid-
derived DC (PDC) (Liu YJ et al., 2001).  
 
 
4.2.1.1  Plasmacytoid-derived DC (PDC) 
 
PDC, which constitute the rarer cell type, comprise approximately < 1% of the total 
blood mononuclear cells. Based on their plasma cell-like morphology, these cells 
have been termed plasmacytoid DC (Nakano H et al., 2001) while others have 
referred to them as natural interferon-producing cells (Asselin-Paturel C et al., 2001). 
In contrast to MDC, PDC play an essential role in the innate immune system by 
secreting various cytokines such as type I interferon after stimulation with TLR7 and 
Figure 4.1: Phase-contrast micrograph 
of a dendritic cell isolated from the 
spleen (Steinman RM and Cohn ZA, 
1973). 
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TLR9 agonists. In addition, they have only a low capacity to activate naïve T cells 
(Cella M et al., 1999; Gibson SJ et al., 2002; Kadowaki N and Liu YJ, 2002; 
Kerkmann M et al., 2003).  
 
PDC develop from haematopoietic stem cells in the bone marrow. FLT-3 ligand (FLT-
3L) has been identified as an important key differentiation and growth factor for these 
cells (Gilliet M et al., 2002; Maraskovsky E et al., 2000; Pulendran B et al., 2000; 
Pulendran B et al., 1997; Shurin MR et al., 1997). Activation with virus or CD40-
ligand together with IL-3 promotes the differentiation of PDC into mature DC which 
can effectively stimulate T cells (Grouard G et al., 1997). Depending on the way of 
activation these PDC induced T cells, are able to produce different types of cytokines 
such as interleukine-10 (IL-10) and interferon-gamma (IFN-γ) after activation of the 
PDC with virus or interleukine-4 (IL-4), and interleukine-5 (IL-5) after activation of the 
PDC with interleukine-3 (IL-3) and CD40L (Cella M et al., 2000; Kadowaki N, 2000; 
Rissoan MC et al., 1999). 
 
 
4.2.1.2 Myeloid-derived DC (MDC) 
 
The major DC populations that develop from bone marrow hematopoitic stem cells 
are the MDC. They are considered the “classical” DC, which are potent APC typically 
associated with the ability to activate naïve T cells and to initiate an adaptive immune 
response (Zuniga EI et al., 2004). In comparison to PDC, MDC express a 
complementary yet distinct set of TLRs (e.g. TLR2, 3, 4, 5, 6 and 7) and thus, 
respond to different PAMPs from a variety of pathogens (Reis e Sousa C, 2004; Ito T 
et al., 2002; Mazzoni A and Segal DM, 2004). MDC, just like PDC, originate from 
myeloid committed CD34pos progenitor cells, and monocytes can be driven to 
become DC in the presence of granulocyte-macrophage colony stimulating factor 
(GM-CSF), c-kit ligand and tumor necrosis factor-alpha (TNF-α) (Caux C et al., 1997), 
or with GM-CSF and IL-4/IL-13 (Bender A et al., 1996;  Sallusto F et al., 1994). 
 
The growth factor GM-CSF, first isolated and characterized by Gough et al. (1984), is 
used in most of the protocols to generate DC. In vivo it is produced by lymphocytes 
and monocytes, as well as by cells not belonging to the immune system (e.g. 
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fibroblasts) in response to immune and inflammatory stimuli (Banchereau and 
Steinman RM, 1998; Channon JY et al., 2002; Gala RR and Shevach EM, 1994; 
Kaplan G et al., 1992). In vitro, GM-CSF stimulates the differentiation and 
proliferation of progenitor cells of granulocytes, macrophages and DC (Burges AW 
and Metcalf D, 1980; Metcalf D et al., 1986; Inaba K et al., 1992; DePaz HA et al., 
2003). In addition, GM-CSF is essential for the development, survival and function of 
DC, including the development of specific DC surface markers (e.g. MHC class II 
expression) (Witmer-Pack MD et al., 1987; Alvaro-Gracia JM et al., 1989; Steinman 
RM, 1991). In combination with the cytokine IL-4, GM-CSF enhances the expression 
of MHC class II molecules on the surface of monocytes, therefore enhancing their 
ability to present antigen (te Velde AA et al., 1988; Paul WE, 1991). However, IL-4 
also enhances the DC numbers generated in vitro (Talmor M et al., 1998), inhibits the 
differentiation of macrophages (Jansen JH et al., 1989) and reduces the amount of 
CD14pos cells (Lauener RP et al., 1990). 
 
 
4.2.2 Dendritic cell maturation stages 
 
The induction of CD4pos T helper (TH) subset responses is a distinct function of DC, 
depending on different stages of DC development (Jonuleit H et al., 2000). DC can 
exist in three different developmental stages: immature, semi-mature and mature 
(Figure 4.2). These different maturational stages seem to be critical for the 
tolerogenic or immunogenic capacity of DC (Hackstein H, 2006). 
 
 
4.2.2.1       Immature DC 
 
DC arising from myeloid- or lymphoid precursors exhibit an immature phenotype 
characterized by a high phagocytic capacity and low expression of MHC class II and 
co-stimulatory molecules such as CD80, CD86 and CD40, and the inability to 
stimulate T cells (Mahnke K et al., 2002). These cells, residing in non-lymphoid 
peripheral tissues in the immune steady-state, constitutively take up antigens, both 
self and foreign by phagocytosis, macropinocytosis or endocytosis (Banchereau J et 
al., 2000; Hawiger D et al., 2001; Sallusto F et al., 1995). Once they have acquired 
and processed the foreign antigens, they migrate to the T cell areas of lymph nodes 
and the spleen, and undergo maturation to stimulate an immune response. 
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However, immature DC are reported to be impaired in their antigen processing and 
presenting capacity (Wilson NS et al., 2004). It is believed that immature DC induce a 
negative selection of autoreactive cells mediating central tolerance to self when 
presenting self antigens to developing T cells in the thymus. During migration to the 
regional lymph nodes immature DC can also mediate Ag-specific peripheral 
tolerance, inducing T cell deletion or induction of Treg cells (Steinman RM and 
Nussenzweig MC, 2002). 
 
 
4.2.2.2     Semi-mature DC 
 
Semi-mature DC, an intermediate stage of DC maturation, was described for the first 
time by Menges and colleagues (Menges M et al., 2002). This dendritic cell subgroup 
is produced in vitro by stimulating immature DC with TNF-α. These in vitro generated 
semi-mature DC, when injected intravenously into mice, prevented experimental 
autoimmune encephalomyelitis (EAE) by inducing IL-10-secreting Treg cells (Menges 
M et al., 2002). In vivo these cells remain in a “steady state” after internalization of 
apoptotic cells, vesicles and/or soluble molecules which enables these cells to induce 
efficient and antigen-specific tolerance (Lutz BL and Schuler G, 2002). Semi-mature 
DC express high levels of MHC class II and medium levels of cell surface markers 
such as CD40, CD80, and CD86, but do not secrete inflammation-inducing cytokines 
such as IL-1, IL-6, and IL-12. Semi-mature DC can be further matured with LPS 
alone or combined with an enhancing CD40 signal (Lutz MB and Schuler G, 2002; 
Verginis P et al., 2005). 
 
 
4.2.2.3  Mature DC 
 
To fully activate naïve T cells, DC residing in non-lymphoid tissue need to undergo a 
process of functional maturation (Quah BJC and O´Neill HC, 2005). DC maturation 
factors are LPS (de Smedt T et al., 1996), dsRNA and bacterial DNA (Aderem A and 
Ulevitch RJ, 2000; Sparwasser T et al., 1998; Bauer M et al., 2001). DC maturation 
also occurs in the absence of infection when T cells express CD40L following 
transplantation, contact allergy, and autoimmunity (Abrams JR et al., 2000; Enk A 
and Katz SI, 1992; Larsen CP et al., 1990). This maturation of immature DC is 
characterized by changes in their capacity to migrate from non-lymphoid peripheral 
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organs to T cell rich areas of the secondary lymphoid tissue (Fossum S, 1988; 
Cumerbatch M and Kimber I, 1995), and reduced antigen capture capacity 
(Banchereau J and Steinman RM, 1998). In addition, maturing DC upregulate MHC 
class II, co-stimulatory molecules such as CD80, CD86 and CD40 as well as 
adhesion molecule ICAM-1 (CD54) to enhance adhesion and signalling to T cells, 
and increase the secretion of cytokines and chemokines (Dietz BA et al., 2000; 
Romani M et al., 1989; Witmer-Pack MD et al., 1988). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Different dendritic cell maturation stages. Immature DC differentiate from myeloid- or 
lymphoid progenitors in response to certain cytokines such as GM-CSF and IL-4. They are 
characterized by a high phagocytic capacity, express low levels of MHC class II and co-stimulatory 
molecules like CD80/CD86, and are not able to secrete inflammation-inducing cytokines such as IL-12 
and IL-10. Upon activation DC travel from non-lymphoid peripheral tissues to the lymphoid organs 
such as the spleen and lymph nodes to efficiently induce primary T cell responses. DC maturation is 
associated with up-regulation of MHC class II and co-stimulatory CD80/CD86 molecules and by 
production of IL-12. However, the existence of a transitional stage of DC maturation between immature 
DC and mature DC has been shown. This subgroup of cells (which are referred to as semi-mature 
DC) is produced in vitro by stimulating immature DC with TNF-α. In vivo these cells remain in a 
“steady state” after internalization of apoptotic cells, vesicles and/or soluble molecules. Semi-mature 
DC express high levels of MHC class II and medium levels of cell surface markers such as CD80 and 
CD86. Semi-mature DC do not secrete inflammation-inducing cytokines such as TNF-α and IL-12 
coupled with enhanced secretion of IL-10. Semi-mature DC can be further matured with LPS alone or 
combined with an enhancing CD40 signal (Hackstein H, 2006; Lutz MB and Schuler G, 2002). 
 
 
  
4.2.3  Dendritic cell-mediated T cell activation 
 
As mentioned before, immature DC undergo phenotypic and functional changes after 
contact with different maturation factors. DC maturation is initiated in the peripheral 
tissue, followed by migration of maturing DC carrying antigen into the T cell area of 
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Figure 4.3: T cell activation. T cell 
activation depends on signal 1, signal 2 and 
signal 3 delivered by an antigen-presenting 
cell through the antigen-specific T cell 
receptor (TCR), co-stimulatory molecules 
and cytokine secretion such as IL-12 and 
others. Signal 1 is delivered through the 
TCR-MHC engagement. Signal 2 is provided 
by co-stimulatory molecules to stimulate T 
cell proliferation. Secretion or lack of 
secretion of cytokines such as IL-12 
promotes the differentiation of naïve T cells 
into TH1 or TH2 cells (referred as to signal 3) 
(from Libscomb MF and Masten BJ, 2002; 
with slide modifications). 
 
 
DC CD4
pos
T cell
MHC class II/peptide TCR
signal 2 CD40 CD40L
PD-L1 PD-1
ICOS-L ICOS
CD80/86 CTLA-4
CD80/86 CD28
PD-L2 PD-1
signal 3 IL-2 secretion TH1 response
no IL-2 secretion TH2 response
signal 1
lymphoid organs. Here they interact with T cells to initiate a specific immune 
response (Lipscomb MF and Masten BJ, 2002). Thereby, DC maturation and 
subsequent migration regulate the outcome of a T cell response: immunity or 
tolerance. DC provide three signals to naïve T cells for T cell activation, proliferation 
and differentiation: T-cell receptor (TCR) binding to MHC-bound antigen, co-
stimulation, and secretion or lack of secretion of factors such as IL-12 by DC 
(Lipscomb MF and Masten BJ, 2002) (Figure 4.3). 
 
DC are able to process and present antigen to activate both naïve CD4pos TH cells 
and naïve CD8pos T cells. Thereby, a cellular contact between a T cell and a DC is 
necessary for antigen recognition. This contact occurs through the TCR that 
recognizes the peptide - MHC complex present at the DC surface (referred to as 
signal 1). To stimulate naïve CD4pos T cells antigenic peptides are loaded on MHC 
class II molecules. In contrast, naïve CD8pos T cells recognize peptides presented by 
MHC class I molecules on the cell surface of APC (Pamer E and Cresswell P, 1998; 
Rock KL and Goldberg AL, 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligation of TCR alone is insufficient to induce full T cell activation. Signal 2, referred 
to as “co-stimulation”, is required together with signal 1 to induce T cell proliferation 
and differentiation into effector T cells. This signal is antigen non-specific and not 
restricted by MHC. The absence of sufficient co-stimulation leads to the induction of 
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T cell anergy or T cell apoptosis, thereby inducing T cell tolerance (Reis e Sousa C, 
2006). The most important co-stimulatory molecules are CD28 on naïve T cells and 
the corresponding ligands, CD80 (B7-1) and CD86 (B7-2), which are upregulated on 
maturing APC (Coyle AJ and Gutierrez-Ramos JC, 2001; Schwartz RH, 2001). Other 
co-stimulator molecules that have been implicated include CD54 (ICAM-1), CD102 
(ICAM-2) and CD50 (ICAM-3) interacting with CD11a/18 (LFA-1), CD58 (LFA-3) with 
CD2, and CD40 with CD154 (CD40 ligand) (Damle NK et al., 1992; McLallan AD et 
al., 1996; Starling GC et al., 1995). However, not all co-stimulatory molecules provide 
a “positive” signal leading to T cell proliferation, cytokine production, and further 
differentiation into effector cells. Some co-stimulatory signals can also provide 
“negative” signals leading to cellular anergy, loss of proliferative capacity, and 
reduction of cytokine production (Pawelec G, 2000; Yamada A et al., 2002). For 
example, cytotoxic T-lymphocyte antigen-4 (CTLA-4) functions to provide such a 
"negative" signal. CTLA-4 has a strong homology to CD28, is upregulated on 
activated T cells, binds with a higher affinity to CD80 and CD86 than CD28, and 
down regulates the immune response (Walunas TL et al., 1994).  
 
Another B-7 family member, PD-L1 (B7-HI), is constitutively expressed on resting T 
cells, B cells, macrophages and DC. It is further upregulated upon activation and 
binds to the programmed cell death 1 (PD-1) receptor on T cells (Coyle AJ and 
Gutierrez-Ramos JC, 2001). This interaction results in a negative regulatory effect 
with inhibition of T cell proliferation and cytokine production. Furthermore, PD-1 
deficiency in PD-1-deficient (PD-1-/-) mice results in a variety of autoimmune 
pathologies, including lupus-like disease in B6-mice, indicating its important role in 
the maintenance of tolerance (Keir ME et al., 2006).  
 
PD-L2 (B7-DC), a second ligand of PD-1, plays a similar role in inhibition and also 
binds to PD-1 but seems to have a distinct function in regulating TH2 responses, 
whereas PD-L1 participates in TH1 inflammation (Coyle AJ and Gutierrez-Ramos JC, 
2001). In contrast to PD-L1 expression, PD-L2 expression is much more restricted. 
PD-L2 is inducibly expressed on DC and macrophages (Latchman Y et al., 2001; 
Tseng SY et al., 2001). PD-L2 can be induced by IFN-γ, IL-4 and GM-CSF (Loke P 
and Allison JP, 2003; Yamazaki T et al., 2002). 
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Signal 3, with either no or secretion of IL-12 by DC, is important for the final 
differentiation of CD4pos T cells into T helper 2 (TH2) or T helper 1 (TH1) effector T 
cells, respectively (Libscomb MF and Masten BJ, 2002; Trinchirie G, 2003).  
 
 
4.3   T cells 
 
4.3.1   Differentiation of effector T cells 
 
Т cells can be divided into two major populations, CD4pos and CD8pos cells. CD4pos T 
cells are able to secrete cytokines, which in turn activate other cells of the immune 
sytem like B cells and CD8pos T cells or macrophages. That is why CD4pos T cells are 
also referred as to TH cells. Thereby, the local cytokine environment, antigen dose 
and the source of co-stimulation determine differentiation into TH1, TH2, or TH17 cells 
(Constant SL and Bottomly K, 1997) (Figure 4.4). In contrast, activated CD8pos T 
cells acquire the ability to lyse their target cells by producing cytotoxic molecules 
such as perforin and granzym B.  
 
 
4.3.1.1 TH1 cells 
 
The TH1 cells, which provide the so called cell-mediated immune response, secrete 
IL-2, tumor necrosis factor-β (TNF-β) and INF-γ under the influence of IL-12 and IFN-
γ, thereby activating phagocytes, NK cells and macrophages. IL-12 is secreted by DC 
whereas IFN-γ is initially secreted by NK cells and by TH1 cells themselves. The main 
transcription factors that control the transition of a TH1 are T-bet and STAT-4 
(Ouyang W et al., 1999; Szabo SJ et al., 2000). 
 
 
4.3.1.2 TH2 cells 
 
In contrast to TH1 cells, TH2 cells express IL-4, IL-5 IL-6, IL-9, IL-10 and IL-13 under 
the influence of IL-4, which mediates B cell activation and differentiation and initiates 
a humoral immune response (Mosmann TR et al., 1986; Paul WE and Seder RA, 
1994; Purkerson J and Isakson P, 1992; Yang J et al., 1999). The main transcription 
factors that control the transition of a TH2 are GATA-3, c-maf and STAT-6 (Aggarwal 
S and Rao A, 1998; Hodge MR et al., 1996; Zhang DH et al., 1997; Zheng WP and 
Flavell RA, 1997). 
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4.3.1.3  TH17 cells 
 
In 2003 Aggarwal and colleagues showed that CD4pos T cells are able to differentiate 
into a TH cell type other than TH1 and TH2 under the influence of IL-23. These so 
called TH17 cells are able to secrete the cytokine IL-17 under the influence of IL-6 
and TGF-β in addition to IL-23 (Bettelli E et al., 2006). IL-17 exerts strong pro-
inflammatory effects, ensures the differentiation, maturation, and activation of 
epithelial, endothelial, and fibroblastic cells, stimulates the production of pro-
inflammatory cytokines and chemokines including IL-6, IL-8, G-CSF, and MCP-1 by 
these cells and activates DC (Cai XY et al., 1998; Chabaud M et al., 1999; Fossiez F 
et al., 1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Differentiation of CD4
pos
 T helper cells. Through the interaction of DC with naïve CD4pos 
T helper cells and associated TCR activation, naïve CD4pos T cells can differentiate into one of several 
lineages of T helper (TH) cells, including TH1, TH2, TH17, and Treg. These different subpopulations vary 
in their profiles of cytokine production and in effector functions. Each linieage of CD4pos T cells is 
controlled by a unique main transcription factor (T-bet, STAT-3, STAT-4, STAT-6, GATA-3, c-maf, 
RORγt/RORα, STAT-5 and Foxp3, respectively). TH1, TH2, Treg, and TH17 cells are characterized by 
their synthesis of specific cytokines and their immuno-regulatory functions. TH1 cells are characterized 
by their production of IFN-γ and are involved in cellular immunity against intracellular microorganisms. 
IL-12 produced by DC polarizes T cells toward the TH1 cells through action of transcription factors 
STAT-4/T-bet). IL-4, IL-5 and IL-13 are major cytokines produced by TH2 cells. IL-4 produced by DC 
polarizes T cells toward TH2 cells through action of transcription factors STAT-6/GATA-3. The recently 
discovered TH17 cells produce IL-17A (IL-17), IL-17F, IL-22, and IL-21 as major cytokines and play 
important roles in clearance of extracellular bacteria and fungi, especially at mucosal surfaces. IL-6, 
IL-21, IL-23 and TGF-β1 produced by mouse DC polarize T cells toward TH17 cells through action of 
transcription factors STAT-3 and RORγt/RORα. Treg cells are characterized by the expression of IL-10, 
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TGF-β1 and transcription factor Foxp3. Treg cells may participate in maintenance of peripheral 
tolerance and prevention of autoimmunity (from Jetten AM, 2009; with slight modifications). 
 
 
 
 
 
The main transcription factor involved in the development of TH17 cells is the orphan 
nuclear receptor RORγt. Maintenance of a TH17 response primarily depends on IL-23 
(Aggarwal S et al., 2003). Binding of IL-23 to its receptor triggers downstream 
activation of STAT-3 transcription factor and subsequent upregulation of ROR-γ and 
production of IL-17A. Since IL-17A leads to the induction of many pro-inflammatory 
factors it has been suggested that TH17 cells might play a crucial role in the induction 
of autoimmune diseases (Weaver CT et al., 2006). 
 
 
4.4  Central and peripheral T cell tolerance 
 
Immunological tolerance can be defined as unresponsiveness to a self- or foreign 
antigen. The main mechanisms of T cell tolerance are central tolerance which occurs 
in the thymus during early T cell activation and peripheral tolerance which occurs in 
the secondary lymphoid tissue after the migration of mature self-reactive T cells from 
the thymus (Sprent J and Kishimoto H, 2001). Unresponsiveness of T cells involves 
different mechanisms such as clonal deletion (death), functional inactivation without 
cell death (anergy) and inhibition of function by regulatory lymphocytes 
(immunoregulation) (Abbas AK and Lichtmann AH, 2005). 
 
 
4.4.1 Central tolerance 
 
Central tolerance can be regarded as a form of self-tolerance induced in the central 
lymphoid organs as a consequence of immature self-reactive lymphocytes 
recognizing self-antigens leading to apoptotic cell death (negative selection, or 
deletion). Clonal deletion is suicide of T-cell progenitors that have high affinity for 
self-antigens (Palmer E, 2003). The main factors leading to negative selection are the 
concentration of self-antigen and the affinity of the TCR that recognizes the antigen. 
But not all mechanisms of central tolerance are able to delete self-reactive T cells. In 
contrast, T cells that can recognize self-determinants with substantial but low affinity 
further progress to maturity. This process is termed positive selection that includes 
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the development of mature Treg cells that enter the peripheral tissue to inhibit immune 
responses that are recognized as self (Abbas AK and Lichtmann AH, 2005; Fink PJ 
and Bevan MJ, 1995). 
 
 
4.4.2 Peripheral tolerance 
 
Although central tolerance is the major mechanism to eliminate self-reactive T cells, 
their deletion is incomplete. Self-reactive T cells with low affinity for self-antigens are 
able to escape negative selection (Bouneaud C et al., 2000). The immune system 
prevents autoimmunity with the mechanisms of peripheral tolerance. Peripheral 
tolerance can be regarded as the maintenance of unresponsiveness of mature T 
cells to self-antigens that are expressed in the peripheral tissue and not abundant in 
the thymus (Hogquist KA et al., 2005). The main mechanisms of peripheral T cell 
tolerance are deletion, T cell anergy and suppression. 
 
When mature T cells are rapidly stimulated by self-antigen, the T cells undergo 
apoptosis, a process called “Activation induced cell death” (AICD) which occurs 
through cross linking and  active signalling to lymphocytes through the death receptor 
Fas (CD95) and its ligand, FasL (CD95L) (Brunner T et al., 1995; Combadiere B et 
al., 1996). Surprisingly the Fas pathway mediated AICD is enhanced by IL-2 since IL-
2 is traditionally thought to be a survival and growth-promoting cytokine (Leonardo 
MJ, 1991). 
 
As mentioned previously (section 4.2.3), full T cell activation requires the recognition 
of antigen by the TCR (signal 1) and recognition of co-stimulatory molecules such as 
CD80 and CD86 by CD28 (signal 2). Induction of functional T cell anergy, the 
functional unresponsiveness of T cells, is associated with a block of T cell 
proliferation and IL-2 production (Schwartz RH, 2003). Anergy is induced by antigen 
recognition through the TCR without adequate co-stimulation or with inhibitory 
signals such as CTLA-4 binding. Thereby, CTLA-4 engagement may be necessary in 
addition to the absence of co-stimulation, to induce anergy in naïve CD4pos T cells in 
vivo. CTLA-4 binds to the B7 molecules with higher affinity than CD28, which might 
explain why CTLA-4 may be the predominant receptor used when self-antigens are 
recognized by T cells (Greenwald RJ et al., 2001; Macian F et al., 2004). 
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Some immune responses are inhibited by cells that block the activation and function 
of effector T cells. Since the 1970s studies have suggested that suppression of 
development and activation of self-reactive T cells can occur through regulatory T 
cells (Treg) (Waldmann H and Munro AJ, 1974; Basten A et al., 1975; see also 
section 4.4.3). Different studies indicate that Treg cells induce tolerance by secreting 
immunosuppressive cytokines such as IL-10 and transforming growth factor-β (TGF-
β) (Weiner HL, 2001; Sundstedt A et al., 2003). IL-10 is produced by TH2 cells and 
monocytes and inhibits macrophage activation and the generation of TH1 cytokines. 
TGF-β inhibits T- and B cell proliferation. 
 
 
4.4.3  Regulatory T (Treg) cells  
 
Treg cells play an important role in silencing self-reactive T cells and are able to inhibit 
autoimmunity and protect against tissue injury (Sakaguchi S et al., 1995). Distinct 
populations of Treg cells have been identified. They can be subdivided into two major 
cell populations by their production of cytokines, expression of cell surface markers 
and distinct suppressive mechanisms:  naturally occurring Treg cells and induced Treg 
cells (Jonuleit H and Schmitt E, 2003).  
 
 
4.4.3.1   Naturally occurring Treg cells 
 
Naturally occurring Treg cells were first described by Gershon in 1975 (Gershon RK, 
1975). They arise during the normal process of maturation in the thymus and 
represent 5-10% of all peripheral CD4pos T cells. It wasn´t until the nineties that more 
focus was put on these cells by Sakaguchi and colleagues. They were able to show 
that a certain type of naturally occurring T cells exhibits a regulatory CD4posCD25pos -
like phenotype (Sakaguchi S et al., 1995). Thereby, one of their substantial functions 
is to maintain natural self-tolerance and to prevent autoimmune disease by 
controlling potential auto-reactive T cells. 
 
During the following years the phenotype and regulatory function of these cells was 
confirmed by several research groups. Naturally occurring Treg cells are characterized 
by high levels of CD25 and the forkhead/winged helix transcription factor Foxp3 
(Takahashi T et al., 1998; Thornton AM and Shevach EM, 1998; Papiernik M et al., 
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1998; Yi H et al., 2006). Additionally they are characterized by the constitutive 
expression of several accessory molecules including GITR (TNFRSF18), CD152 
(CTLA-4) and CD134 (OX40) (Shimizu JS et al., 2002; Read S et al., 2000; McHugh 
RS et al., 2002). However, none of these molecules, including CD25, is exclusive for 
CD4posCD25pos Treg cells since conventional effector CD4
pos T cells without regulatory 
function do express CD25 after activation. Currently, the transcription factor Foxp3 
appears to be the most specific and critical marker regarding the development and 
function of  Treg cells (Fontenot JD et al., 2003; Hori S et al., 2003; Khattri R et al., 
2003; Picca CC and Caton AJ, 2005; Sakaguhi S, 2005). 
 
CD4posCD25pos Treg cells are non-proliferative (anergic) themselves and suppress the 
activation/proliferation of other T cells when they are co-cultured with APC and 
stimulated with antigen. This anergic/suppressive state can be abrogated by TCR 
stimulation and IL-2 (Sakaguchi S et al., 2001). The suppressor effector function of 
Treg cells is antigen
 non-specific (Thornton AM and Shevach EM, 2000). 
CD4posCD25pos Treg cells exert their suppressive effects in a contact-dependent 
manner by membrane-bound molecules that in some models seems to be 
independent of the production of cytokines like IL-10 and TGF-β (Jonuleit H et al., 
2001; Thornton AM and Shevach EM, 1998). However, some studies show that the 
suppressive function of CD4posCD25pos Treg cells might be dependent on the 
production of immunoregulatory cytokines. The role of these cytokines during the 
induction of regulatory function is still controversy discussed. For example, in vivo 
administration of IL-10 and TGF-β antibodies resulted in abrogation of the T cell-
mediated suppression in some experimental autoimmune and inflammatory models 
(Asseman C et al., 1999; Powrie F et al., 2000). However, this could not be 
confirmed in vitro (Thornton A et al., 1998). 
 
The suppression of immune responses seems to occur only when the CD4posCD25pos 
Treg cells are stimulated through their TCR and seems to be related to their 
constitutive expression of CTLA-4 (Takahashi T et al., 2000; Read S et al., 2000). 
Thereby, not only polyclonal but also allogenic stimulation of CD4posCD25pos Treg cells 
results in suppression of both CD4pos T cells as well as CD8pos T cells (Itoh M et al., 
1999; Takahashi T et al., 1998). The result of this suppression is the direct or indirect 
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inhibition of IL-2 production in the responder cell population. This suppression can be 
overcome by the addition of exogenous IL-2 or enhancement of endogenous IL-2 
production (Thornton AM and Shevach EM, 1998). However, the mechanisms of the 
suppressive functions of CD4posCD25pos Treg cells are still incompletely understood 
and are still under intensive investigation. Presently, human and murine Treg cells are 
well characterized whereas only few studies have focused on the characterization of 
rat Treg cells. Since the rat is one of the most important animal models for 
experimental organ transplantation in a clinic-relevant procedure (Timmermann W et 
al., 1998), intensive investigation of rat Treg cells might open up exciting opportunities 
for new therapies, not only in transplantation but also in the prevention of 
autoimmune diseases. 
 
 
4.4.3.2  Induced Treg cells 
 
Besides thymus-derived, naturally occurring CD4posCD25pos Treg cells, there are 
various types of induced Treg cells. Three types of secondary suppressive T cells 
have been described so far: T helper 3 (TH3) cells, type 1 T regulatory (Tr1) cells and 
CD8pos regulatory T cells (Mills KGH, 2004; Roncarolo MG et al., 2001; Weiner HL et 
al., 2001). Induced Treg cells have acquired their regulatory activity during activation 
in vitro or in vivo. These populations of mainly antigen-specific Treg cells can be 
induced from naïve CD4posCD25neg or CD8posCD25neg T cells in the periphery under 
the influence of IL-10, TGF-β, semi-mature DC. The suppressive capacity of these 
cell populations is in contrast to CD4posCD25pos Treg cells contact-independent and 
mainly mediated through suppressive cytokines (Buer J et al., 2005). In vitro these 
cells demonstrate limited proliferation (Mittrücker HW and Kaufmann SHE, 2004). 
 
The development of Tr1 cells in vitro was first shown by Groux and colleagues in 
1997. They showed that chronic activation of CD4pos T cells by an IL-10-dependent 
process leads to the development of IL-10 producing Tr1 cells which are able to 
prevent the induction of colitis. Tr1 cells are characterized by a unique pattern of 
cytokine production distinct from that of TH1 and TH2 cells. Upon TCR mediated 
activation these cells secrete high levels of IL-10 and/or TGF-β, low amounts of IL-2 
and no IL-4 (Asseman C et al., 1999; Jonuleit H et al., 2000; Powrie F et al., 1996). 
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Depending on the experimental conditions Tr1 cells produce either low levels of IFN-γ 
and IL-5 or none at all (Bacchetta R et al., 1990). Tr1 cells proliferate poorly after 
activation with antigen in vitro and do show immunosuppressive functions by 
preventing the development of T cell mediated immune responses (Levings MK et 
al., 2001). In addition, supernatants of activated Tr1 cells are able to impair the ability 
of DC to induce alloantigen mediated T cell proliferation (Lecart S et al., 2001; 
Cavani A et al., 2000). 
 
TH3 cells were identified during the investigation of mechanisms associated with oral 
tolerance. Oral tolerance is a natural immunogenic event induced following oral 
antigen administration. The development of TH3 cells was first described by Chen Y 
and colleagues in 1994 after oral tolerance induction to myelin basic protein (MBP). 
TH3 cells in contrast to Tr1 cells primarily secrete high levels of TGF-β. They support 
IgA production and have suppressive properties for TH1 and TH2 cells in an antigen 
non-specific fashion (Weiner HL, 2001). 
 
In addition to Tr1 and TH3 cells there is also evidence for a subtype of CD8
pos cells 
with regulatory functions. These cells are able to secrete IL-10 or TGF-β and have 
been therefore called CD8pos regulatory T cells (Garba M et al., 2002; Haynes LM et 
al., 2000). They can be generated in vitro by stimulation of naïve CD8pos T cells with 
CD40L-activated plasmacytoid DC or with IL-10 treated myeloid DC (Gilliet M and Liu 
YJ, 2002; Steinbrink K et al., 1999). Recently it has been demonstrated that an anti-
CD45RO/RB monoclonal antibody also induces CD8pos cells with suppressive activity 
(Gregori S et al., 2005). 
 
 
4.5  Tolerogenic DC and Treg cells 
 
As mentioned earlier the ability of the immune system to distinguish between self and 
non-self is controlled by different mechanisms of central and peripheral tolerance 
(section 4.4). These mechanisms involve deletion of self-reactive T cells through the 
interaction with DC followed by the induction of cell death or T cell anergy or the 
active suppression by Treg cells. However, the mechanisms of Treg cell development 
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and how they exert their immune regulatory properties are still under intensive 
investigation.  
 
Besides their well-known immunostimulatory properties, DC have been found to play 
a crucial role in induction/maintenance of peripheral T-cell tolerance by acting on Treg 
cells. There is growing evidence that interactions between DC and Treg cells play an 
important role in the balance between immunity and tolerance. Thereby, the 
communication between these two cell types appears to be very complex and 
mediated by soluble or cell surface molecules (Figure 4.5). The regulatory properties 
of DC include induction of T cell anergy, apoptosis, and the generation of T cells with 
regulatory capacities as well as the generation of T cells that secrete 
immunomodulatory cytokines.  
 
Direct killing of T cells by the induction of T cell apoptosis was first described by Süss 
and Shortman (Süss G and Shortman K, 1996). They showed that a subclass of DC 
is able to kill CD4pos T cells via Fas/Fas-ligand-induced apoptosis. In 2008 Vassiliou 
EK and colleagues showed that BM-DC generated in the presence of resolvin E1, a 
strong anti-inflammatory lipid, induce apoptosis of activated CD4pos T cells (Vassilio 
EK et al., 2008). 
 
The immuneregulatory functions of DC seem to be strictly dependent on their 
different stages of maturation and activation. It has been shown that immature DC 
are more likely to actively exert tolerogenic function than be inactive (Mahnke K et 
al., 2002; Mahnke K et al., 2003). In general immature tolerogenic DC are derived 
from processing and presentation of apoptotic cells (Steiman RM et al., 2000). In 
2002 Stuart and colleagues demonstrated that DC that ingested apoptotic cells have 
diminished capacity to stimulate naïve T cells.  In addition, Marguti et al. showed that 
expansion of suppressive Treg cells is favoured when immature DC were loaded with 
allogenic apoptotic thymocytes (Marguti I et al., 2008). 
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Figure 4.5: Bidirectional interplay between different DC subsets and Treg cells. Different subsets 
of tolerogenic DC with distinct phenotypic profiles induce Treg cells with a low ability to proliferate. Treg 
cells in turn inhibit effector cells but also program the generation of tolerogenic DC from DC 
progenitors. In contrast, fully mature DC induce effector T cells with a high ability to proliferate (from 
Hubert P et al., 2007; with slight modifications). 
 
 
 
There is a rapid expansion of literature regarding the effects of DC on Treg cells. The 
first evidence that immature DC are able to induce tolerance came from studies by 
Jonuleit and colleagues in 2000 (Jonuleit H et al., 2000). They showed that repeated 
stimulation with ex vivo prepared immature DC induce IL-2 receptor expression on T 
cells which is an indicative marker for Treg cells. These T cells were not able to 
proliferate and did suppress proliferation of CD4pos and CD8pos effector T cells. This 
suppression was mediated by cell-cell contact, independent of soluble factors. 
Steinman and colleagues (Steinman RM and Nussenzweig MC, 2002; Steinman RM 
et al., 2003) have proposed that under steady-state conditions (in the absence of 
acute infection and inflammation), antigen-loaded immature DC with low cell-surface 
expression of MHC class II and co-stimulatory molecules may have the capacity to 
induce peripheral tolerance to those peptides presented to Ag-specific T cells by 
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silencing T cells either by deletion (induction of apoptosis) of effector T cells or by 
expanding Treg cells that suppress effector immune responses. Two papers, one by 
Jenkins MK et al., 1990 and one by Jonuliet H et al., 2000, strongly suggest that this 
is due to TCR binding to the MHC class II complex, either in the absence of co-
stimulatory molecules or with low levels, leading to anergy or apoptosis of the 
antigen-specific T cells or to the generation or regulatory antigen-specific T cells. In 
contrast, Treg cells that produce IL-10 and TGF-β are able to program the generation 
of tolerogenic DC from DC progenitor cells (Cederbom L et al., 2000; Frasca L et al., 
2002; Min WP et al., 2003). 
 
 
 
4.5.1 Tolerogenic DC and Treg cells in autoimmunity, transplantation and 
tumorimmunity 
 
Tolerogenic DC and Treg cells have been shown to be attractive cell types for 
therapeutic manipulation of the immune system in order to enhance the insufficient 
immune responses during infectious disease and cancer or to inhibit excessive 
immune responses in autoimmune disorders and transplant rejection (Trabell KV et 
al., 2004; Zhang X et al., 2008; Pardoll DM, 1999). The following sections highlight 
the therapeutic potential of tolerogenic DC and Treg cells. 
 
 
4.5.1.1 Autoimmunity 
 
A key feature in the development of autoimmune diseases is a failure of 
immunological self-tolerance leading to aberrant immune responses to self-antigen. 
In addition to the potential of DC to induce autoimmune responses, their role in 
controlling autoimmune responses was examined. Under certain conditions antigen 
loaded DC are able to induce T cell tolerance, either through induction of T cell 
anergy or deletion of T cells, or by induction of Treg cells. It has been shown that both 
immature and mature DC can prime Treg cells that prevent autoimmunity (Trabell KV 
et al., 2004; Yamazaki S et al., 2003). Some reports also describe a regulatory 
capacity for semi-mature DC. For example in 2002 Menges and colleagues showed 
that repeated injections of DC matured with TNF-α are able to induce IL-10 
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producing peptide-specific T cells in vivo and protect mice from autoimmune 
encephalomyelitis. 
 
Evidence is accumulating that CD4posFoxp3pos Treg cells contribute to maintaining 
self-tolerance by down-regulating immune response to self and non-self antigens in 
an antigen-nonspecific manner in which they actively suppress self-reactive T cells. 
Recently Kim and colleagues (Kim JM et al., 2007) showed that Treg cells prevent 
catastrophic autoimmunity throughout the life span of mice. The frequency and 
function of naturally occurring Treg cells have been examined in a number of human 
autoimmune diseases like systemic lupus erythematosus (SLE) ( Valencia X et al., 
2007), rheumatoid arthritis  (Flores-Borja F et al., 2008), type 1 diabetes  (Lindley S 
et al., 2005), and multiple sclerosis (MS) (Hafler DA et al., 2005). Depletion or 
functional abrogation of naturally occurring Treg cells from the periphery of normal 
mice leads to the spontaneous development of various autoimmune diseases. 
Inoculation of normal CD4posCD25pos T cells prevented these autoimmune 
developments in a dose-dependent manner (Sakaguchi S et al., 1995; Asano M et 
al., 1996). 
 
 
4.5.1.2 Transplantation 
 
Continued advances in surgical techniques and immunosuppressive therapy have 
allowed transplantation of organs, tissues and cells to become the therapy of choice 
for patients with end-stage organ failure. However, despite the success of today’s 
immunosuppression strategies clinical transplantation is still limited by the side 
effects associated with long-term immunosuppression. At the present time no 
alternative to immunosuppression exists in the clinic. Immunosuppressive agents are 
non-specific and target different sites in the T cell activation cascade, usually by 
inhibiting activation of alloreactive T cells or via depletion of alloreactive T cells. 
Strategies aimed at specific depletion of alloreactive T cells are needed for new 
therapeutic roles in reducing this barrier to transplantation tolerance. Crucial to 
finding new ways of influencing allograft rejection is our understanding of 
alloactivation which occurs by two major pathways, the direct and indirect pathway of 
allorecognition (Gokmen MR et al., 2008) (Figure 4.6).   
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The direct pathway of alloactivation results from the direct interaction between the 
TCR on recipient T cells and allogenic MHC class I and class II molecules on donor 
APC, resulting in the generation of cytotoxic CD8pos T cells and CD4pos TH cells 
(Lechler R and Batchelor JR, 1982). The indirect pathway of allorecognition involves 
processed peptides of allo-MHC molecules presented by antigen-presenting cells of 
the recipient, mainly by DC, to effector T cells in the context of self-MHC (Figure 
4.6).  
 
Our knowledge of the role of tolerogenic DC and Treg cells in the generation and 
maintenance of T-cell tolerance has expanded rapidly and is now a key area of 
research in transplant rejection. Therefore, attention has been focused on the 
utilization of Treg cells and tolerogenic DC in adoptive cell-based therapy to induce 
allograft tolerance without the need for additional immunosuppression. A number of 
studies have investigated the use of in vitro generated tolerogenic DC and Treg cells 
to promote allograft acceptance. Recently, Zhang and colleagues (Zhang X et al., 
2008) showed that tolerogenic DC generated in vitro by treatment with LF 15-0195 
are capable of augmenting CD4posCD25posFoxp3pos Treg cell numbers and activity 
resulting in the prevention of allograft rejection. Lutz and colleagues (Lutz MB et al., 
2000) were able to show that pre-treatment of CBA mice with allogenic immature DC 
7 days before cardiac transplantation resulted in prolonged survival of allografts. 
However, data demonstrating prolonged graft survival without immunosuppression 
are rare (Horibe EK et al., 2008; Ikeguchi R et al., 2008).  
 
  
 
 
 
 
 
 
 
 
Figure 4.6: Direct and indirect antigen recognition. MHC alloantigens can be recognized by T cells 
via two distinct pathways: the direct and the indirect pathway. In the direct pathway it comes to ligation 
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of the TCR on alloreactive T cells (recipient T cells) to intact MHC molecules on donor APC. The 
indirect pathway results from the presentation of processed peptides of allo-peptide molecules by 
recipient APC to the recipient effector T cells in the context of self-MHC. 
 
 
 
 
4.5.1.3 Tumorimmunity 
 
Although Treg cells are able to prevent autoimmune diseases through the induction of 
immune tolerance by suppressing host immune responses against self- or non-self-
antigens, emerging evidence suggests that they are also able to inhibit the immune 
response of immune cells against tumor cells, thus promoting tumor growth and 
progression. Already during the 1970s and 1980s it was suggested that suppressor T 
cells contributed to tumor growth (Rotter V and Trainin N, 1975; Berendt MJ and 
North RJ, 1980). These studies have shown that depletion of suppressor T cells is 
associated with delayed tumor growth and prolonged survival in murine cancer 
models. Removal of CD4posCD25pos Treg cells can abrogate immunological 
unresponsiveness to syngenic tumors in vitro and in vivo, thus leading to tumor-
specific or non-specific effector T cells (Shimizu J et al., 1999; Onizuka S et al., 
1999). However, since Treg cells
 are engaged in suppressing immune responses 
toward both self and non-self, one challenge would be to find ways to distinguish 
between Treg cells required for immune homeostasis
 and those involved in 
pathological processes such as tumor immune evasion. This could lead to novel 
immunomodulatory strategies for the treatment of cancer. 
 
Clinical and experimental studies have demonstrated that tumor growth is closely 
associated with defects in DC function. These dysfunctions of DC have been 
associated with impaired differentiation and maturation of DC caused by tumor 
produced cytokines such as IL-10, TGF-β and VEGF that downregulate the 
effectiveness of DC (Kobie JJ et al., 2003; Sharma S et al., 1999; Gabrilovich DI et 
al., 1996). In vitro maturation of DC is inhibited by IL-10 and VEGF and immature DC 
convert into tolerogenic DC by sensing IL-10 and TGF-β, making them unable to 
respond to inflammatory stimuli and inducing the development of anergic or 
suppressor T cells instead of effector T cells. However, different studies have shown 
that DC-based anti-tumor immunotherapy is able to generate protective anti-tumor 
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immune responses in vivo. Several researches have focused on the possibility of 
inducing autoimmune diseases to treat cancer (Pardoll DM, 1999). Previous studies 
have shown that vaccination with DC loaded with tumor-antigen in animal tumor 
models can inhibit tumor growth and induce autoantibodies transiently without clinical 
or histological features of autoimmunity (Tsai BY et al., 2009).  
 
In summary, all these findings support the importance of the development of 
therapeutic approaches concurrently promoting tolerogenic DC and Treg cell 
generation for clinical conditions, ranging from organ transplantation over 
autoimmunity to treatment of cancer. A very careful characterization, especially of the 
different subsets of Treg cells and tolerogenic DC and their respective 
immunosuppressive properties, will be an indispensable prerequisite for future 
studies. Thereby, a better understanding of the interactions between Treg cells and 
tolerogenic DC will lead to improved tools for the treatment of different diseases such 
as autoimmunity, transplant rejection and cancer. 
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5 Aims of the study 
 
In addition to the key role of DC in the induction of immunity, DC also play a role in 
the induction/maintenance of peripheral T cell tolerance by generating T cells with 
regulatory properties. These capacities have raised great interest in their therapeutic 
manipulation of the immune system in order to enhance the insufficient immune 
responses during infectious disease and cancer or to inhibit excessive immune 
responses in autoimmune disorders and transplant rejection.  
The rat is widely used as an experimental animal system in a variety of areas such 
as immune responses to pathogens, tumors, self-antigens, or allografts. However, 
their DC and Treg cells have not been as well characterized as research has mainly 
focused on the characterization of DC and Treg cells of the mice system. Interestingly, 
the rat immune system offers a close analogy to that of humans, for example, the 
expression of MHC class II by activated T cells (Reizis B et al., 1994; Ko HS et al., 
1979) that could make the rat model more attractive than the mouse model for some 
specific immunological studies. 
The present study analyses the importance of rat tolerogenic immature DC and Treg 
cells with immune regulatory properties. Since only few studies have focused on the 
generation of a defined population of immature DC from rat bone marrow, information 
on the culture conditions and the influence of different culture conditions on 
generating rat tolerogenic immature BM-DC still requires clarification to develop new 
strategies for the treatment or prevention of different diseases. Therefore, one aim of 
this study was to generate and characterize immature rat BM-DC. Cytokines such as 
GM-CSF and IL-4 seem to influence the yield of these cells in vitro (Lutz MB et al., 
1999; Grauer O et al., 2002). Thus, the optimal growth conditions required for the 
generation of a defined population of immature BM-DC was systematically evaluated. 
In addition, these cells were phenotypically and functionally characterized to confirm 
their expected immature tolerogenic character. Furthermore, their ability to generate 
Treg cells was investigated in addition to functional characterization of possibly 
induced Treg cells.  
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5.1  Questions 
 
(A) What is the optimal culture condition required for the generation of immature   
IL-4 DC? 
 
(B)  What are the main phenotypic characteristics of IL-4 DC? 
 
(C) What is the effect of IL-4 DC on naïve T cells in vitro? 
 
(D)  Do IL-4 DC exhibit a stable immature phenotype? 
 
(E)  Are IL-4 DC able to generate Treg cells from naïve T cells in vitro? 
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6  Materials 
 
6.1 Animals 
 
Inbred male Lewis (LEW), Wistar Furth (WF) and Brown Norway (BN) rats (8-10 
weeks old, 200-350g) were purchased by Harlan Winkelmann GmbH (Borchen, 
Germany; Table 6.1).  
 
Table 6.1: Rat Strains used in this study for cell isolation. The haplotype and reference are 
shown. 
 
 
Rat Strain (inbreed) 
 
MHC-Haplotype 
 
Reference 
 
Lewis (LEW/HanTMHsd) 
 
RT l 
 
Harlan Winkelmann GmbH 
(Borchen, Germany) 
 
Brown Norway (BN/RijHsd) 
 
  
RT1n 
 
Harlan Winkelmann GmbH 
(Borchen, Germany) 
Wistar Furth (WF/NHsd) RT1u Harlan Winkelmann GmbH 
(Borchen, Germany) 
 
 
 
Femurs, spleen and lymph nodes for the isolation of dendritic cell progenitor cells, 
mature dendritic cells and naïve T cells were regulary isolated from Lewis rats. In 
addition, naïve T cells were isolated from lymph nodes of Wistar Furth or Brown 
Norway rats. All animals were handled according to national and institutional animal 
care policies. 
 
 
6.2 Antibodies 
 
The following antibodies were used in this study for flow cytometry and western 
Blotting (Table 6.2 and 6.3): 
 
 
Table 6.2 (see next page): Antibodies for phenotyping of rat dendritic cells and rat T cells by 
flow cytometry. The name (clone) specificity and source of antibodies are shown. 
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Name (clone) Specificity Source 
 
donkey anti-mouse IgG 
(H+L):RPE 
 
 
whole molecule mouse IgG 
  
Dianova, Germany 
CD80*) 
 
CD80  
Linaris Biologische 
Produkte, Wertheim-
Bettingen, Germany 
CD86*) 
 
CD86 
mouse anti-rat CD25:RPE 
(MRC Ox39) 
 
rat CD25 cell surface 
antigen 
mouse anti-rat CD28, 
monoclonal (JJ319) 
 
rat CD28 cell surface 
antigen 
mouse anti-rat RT1B:RPE, 
monoclonal (Ox6) 
 
rat MHC II (RT1B) 
mouse anti-rat TCR 
alpha/beta, monoclonal 
(R73) 
 
constant determinant on the 
beta chain of the rat 
alpha/beta T cell receptor 
mouse anti-rat CD4:FITC 
(W3/25) 
 
rat CD4 cell surface 
glycoprotein 
mouse anti-rat CD54:FITC, 
Monoclonal (1A29) 
 
rat cell surface CD54 
(ICAM-1) antigen 
mouse anti-rat CD45 
(LCA):RPE, monoclonal 
(MRC Ox1) 
 
rat leukocyte common 
antigen 
mouse anti-rat CD25 
(NDS61) 
 
rat CD25 cell surface 
antigen 
mouse anti-rat CD11b/c 
(Ox-42) 
 
rat CD11b/c (dendritic cells) 
FITC mouse IgG1, κ isotype 
control (MOPC-31C) 
 
unknown specificity  
BD Biosciences, 
Germany 
PE mouse IgG1, κ isotype 
control (MOPC-21) 
 
unknown specificity 
FITC hamster anti-mouse 
CD40 (HM40-3) 
 
rat CD40 glycoprotein 
PE-CyTM5 mouse anti-rat 
CD4 (Ox-35) 
 
CD4 antigen 
mouse anti-rat Ox62, 
monoclonal (MRC Ox-62) *) 
 
rat α-E2 Integrin  Serotec, Germany 
7-amino actinomycin D (7-
AAD) 
 
staining dye for dead cell 
exclusion 
 BD Via-ProbeTM, 
Germany 
 
*) stained with secondary donkey anti-mouse IgG (H+L): RPE 
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Table 6.3: Antibodies for western blotting used in this study. The name (clone) specificity and 
source of antibodies are shown. 
 
Name (clone) Specificity Source 
    
anti-PD-L1 
 
17 amino acid peptide from 
near the center of human 
PD-L1 
 
 
ANASPEC, San Jose, 
Canada 
 anti-PD-L2 
 
16 amino acid peptide from 
near the center of human 
PD-L2 
 
monoclonal antibody to 
GAPDH-loading control 
(GAPDH 1D4) 
 
GAPDH  IMGENEX, San Diego, 
Canada 
polyclonal goat anti-rabbit 
immunoglobulins/HRP*) 
 
rabbit immunoglobulin  
DakoCytomation, 
Denmark polyclonal rabbit anti-mouse 
immunoglobulins/HRP **) 
 
mouse immunoglobulin 
rabbit anti-nitric oxide 
synthase II (iNOS) 
polyclonal antibody 
 
iNOS protein   Stressgen Bioreagents 
Corp., Victoria, Canada 
phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
antibody 
 
endogenous levels of p44 
and p42 MAP Kinase (Erk1 
and Erk2) when 
phosphorylated 
 
 
 
Cell Signalling, USA 
 p44/42 MAPK (Erk1/2) 
antibody 
 
endogenous levels of total 
p44/42 MAP Kinase (Erk1 
and Erk2) protein 
 
 
 
*)  secondary antibody for anti-PD-L1, anti-PD-L2, anti-iNOS, anti-phosphop44/42 MAPK, anti-p44/42 
MAPK 
**) secondary antibody for monoclonal antibody to GAPDH-loading control 
 
 
 
 
6.3 Primer for Reverse transcriptase-polymerase chain reaction (RT-PCR) 
 
The following primers were used in this study for RT-PCR: 
 
Table 6.4 (see next page): The sequences of the primers used in this work. The forward and 
reverse sequence, PCR product size (bp), and the annealing temperature are presented. All the 
primers were synthesized by MWG Biotech AG (Ebersberg, Germany) according to published 
sequences: GAPDH (Kruse et al., 1999); MHC class II (Syha-Jedelhauser et al., 1991); CD40 (Matsui 
et al., 2002); CD80 (Holowachuk and Ruhoff, 2001); CD86 (self made with GeneFisher), IL-10 
(Siegling et al., 1994), iNOS (Sterin-Borda et al., 2003); IL-12 (Stumbles PA et al., 1998); TGF-β 
(Siegling A et al., 1994). In addition, the related nucleotide sequences are listed in PubMed. 
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Primer bp Temp Sequence 5´→ 3´ 
GAPDH 319 62  for GGT CGG TGT GAA CGG ATT TG 
 rev GTG AGC CCC AGC CTT CTC CAT 
TGF-β 396 60 
 for GCC TCC GCA TCC CAC CTT TG 
 rev GCG GGT GAC TTC TTT GGC GT 
iNOS 578 60 
 for GAT CAA TAA CCT GAA GCC CG 
 rev GCC CTT TTT TGC TCC ATA AGG 
IL-10  371 55 
 for CTC GCT TCA CAG TGG ATG AA 
 rev TAA ATA CGG TGG TGC GTG AA 
IL-12 484 58 
 for TGG AGT CAT AGG CTC TGG A 
 rev GAT GAA GAA GCT GGT GCT G 
MHC II  517 55 
 for CAG GAT CTG GAA GGT CCA 
 rev AGC TGT GGT TGT GCT GA 
CD40 401 58 
 for CGC TAT GGG GCT GCT TGT TGA CAG 
 rev GAC GGT ATC AGT GGT CTC AGT GGC 
CD80  517 50 
 for TGG TGA AAC ACC TGA CCA 
 rev GTT TCT CTG CTT GCC TCA 
CD86  518 53 
 for TGG GAA ACA GAG CTC TCA 
 rev AGG TTG ATC GAC TCG TCA 
bp = base pair; Temp = annealing temperature of the primer in °C; for = forward, rev = reverse. 
 
 
 
 
6.4 Chemicals, reagents, cytokines and commercial kits 
 
The following chemicals, reagents, cytokines and commercial kits were used 
throughout this study: 
 
 
Table 6.5 (see also next page): Chemicals, reagents and commercial kits. Chemicals, Reagents 
and commercial kits are shown together with the source of supply. 
 
 
Chemicals, reagent, 
cytokines and 
commercial kits 
 
 
Source 
 
Chemicals, reagent, 
cytokines and 
commercial kits 
 
 
Source 
 
Annexin V 
Apoptosis Detection 
Kit I 
 
 
BD Pharmingen, 
Germany 
 
Griess reagent 
(modified) 
 
 
Sigma, Deisenhofen, 
Germany 
 
 
Blue/Orange 6x 
loading dye 
 
 
Promega GmbH, 
Mannheim, Germany 
  
Isopropanol 
 
 
 
Merck Eurolab,    
Nürnberg, Germany 
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Chemicals, reagent, 
cytokines and 
commercial kits 
 
 
Source 
 
Chemicals, reagent, 
cytokines and 
commercial kits 
 
 
Source 
 
CD40L 
 
 
ALEXIS Biochemicals, 
USA 
 
Lipopolysaccharide 
(LPS) 
 
 
Sigma-Aldrich, 
Germany 
 
CellectionTM Pan 
Mouse IgG Kit 
 
Invitrogen, Karlsruhe, 
Germany 
 
M-PER® Mammalian 
Protein Extraction 
Reagent 
 
Thermo Scientific 
Chloroform 
 
Carl Roth GmbH, 
Karlsruhe, Germany 
 
NG-methyl-L-arginine 
acetate 
(NMMA) 
 
Sigma-Aldrich, 
Germany 
 
Rat IL-2 and rat IL-4 Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
 
nuclease free water Promega GmbH, 
Mannheim, Germany 
Dextran-Alexa488 kindly provided by 
Prof. Lutz, Institute for 
Virology and 
Immunobiology, 
University of Würzburg 
 
rat IL-2, rat IFN-γ and 
rat IL-10 ELISA 
 
eBioscience, Canada 
DMSO Sigma-Aldrich, 
Germany 
Ready-to-use reagent 
Trizol Reagent 
 
Invitrogen GmbH, 
Karlsruhe, Germany 
 
ECL Plus Western 
Blotting Detection 
System 
 
GE Healthcare, UK RNA storage solution Ambion (Europe), 
Huntingdon, United 
Kingdom 
 
ethidium bromide  
 
 
 
Amresco, Solo, Ohio, 
USA 
 
  
SYBR Green PCR 
Master Mix 
 
 
Applied Biosystems 
GmbH, Weiterstadt,    
Germany 
 
Ethanol 
 
Merck Eurolab [3H]-thymidine  
 
 
 
Biomedicals Germany 
GmbH, Eschwege, 
Germany 
 
Fetal calf serum 
(FCS) 
 
Cell Concepts, 
Germany 
TNF-α 
 
R&D Systems, 
Heidelberg, Germany  
 
GeneAmp RNA-PCR-
Kit 
Applied Biosystems 
GmbH, Weiterstadt,    
Germany 
 
UO126 MEK1/2 
inhibitor 
 
Cell Signaling 
Technology, INC., 
USA 
 
GM-CSF R&D Systems, 
Heidelberg, Germany  
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6.5 Culture medium, buffer und stock solutions 
 
All buffers and stock solutions (Table 6.6 and 6.7) were prepared with deionised 
water. Heat-insensitive solutions were autoclaved (135 °C, 2 bar, 20 min) for use in 
the cell culture, while heat-sensitive solutions were sterile-filtered (pore size 0.2 µm). 
To inactivate the complement factors fetal calf serum (FCS) was heated for 30 min to 
56 °C and stored until needed at -20 °C. 
 
 
Table 6.6: Composition of culture medium, buffer and stock solutions. The name, components 
and concentration are presented (see also next page). 
 
 
Name 
 
 
Components 
 
Concentration 
 
2% Agarose gel  
 
 
agarose 
1xTAE buffer 
 
 
2         g 
200     ml 
Culture medium *) 
 
 
 
 
 
 
 
 
RPMI 1640  
HEPES 
L-glutamine 
penicillin 
streptomycin 
2-mercaptoethanol 
non-essential amino acids 
fetal calf serum (FCS) 
500     ml 
20       mmol/L 
2         mmol/L 
100     U/ml 
100     µg/ml 
5x10-5 mol/L 
1         % 
10       % 
Phosphate-buffered saline 
(PBS) **) 
sodium chloride 
potassium chloride 
sodium dihydrogen phosphate 
potassium hydrogen phosphate 
pH was adjusted to 7.2 
 
140     mmol/L 
2.7      mmo/L 
7.2      mmol/L 
1.47    mmol/L 
RBCs-lyse-buffer 
(10-fold concentrated) 
 
ammonium chloride 
potassium hydrogen carbonate 
EDTA 
 
1.68    mol/L 
99.88  mmol/L 
12.6    mmol/L 
TAE buffer (50x) 
 
Tris (ultrapure) 
acetic acid 
0.5M EDTA (pH 8.0) 
add 1,000 ml ddH2O 
 
242     g 
57.1    ml 
100     ml 
Tris-NaCl buffer  Tris-HCl 
 NaCl 
 bovine serum albumine (BSA) 
 pH was adjusted to 7.4 
 
0.6      g/L 
8.1      g/L 
2         g/L 
 
*)   Roswell Park Memorial Institute (RPMI) 1640 cell culture medium (Gibco/ Invitrogen, Karlsruhe,   
    Germany) was used as the standard culture medium supplemented with reagents listed above. 
**) The solution was sterilized and kept at 4°C. 
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The following buffers and stock solutions were used for western blotting: 
 
 
Table 6.7: Composition of buffer and stock solutions for western blotting. The name, 
components and concentration are presented. 
 
 
Name 
 
 
Components 
 
Concentration 
 
dry milk  
 
dry milk powder 
 
5          % 
(disolved in 1xTBS) 
 
Reduction mix Tris-HCl 
SDS 
ß-mercaptoethanol 
Glycerol 
bromphenolblue 
130      mM 
4.2       % 
10        % 
21        % 
0.01     % 
 
Running buffer Tris (ultrapure) 
SDS 
Glycine 
add 2,000 ml ddH2O 
pH was adjusted to 8.3 
 
6.2       g 
2          g 
28.8     g 
10% SDS polyacrylamide 
gel  
30% acrylamide mix 
1.5M Tris (ultrapure, pH 8.8) 
10% SDS 
10% amonium persulfate 
TEMED 
ddH2O 
 
3.3       ml 
2.5       ml 
0.1       ml 
0.05     ml 
0.004   ml 
4          ml 
10xTBS Tris (ultrapure) 
NaCl 
HCl 
add 1,000 ml ddH2O 
 
24.2     g 
80        g 
38        ml 
Towbin buffer Tris (ultrapure) 
Glycin 
MetOH 
add 1,000ml ddH2O 
pH was adjusted to 8.3 
 
25        mM 
152      mM 
20        % 
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6.6 Equipment and aids 
 
 
 
Table 6.8: Equipment and aids. The item and source of supply are shown. 
 
 
Item 
 
 
Source of supply 
 
70 µm nylon cell strainer 
 
 
Becton Dickinson Biosciences, Germany 
5, 10, 20 ml syringe piston 
 
Becton Dickinson Biosciences, Germany 
1450-421 Filtermat A Wallac, Perkin-Elmer Life and Analytical 
Sciences, Rodgau, Germany 
 
96-well round-bottom plates 
 
NUNC, Denmark 
argon-laser flow-cytometer FACSscan 
 
Becton Dickinson Biosciences 
FlowJo 
 
Tree Star, Inc., USA 
ImageMaster workstation 
 
Amersham Pharmacia Biotech, 
Piscataway,    
USA 
 
MicroBeta Filtermat-96 cell harvester 
 
Wallac, Turku, Finland 
Neubauer chamber 
 
Optik Labor, Germany 
Opticon 2 Cycler 
 
M.J. Research, Bio-rad, USA 
plastic bags 
 
Wallac, PerkinElmer 
Wallac-MicroBeta TriLux β-radiation  
counter 
Institut für Virologie und Immunbiologie, 
Würzburg 
 
PROTRAN® Nitrocellulose Transfer    
Membrane 
 
Whatman® Schleicher & Schnell 
X-Ray Medical Film 
 
Konica Minolta 
6-well, 24-well plate 
 
Greiner Bio-One, Germany 
petri dishes (Ø 100 mm) 
 
Becton Dickinson Biosciences 
microplate reader 
 
Dynatech laboratories, USA 
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7  Methods 
 
7.1  Preparation of bone marrow-derived immature dendritic cells 
 
Femur bones of Lewis rats were removed from the surrounding muscle tissue and 
purified by scraping with a scalpel. Thereafter intact bones were left in 70% ethanol 
for 3 minutes for disinfection and washed 2 times in sterile PBS. Then, both ends of 
the bone were cut off with surgical scissors and marrow flushed with 20 ml PBS for 
each bone through a 70 µm nylon cell using a syringe with a 20-gauge needle. The 
bone marrow cells, after lysis with 1-fold concentrated red blood cell (RBC) lyse 
buffer, were plated in petri dishes with a diameter of 100 mm at a cell density of 
5x105 cells/ml in medium supplemented with rat rGM-CSF (5 ng/ml) and rat rIL-4 (5 
ng/ml) for the generation of IL-4 DC. The cells were cultured at 37°C in a 5% 
humidified CO2 atmosphere and on day 3 or 4, half of the culture was removed, spun 
down, and replaced with fresh medium and cytokines. Non-adherent single cells and 
loose adherent cell clusters were harvested for use on day 6 or 7.  
 
For evaluation of optimal growth conditions as mentioned above, freshly isolated 
bone marrow cells were plated on 24-well plates in 1 ml culture medium per well at a 
density of 1x105 cells per ml with varying GM-CSF concentrations ranging from 0.2 to 
60 ng/ml, either alone or in combination with varying IL-4 concentrations ranging from 
1 to 20 ng/ml. On day 3 or 4, culture medium was replaced by fresh medium and 
cytokines as mentioned above.  
 
For maturation experiments non-adherent single cells and loose adherent cell 
clusters were replated on day 6 at a density of 5x105 cells/ml on 6-well plates in 3 ml 
medium per well and cultured until day 8 with 2.5 ng/ml GM-CSF only. In a second 
round, on day 8, cells were replated again at a density of 5x105 cells/ml on new 6- 
well plates in 3 ml fresh medium supplemented with LPS (1 µg/ml), TNF-α (20 ng/ml) 
or CD40L (1 µg/ml) until day 10.   
 
 
7.2  Isolation of mature splenic dendritic cell population 
 
Harvested spleens of Lewis rats were passed through a 70 µm nylon cell strainer 
with a 5 ml syringe piston to generate a single-cell suspension and RBCs were lysed 
for 5 minutes using 1-fold concentrated RBC lyse buffer. Then, the cells from the 
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spleen of one rat were plated in two petri dishes with a diameter of 100 mm overnight 
in culture medium at 37°C in a 5% humidified CO2 atmosphere. The next day, the 
non-adherent cells were collected and centrifuged over a 14.5% Metrizamide - or 
10.5% OptiPrep - gradient at 4°C and 1,823 x g for 13 minutes for density gradient 
separation. Mature spleen DC (S-DC) were collected from the interface and counted 
in a Neubauer chamber. 
 
 
7.3  Isolation of lymph node T cells 
 
Lymph node (LN) cells from Wistar Furth or Brown Norway rats were prepared from 
popliteal and mesenteric LN by gentle homogenization with a 5 ml syringe piston 
through a 70 µm nylon cell strainer. After washing and lysing the RBCs with 1-fold 
concentrated RBC lyse buffer for 5 minutes, the viable cells (cells that did not 
incorporate trypan blue) were counted in a Neubauer chamber. 
 
 
7.4  Depletion of CD25pos T cells from lymph node cell suspension 
 
The CellectionTM Pan Mouse IgG Kit was used for the depletion of CD25pos T cells 
from lymph node cell suspension. The depletion was performed following the 
manufacturer’s instructions using anti-CD25-antibody NDS61. Alternatively, 
CD4posCD25neg and CD4posCD25pos T cells were sorted using CD4 and CD25 
expression with a FACS DIVA sorter (Becton Dickinson).  
 
 
7.5       Cell yield evaluation 
 
Cultured cells were washed once and an aliquot volume mixed 1:10 in Trypan Blue 
solution. Trypan Blue negative cells were counted as viable under the microscope in 
a Neubauer chamber. 
 
 
 
7.6  Flow cytometric analysis 
 
7.6.1  Phenotyping 
 
Surface antigen expression by IL-4 DC was determined by two-colour flow cytometry. 
5x105 cells were suspended in in 50 µl PBS and incubated for 20 minutes at 4°C with 
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the optimal concentrations of specific fluorescein isothiocyanate (FITC) - or 
phycoerythrine (RPE) - conjugated antibodies (Table 6.2). The non-conjugated 
antibodies Ox-62, CD80 and CD86 were detected with the RPE-conjugated, affinity-
purified F(ab´)2 fragments of donkey anti-mouse IgG. The nonviable cells were 
identified with 7-amino actinomycin D (7-AAD). The non-specific binding was 
controlled with appropriate isotype-matched, non-reactive negative control 
antibodies. The samples were measured using an argon-laser flow-cytometer 
FACSscan. The analysis was performed with the FLOWJO program. 
 
 
7.6.2  Apoptosis assay 
 
After co-culture of S-DC or IL-4 DC with T lymphocytes for 72 hours, apoptosis of T 
cells was measured using the Annexin V Apoptosis Detection Kit I, and the cells were 
then analyzed on FACSscan. Staining with FITC Annexin V allows the detection of 
early apoptotic cells, relying on the property of cells to lose membrane asymmetry. 
Thereby, phosphatidylserine (PS) is translocated from the inner (cytoplasmic) leaflet 
of the plasma membrane to the outer (cell surface) leaflet. The Annexin V protein has 
a high affinity for PS which provides the basis for identifying apoptotic cells. 
 
 
7.6.3  Quantitation of antigen uptake by dendritic cells 
 
The capacity of day 6 or 7 IL-4 DC to take up antigen was tested using Dextran-
Alexa 488. 2x105 cells diluted with 200 µl PBS were incubated with 5 µl of Dextran-
Alexa 488 stock solution for 30 minutes in the dark at 37°C, or at 4°C for 
determination of background staining. The samples were measured using an argon-
laser flow-cytometer FACSscan. The analysis was performed with the FLOWJO 
program. 
 
 
7.7  Cytokine analysis by ELISA (enzyme-linked immunosorbent assay) 
 
Cytokines were measured in the supernatants of IL-4 DC replated on day 6 and in 
the supernatants of MLR, respectively. Rat IL-2, rat IFN-γ and rat IL-10 were 
measured following the instructions provided by the supplier. 
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7.8  Nitric Oxide (NO) assay 
 
For measurement of NO production by DC in general, cells were re-cultured at 5x105 
cells/150 µl in 96-well round-bottom plates in the presence or absence of LPS (1 
µg/ml). For measurement of NO production during 72 hour MLR, culture was set up 
as described under section 7.9 or 7.10.1. Cell-free culture supernatants were 
collected after 24 hours and the formation of stable oxidative end product of NO, 
inorganic nitride (NO2-), was assessed as a quantitative indicator of NO production 
by using Greiss reagent. Briefly, 100 µl of Greiss reagent were added to each well of 
a 96-well flat-bottom plate containing 100 µl of culture supernatant. After 10 minutes 
of incubation, absorbance was measured at 575 nm in a microplate reader. For each 
sample, a negative control was included, either without LPS or containing 250 µg/ml 
NMMA. The values were referred to a standard curve with defined sodium nitride 
concentrations (7.8-500 µM).  
 
 
7.9  Proliferation assay for naïve T cells 
 
The allo-stimulatory potential of IL-4 DC was evaluated in an allogenic mixed 
leukocyte reaction (MLR). Day 6 or 7 Lewis IL-4 DC (104 cells/well) or irradiated 
(20 Gy) Lewis S-DC as stimulators, and naïve T cells (105 cells/well) from lymph 
nodes of Wistar Furth or Brown Norway rats as responders were co-cultured in a 
round-bottomed 96-well plate in a total volume of 150 µl/well. After 72 hours at 37°C 
in a 5% humidified CO2 atmosphere, cells were pulsed with 0.5 µCi/well [
3H]-
thymidine for 6 hours. Control wells consisted of naïve T cells cultured alone. The 
cells were harvested with the MicroBeta Filtermat-96 cell and their DNA was 
collected on special filter paper. The filter paper was dried for 1 hour and then sealed 
in special plastic bags with liquid scintillation. The level of [3H]-thymidine 
incorporation was measured with a Wallac-MicroBeta TriLux β-radiation counter and 
the results were expressed as counts per minute (cpm). All experiments were set up 
in 6 replicates. 
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7.10  Inhibition assay 
 
7.10.1  IL-4 DC mediated inhibition of T cell proliferation assay 
 
With this assay the ability of IL-4 DC to inhibit T cell proliferation induced by S-DC 
was tested. 104 IL-4 DC from day 6 or 7 were added to the culture of 104 S-DC and 
105 T lymphocytes for 6 (the end of the culture), 24 or 72 (the starting point of the 
culture) hours. After 72 hours cells were pulsed with 0.5 µCi/well [3H]-thymidine for 6 
hours. Subsequently, after 72 hours, the cells were pulsed with [3H]-thymidine for 6 
hours. The incorporation of radioactivity was measured using a beta-radiation 
counter as previously described (section 7.9). 
 
 
7.10.2 T cell-mediated inhibition after incubation with immature IL-4 DC 
 
Possible regulatory or inhibitory properties of T cells, which were pre-incubated with 
IL-4 DC, on freshly isolated T cells in the proliferation assay were tested with this. 105 
T lymphocytes were incubated with 104 IL-4 DC for 72 hours. The CellectionTM Pan 
Mouse IgG Kit was used for depletion of IL-4 DC. The depletion was performed 
following the manufacturer’s instructions using anti-CD11c/b-antibody Ox-42 (Table 
6.2). After depletion of IL-4 DC, T cells were collected (purity > 90%) and transferred 
to the T cell proliferation assay (freshly isolated T cells and S-DC). The cells were 
cultured for 72 hours and pulsed with [3H]-thymidine for the last 6 hours of culture. 
The incorporation was measured as described before (section 7.9). 
 
 
7.11  Restimulation assay 
 
The ability of T cells, which were pre-incubated with IL-4 DC, to proliferate in the 
presence of mature splenic DC was tested. 105 T cells were incubated with 104 IL-4 
DC for 72 hours. Depletion of IL-4 DC with Ox-42 was performed as described before 
(see section 7.10.2). After depletion of IL-4 DC, T cells were collected (purity > 90%) 
and transferred to the T cell proliferation assay. 105 purified T cells, which were pre-
incubated with IL-4 DC, were incubated with freshly isolated 104 S-DC for 72 hours. 
After 72 hours, cells were pulsed with 0.5 µCi/well [3H]-thymidine for 6 hours. The 
incorporation of radioactivity was measured using a beta-radiation counter as 
previously described (section 7.9). 
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7.12  Reverse transcriptase-polymerase chain reaction (RT-PCR) 
 
Extraction of total mRNA from 1x106 cells was performed using ready-to-use Trizol 
reagent according to the manufacturer's instructions. After homogenization of cells 
with Trizol reagent, the cells were separated into an aqueous phase containing the 
RNA and an organic phase by adding chloroform followed by centrifugation 
(15 minutes, 16,000xg, at 4°C). The RNA, recovered from the aqueous phase, was 
precipitated with isopropanol overnight at -20°C. After centrifugation at 13,000 rpm 
for 10 minutes, the pellet was washed with ethanol, air-dried, dissolved in 40 µl RNA 
storage solution and stored at -80°C until use. The cDNA synthesis was performed 
by reverse transcription of 5 µl RNA with reverse-transcriptase (2.5 U/µl) and Oligo 
d(T)16 primer (2.5 µmol/L), using the GeneAmp RNA-PCR-Kit. Amplification of 5 µl 
cDNA was performed by using Gold AmpliTaq DNA-Polymerase (0.05 U/µl) and the 
specific primers (5 µmol/L each) (Table 6.4) mixed in nuclease free water to an end 
volume of 50 µl per sample. Ten µl of PCR product were mixed with 1.5 µl 
Blue/Orange 6x loading dye and transferred to an ethidium bromide loaded 2% 
agarose gel. The gel was run at 80 volt for 30 minutes. The separated PCR products 
were photographed in the gel with UV light illumination. The house-keeping gene 
Glycerinaldehyd-3-Phosphat-Dehydrogenase (GAPDH) was used as positive control. 
 
 
7.13  Real time PCR 
 
Real time PCR is a method used to quantitate differences in mRNA expression. All 
real time PCR reactions were performed in a 25 µl mixture containing 1 µL of sample 
cDNA, specific primers (Table 6.4) and 2-fold concentrated solution of the SYBR 
Green PCR Master Mix containing Ampli Taq Gold polymerase and dNTPs. The real 
time quantitation was performed using Opticon 2 Cycler. The reactions were run 
online at 95°C for 15 minutes, and 35 cycles [95°C 15 seconds, annealing 
(temperatures see Table 6.4) 30 seconds, 72°C 30 sec]. The housekeeping gene 
GAPDH and nuclease free water were used as positive controls. The threshold cycle 
(Ct) data was calculated using default threshold settings. The Ct is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold (for 
more details see appendix Figure 12.1). A melting curve was recorded to analyse 
product homogeneity. To assess the quality of PCR products by agarose gel, 10 µL 
of each PCR product were mixed with 1.5 µL Blue/Orange 6x loading dye and 
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transferred to a 2% agarose gel loaded with ethidium bromide. The gel was run at 
80 volt for 30 minutes. The separated PCR products were photographed in the gel 
with UV light illumination. The house-keeping gene GAPDH was used as positive 
control. 
 
 
7.14  Western Blotting 
 
For determination of iNOS or PD-L1 and PD-L2 protein expression 1.5x106 cells were 
resuspended in 10 µl M-PER® Mammalian Protein Extraction Reagent and 
ultrasonicated for 10 minutes. Then lysates were gently shacked at room 
temperature for 10 minutes and clarified by centrifugation at 20,442 x g at 4°C for 30 
minutes. Cell-free culture supernatants were collected. After a short spinning, 
addition of reduction mix and subsequent boiling at 99°C for 10 minutes, whole cell 
lysates were loaded and separated by electrophoresis in 10% SDS-polyacrylamide 
gels and transferred to a nitrocellulose transfer membrane. The membrane was 
blocked in 5% dry milk for 1 hour. Washes with 1xTBS buffer were performed 3 times 
for 10 minutes. Then the membrane was blotted with the corresponding antibody: 
rabbit anti-nitric oxide synthase II (iNOS) polyclonal antibody (1:10,000), anti-PD-L1 
(0.5 µg/ml), anti-PD-L2 (1 µg/ml), phospho-p44/42 MAPK (Erk1/2) antibody (1:1,000), 
p44/42 MAPK (Erk1/2) antibody (1:1,000) and monoclonal antibody to GAPDH 
(1:1,000) over night at 4°C in the dark. After washing, as described above, the 
membrane was incubated with a secondary, HRP-conjugated goat anti-rabbit IgG or 
HRP-conjugated rabbit anti-mouse IgG antibody at 1:10,000 for 1 hour at 4°C in the 
dark. After additional washings as mentioned above, the membrane was treated with 
ECL reagents according to the manufacturer’s instruction. The blotted bands were 
detected with X-Ray Medical Film. 
 
 
7.15  Signal transduction analysis 
 
To study the signal transduction pathway involved in PD-L1 and PD-L2 expression, 
day 6 IL-4 DC were plated on 6-well plates in 3 ml culture medium per well at a 
density of 1.5x106 cells with UO126 MEK1/2 inhibitor (10 µM or 50 µM) for 1, 24, 48 
and 72 hours. Incubation with DMSO (50 µM) for 72 hours served as a control. For 
the analysis of PD-L1 and PD-L2 expression after incubation with the UO126 
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MEK1/2 inhibitor at the indicated time points, the IL-4 DC were collected and 
prepared for western blot analysis (see section 7.14). 
 
 
7.16  Statistical analysis 
 
All data are expressed as mean ± standard error of the mean (S.E.M.) or ± standard 
deviation (S.D.). Differences among groups were determined by the Student t-test for 
paired data. Differences between groups were considered significant when P < 0.05.
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8 Results 
 
In the present study, a comprehensive characterization of immature rat DC called IL-
4 DC is described. The effect of GM-CSF plus IL-4 on the generation of IL-4 DC was 
analysed (section 8.1). An extensive phenotypic analysis of IL-4 DC was performed 
to confirm their maturation status and their endocytic activity (section 8.2). Since 
immature DC are known to be unable to stimulate T cells, the inhibitory effect of IL-4 
DC on the activation of naïve T cells in both proliferation and inhibition assays was 
investigated (section 8.3). In addition, the “origin” of the IL-4 DC-mediated inhibitory 
effect was determined. For this, different properties such as the secretion of soluble 
factor(s), the induction of T cell apoptosis and the expression of inhibitory molecules 
such as PD-L1 and PD-L2 were analysed (section 8.4). A further interesting property 
of IL-4 DC was analysed in section 8.5: the induction of regulatory T cells with an 
immune inhibitory effect. 
 
 
8.1 Generation of bone marrow-derived immature IL-4 DC 
 
8.1.2 Evaluation of growth conditions required for the generation of IL-4 DC 
 
One major part of this study was the characterization of IL-4 DC, a type of DC with 
tolerogenic properties (Tiurbe C et al., 2009). In order to explore the importance of 
such a DC population in immunomodulation, large numbers of these cells are 
required (Freudenthal PS and Steinman RM, 1990; O'Doherty U et al., 1993; 
O'Doherty U et al., 1994). In this study, the differentiation of unfractionated bone 
marrow precursor cells into IL-4 DC in the presence of granulocyte-macrophage 
colony stimulating factor (GM-CSF) and interleukine-4 (IL-4) was examined. Cells 
with high surface expression of Ox-62, an integrin-like molecule used as a marker for 
rat DC (Brenan M and Puklavec M, 1992), were considered as DC and in 
combination with low surface expression of MHC class II they were considered as 
immature rat DC.  
 
In order to optimise the culture conditions with an acceptable amount of cytokines 
and to generate high yields of an IL-4 DC population on day 6, culture conditions 
were tested under the influence of different cytokine combinations (Figure 8.1). 
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Femur bones of 8-10 week old male Lewis rats were removed and approximately 
1.2 x 108 to 1.5 x 108 bone marrow cells were flushed out from 2 femur bones. 
Freshly isolated bone marrow cells were transferred into 24-well plates with 1 ml 
culture medium per well. The cells were seeded at a density of 1x105 cells per ml and 
the GM-CSF concentrations ranged from 0.2 to 60 ng/ml. The effect of GM-CSF was 
tested either alone or in combination with diverse IL-4 concentrations ranging from 1 
to 20 ng/ml. Cell yield, formation of cell clusters and number of MHC class II-positive 
as well as Ox-62 positive cells were determined under different culture conditions on 
day 6 of cell culture (Figure 8.1; Table 8.1). 
 
Bone marrow cells did not proliferate when cultured without GM-CSF (Table 8.1), 
whereas under the influence of even low concentrations of GM-CSF the cells started 
to proliferate (Table 8.1), confirming the indispensability of GM-CSF for DC 
generation (Inaba K et al., 1992; Lu L et al., 1995; Masurier et al., 1999). With 
increasing GM-CSF concentrations the number of proliferating cells increased (Table 
8.1). Cell yield could be further increased by adding IL-4 to the cultures, however, 
high concentrations (20-60 ng/ml) of both cytokines resulted in decreasing cell yields 
(Table 8.1). 
 
It is well described that murine DC are continuously released from cell aggregates 
formed by growing bone marrow cells cultured in the presence of GM-CSF (Inaba K 
et al., 1992). As shown in Figure 8.1 rat bone marrow progenitor cells developed 
loosely adherent cell clusters only under the influence of IL-4 (5 ng/ml, indicated by 
arrows). Within these cell clusters proliferating rat immature IL-4 DC were found 
(Talmor et al., 1998). The combination of GM-CSF and IL-4 resulted, as mentioned 
above, in an increased cell yield (Table 8.1). This suggests an accessory role of IL-4 
for generation and proliferation of immature IL-4 DC. 
 
Flow cytometric analysis clearly confirmed the generation of immature IL-4 DC. More 
than 85% of the cells isolated on day 6 of culture expressed Ox-62 molecules on 
their cell surface regardless of which cytokine combination was used (Table 8.1). In 
addition, flow cytometric analysis also revealed the expression of MHC class II on 
Ox-62 positive DC. Thereby, the percentage of MHC class II positive cells decreased 
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with increasing GM-CSF and IL-4 levels. Under these conditions primarily DC with an 
immature phenotype were found (Table 8.1). 
 
 
Table 8.1: Combinations of different levels of GM-CSF and IL-4 strongly influence the yield of 
IL-4 DC, formation of IL-4 DC clusters and IL-4 DC phenotype during a 6-day culture period. 
Bone marrow cells were cultured with varying GM-CSF concentrations (0.2 to 60 ng/ml) either alone or 
in combination with varying IL-4 concentrations (1 to 20 ng/ml). Prior to cell harvesting on day 6, the 
cultures were optically analysed for cell cluster formation. Non-adherent single cells and loosely 
adherent cell clusters were dislodged and the cells were counted and analysed for their MHC class II 
and Ox-62 expression by flow cytometry. The cell yield (%) corresponds to the number of initially 
plated bone marrow cells (1x105 cells per well). Data are presented as means ± S.E.M. in four 
independent experiments. See also Figure 8.1. 
Cytokines  
(ng/ml) 
Cell yield  
(%) 
Cell cluster 
formation 
MHC class II 
expression (%) 
Ox-62 
expression (%) 
 
GM-CSF 
 
 
IL-4 
 
24-well plate  
0 0 no proliferation No 0 0 
0.2 0 61±8 No 87±3 96±2 
2 0 87±19 No 66±7 89±5 
5 0 132±19 No 65±5 87±5 
20 0 128±29 No 65±6 91±4 
60 0 103±15 No 66±5 93±3 
0 1 no proliferation No 0 0 
0.2 1 67±7 No 83±4 93±3 
2 1 139±18 No 50±5 93±3 
5 1 143±23 No 45±5 94±3 
20 1 136±28 No 45±5 93±4 
60 1 114±16 No 51±5 94±3 
0 5 no proliferation No 0 0 
0.2 5 97±14 No 65±10 97±1 
2 5 159±26 Yes 45±13 94±2 
5 5 193±35 Yes 38±14 95±2 
20 5 139±31 Yes 41±12 93±2 
60 5 133±29 Yes 43±13 94±2 
0 20 no proliferation No 0 0 
0.2 20 124±26 Yes 60±10 94±3 
2 20 159±32 Yes 43±7 95±1 
5 20 213±46 Yes 39±7 94±2 
20 20 124±21 Yes 39±7 91±4 
60 20 72±8 Yes 37±8 94±3 
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Figure 8.1: Combinations of different levels of GM-CSF and IL-4 strongly influence the yield of 
IL-4 DC and formation of IL-4 DC clusters during a 6-day culture period. Bone marrow cells were 
cultured with varying GM-CSF concentrations (0.2 to 60 ng/ml) either alone or in combination with 
varying IL-4 concentrations (1 to 20 ng/ml) on a 24-well plate at a density of 1x105 cells per well. On 
day 6 of culture cells were analysed for cluster formation by eye. One example of at least 3 different 
experiments is shown. See also Table 8.1 for more information.  
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Altogether, the results revealed that GM-CSF appears to be a key factor necessary 
for the induction of IL-4 DC proliferation and differentiation, whereas bone marrow 
progenitor cells cultured without GM-CSF did not proliferate. IL-4 seems to play an 
accessory role for the generation of cell clusters from which high numbers of 
proliferating IL-4 DC are released. With respect to the generation of high cell yield of 
immature IL-4 DC, addition of 5 ng/ml GM-CSF and 5 ng/ml IL-4 produced the best 
results at the end of the culture period with high cell yield of 193 ± 35% cells with 38 
± 14% MHCIIlow cells and 95 ± 2% Ox-62pos cells. Similar results were observed at a 
concentration of 5 ng/ml GM-CSF and 20 ng/ml IL-4 with a high cell yield of 213 ± 
46% cells (MHCIIlow: 39 ± 7%; Ox-62pos: 94 ± 2%). However, since one major aim of 
the present study was in keeping the amount of cytokines as low as possible, a 
cytokine combination of 5 ng/ml GM-CSF and 5 ng/ml IL-4 provided the best results 
and was chosen for further experiments. For high yield of IL-4 DC, bone marrow cells 
were cultured in petri dishes with a diameter of 100 mm at a cell density of 5x105 
cells/ml and the medium was supplemented with 5 ng/ml GM-CSF and 5 ng/ml IL-4. 
The phenotypic and functional characterization of the IL-4 DC is shown in the 
following sections. 
 
 
8.2 Characterization of the phenotype of immature IL-4 DC generated with
 5 ng/ml GM-CSF and 5 ng/ml IL-4 
 
8.2.1 Cluster formation and changes in cell size during the development of   
IL-4 DC from bone marrow progenitors 
 
Under the influence of 5 ng/ml GM-CSF and 5 ng/ml IL-4 bone marrow cells started 
to proliferate within 48 hours  indicated by an increase in cell size (Figure 8.2: right 
hand panel). Around day 2 to day 4 some of these enlarged cells were still floating 
and started to form cell clusters while others became adherent (Figure 8.2: left hand 
panel). In association with proliferation and cluster formation an increase in cell size 
and cell granularity could be seen. On day 2 the proportion of the cell population of 
interest was about 52.6% and increased up to 75.3% on day 4 (Figure 8.2: FACS 
diagrams, right hand panel). On day 6 of culture, the cells developed large clusters 
loosely attached to the plate which could easily be dislodged with a pipette. These 
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cells were identified as a homogenous cell population of IL-4 DC (Figure 8.2: day 6, 
79.1%) as indicated by a large Forward Scatter (FSC) and a low Side Scatter (SSC). 
 
 
  
 
 
    Day 1 
 
 
 
 
 
 
 
 
 
    Day 2 
 
 
 
 
 
 
 
 
 
    Day 4 
 
 
 
 
 
 
 
 
 
    Day 6 
 
 
 
 
 
 
 
Figure 8.2: Cluster formation and changes in cell granularity and cell size of immature IL-4 DC 
during a 6-day culture period. Between day 2 and day 4 bone marrow progenitors started to form 
growing cell aggregates. On day 6 most of the cells were developing in clusters. Outside the clusters, 
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cells were forming an adherent cell layer (left hand panel; magnification: x100 or x200, phase contrast 
microscopy. Images were captured using an Olympus digital camera C-5050 and processed with 
Microsoft Office Picture Manager). An increase in cell size and cell granularity could be seen as 
indicated by Forward Scatter (FSC) and Side Scatter (SSC) by using flow cytometry shown on the 
right hand panel. One representative example of three different experiments is shown. 
 
 
8.2.2 Phenotypic changes during the development of immature IL-4 DC from 
bone marrow progenitors 
 
The phenotype of IL-4 DC at different developmental stages during their generation 
from bone marrow precursor cells was characterized. An increase in cell size and cell 
granularity was observed and in addition, an up-regulation of the co-stimulatory 
molecules CD80, CD86 and CD40 as well as MHC class II and Ox-62 was measured 
over time (day 0 to day 6) by flow cytometry (Figure 8.3 and Table 8.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3: Changes in surface antigen expression during culture indicates the generation of 
immature IL-4 DC from bone marrow precursor cells. Fresh isolated bone marrow cells were 
seeded in culture dishes (100 mm ∅ ) and cells were collected at different time points (day 0, 2, 4 and 
6). They were analysed for different cell surface markers [Ox6 (MHC class II), Ox-62 (α-E2 integrin), 
CD80, CD86 and CD40] by flow cytometry. Over time (day 0-6), an increase in cell size and cell 
granularity as indicated by Forward Scatter (FSC) and Side Scatter (SSC) on the left hand panel could 
be seen in association with an up-regulation of cell surface antigens (solid histograms) mentioned 
above. Isotype control antibodies were used for background staining (dashed histograms). One 
representative example of at least 3 different experiments is shown (see also appendix Table 12.1). 
The values of mean fluorescence and percentage of positive cells are shown in Table 8.2. 
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The bone marrow cells were clearly negative for most of the investigated surface 
markers (Figure 8.3, Table 8.2). Nearly half (10.9%) of the investigated cell 
population on day 0 showed a low expression of CD40 molecule with a mean 
fluorescence value (MF) of 28.1 (Table 8.2). On day 2 the amount of proliferating 
cells increased to 52.6% of the total precursor cell population (Figure 8.3: left hand 
panel). The percentage of these cells expressing the surface molecules of interest 
increased (Table 8.2) as well as the number of these molecules (Table 8.2). 
 
 
Table 8.2: Changes in the expression of different surface molecules during culture indicates 
the generation of immature IL-4 DC from bone marrow precursor cells (see also Figure 8.3). 
Cells were collected at different developmental stages (day 0, 2, 4 and 6). Differences in the cell 
surface expression were quantified by mean fluorescence (MF) values of antibody binding. One 
representative example of at least 3 different experiments is shown (see also appendix Table 12.1). In 
addition, percentage of positive cells (P= Proportion) is shown.  
Antigen day 0 day 2 day 4 day 6 
 MF P (%) MF P (%) MF P (%) MF P (%) 
MHC II 1.39 1.34 11.1 10.3 43.3 40.7 119 84.6 
Ox-62 8.23 2.74 29.7 23.4 60.7 51.8 119 73.4 
CD80 5.89 12.0 11.6 12.8 53.9 48.6 114 70.7 
CD86 7.14 5.22 10.2 11.5 39.2 45.5 133 77.7 
CD40 28.1 10.9 68 10.7 190 37.5 172 61.9 
 
 
On day 4, after culture medium was changed and “fresh” cytokines were added on 
day 3 (see materials and methods), the investigated cell population constituted 
75.3% of the total precursor cell population and these proliferating cells expanded 
into immature IL-4 DC (Figure 8.3: left hand panel) with an increased expression of 
surface molecules (Table 8.2).  
 
On day 6 the flow cytometric analysis revealed the development of IL-4 DC 
constituting 79.1% of the total cell population (Figure 8.3: left hand panel). These 
cells were positive for the co-stimulatory molecules CD80, CD86, CD40 as well as 
MHC class II and Ox-62 indicated by elevated mean fluorescence (MF) values 
(Table 8.2).  
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Although the cell surface expression of these molecules on IL-4 DC increased during 
the 6 day culture, it should be considered that this expression was clearly reduced in 
comparison to the expression of these molecules on mature S-DC (see section 
8.2.3; Figure 8.4). The expression of surface molecules of both immature IL-4 DC 
and mature S-DC is shown in the following section 8.2.3. 
 
 
8.2.3  IL-4 DC demonstrate an immature phenotype: A comparison of the 
surface expression of different molecules by immature IL-4 DC and 
mature S-DC  
 
High expression of MHC class II and co-stimulatory molecules such as CD80, CD86, 
and CD40 characterizes mature DC and is needed for full T cell activation (Reis e 
Sousa C, 2004; McLellan AD et al., 1996). Other co-stimulatory molecules such as 
ICAM-1 have also been implicated in co-stimulatory signalling for T cell receptor-
initiated activation (Damle NK et al., 1992). In addition, CD45 molecule helps to 
regulate T cell proliferation and differentiation (Montoya M et al., 2006; Pricket TCR 
and Hart DN, 1990). CD25 molecule was found to be a clear distinguishing feature of 
DC maturity correlating with the ability these CD25 expressing mature DC to direct 
the immune response toward TH1 (Mnasria K et al., 2008; Pilon C et al., 2009).  
 
In the next set of experiments the “status of immaturity” of IL-4 DC on day 6 of culture 
was analysed in more detail by comparing their phenotype to that of mature S-DC. 
For this, IL-4 DC and S-DC were labelled with several antibodies recognizing 
different surface molecules and analysed by flow cytometry.  
 
Figure 8.4 compares the expression of Ox-62, ICAM-1, CD40, CD45, MHC class II, 
CD80, CD86, and CD25 by IL-4 DC and mature S-DC on day 6.  
 
Table 8.3 shows both the corresponding mean fluorescence (MF) values of antibody 
binding and the percentage of positive cells.  
 
Figure 8.5 shows that differences in the surface expression between IL-4 DC and S-
DC are statistically significant.
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Figure 8.4: Comparison of surface expression of different molecules by immature IL-4 DC and 
mature S-DC. IL-4 DC were cultured with 5 ng/ml GM-CSF and 5 ng/ml IL-4 and were collected on 
day 6 of culture. S-DC were isolated from spleen cells and collected on day 1 of culture (see materials 
and methods). Cells were analysed by flow cytometry for the following cell surface markers (solid 
histograms): Ox-62, MHC class II, CD80, CD86, CD40, ICAM-1, CD45 and CD25. Isotype control 
antibodies were used for background staining (dashed histograms). In comparison to S-DC, IL-4 DC 
demonstrated a clear reduced expression of most surface molecules analysed in this study. One 
representative example of at least 3 different experiments is shown (see also Figure 8.5). The values 
of mean fluorescence and percentage of positive cells are shown in Table 8.3. 
 
 
 
The flow cytometric analysis revealed both considerable surface expression of Ox-62 
and comparable amounts of Ox-62 positive cells for IL-4 DC and mature S-DC 
(Table 8.3). Most of the IL-4 DC (between 62% and 87%, Figure 8.4 and Table 8.3) 
showed a moderate expression of the following surface molecules: ICAM-1, CD45, 
MHC class II, CD80, CD86, and CD25 with mean fluorescence (MF) values between 
48 and 469 (Table 8.3). The lowest MF value was found for ICAM-1 surface 
Ox-62 ICAM-1 CD40 CD45
MHCII CD80 CD86 CD25
IL
-4
D
C
c
e
ll
n
u
m
b
e
r
S
-D
C
c
e
ll
n
u
m
b
e
r
Ox-62 ICAM-1 CD40 CD45
MHCII CD80 CD86 CD25
10
0
10
1
10
2
10
3 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
30
60
90
120
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
100 101 102 103 104
0
10
20
30
40
IL
-4
D
C
c
e
ll
n
u
m
b
e
r
S
-D
C
c
e
ll
n
u
m
b
e
r
8 Results 
 62
expression with a MF of 48.4 (Table 8.3). A small proportion of IL-4 DC (42.9%, 
Table 8.3) expressed CD40 at higher levels (MF: 200) on their surface (Table 8.3).  
 
However, the expression of all investigated molecules was significantly lower in 
comparison to mature S-DC (Figure 8.5 upper panel). The most striking difference 
was observed for MHC class II with a nearly 20-fold reduced expression on IL-4 DC 
(Table 8.3 and Figure 8.5), and the co-stimulatory molecules CD80, CD86 and 
ICAM-1. Their surface expression was reduced between 11- and 26-fold (Table 8.3 
and Figure 8.5). 
 
 
Table 8.3: Comparison of surface expression of different molecules by immature IL-4 DC and 
mature S-DC (see Figure 8.4). Differences in the cell surface expression were quantified by mean 
fluorescence (MF) values of antibody binding. In addition, percentage of positive cells (P= Proportion) 
is shown. One representative of at least 3 different experiments is shown (see also Figure 8.5). 
 Surface molecules 
 
Ox-62 ICAM-1 CD40 CD45 MHCII CD80 CD86 CD25 
 MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
MF P 
(%) 
IL-4  
DC 
469 87.4 48.4 61.9 200 42.9 152 65.7 130 82.7 121 71.0 156 84.9 149 72.2 
S-DC 608 95.8 532 99.8 520 93.5 592 95.2 2537 96.8 2295 99.5 4024 98.6 763 88.7 
Fold 
exp.*) 
1.2 1.1 10.9 1.6 2.6 2.1 3.8 1.0 19.5 1.2 18.9 1.4 25.7 1.2 5.1 1.2 
 *) Fold expression (S-DC over IL-4 DC) 
 
 
 
 
Figure 8.5 (see next page): Comparison of immature IL-4 DC and mature S-DC for the surface 
expression of Ox-62, ICAM-1, CD40, CD45, MHC class II, CD80, CD86 and CD25. IL-4 DC were 
collected at day 6 of culture and S-DC were freshly isolated and collected on day 1 of culture (see 
materials and methods). Cells were analysed for different cell surface markers as mentioned above by 
flow cytometry. The upper panel shows the intensity of expression (MF). In the lower panel the 
proportion of DC expressing the given antigens is shown. Immature IL-4 DC (grey bars) did 
demonstrate significantly reduced surface antigen expression of all antigens investigated in 
comparison to mature S-DC (black bars). The proportion of immature IL-4 DC expressing Ox-62, 
ICAM-1, CD40, MHC class II, CD80, CD86 and CD25 is significantly lower compared to mature S-DC. 
Data are presented as means ± S.E.M. in a minimum of five independent experiments. Statistical 
significance of antigen expression by immature IL-4 DC and mature S-DC is indicated using the paired 
Student t-test (n.s. = not significant). 
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In summary, flow cytometric analysis revealed that a cytokine combination of 5 ng/ml 
GM-CSF plus 5 ng/ml IL-4 promotes the differentiation of rat bone marrow progenitor 
cells into immature IL-4 DC. Their immature phenotype was characterized by 
significantly reduced levels of surface expression of MHC class II, the co-stimulatory 
molecules CD80, CD86, CD40 as well as ICAM-1, CD45 and CD25 compared to 
mature S-DC (Figure 8.5). Thereby, the most striking differences were observed for 
MHC class II, CD80, CD86, ICAM-1 and CD25 (Table 8.3). The increased 
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expression of these molecules on the cell surface of S-DC is typical for fully mature 
DC.  
 
The immature stage of IL-4 DC verified by flow cytometry was also confirmed by RT-
PCR analysis (section 8.2.4) and endocytosis assay (section 8.2.5). 
 
 
8.2.4 RT-PCR analysis revealed specific mRNA for MHC class II molecules, co-
stimulatory molecules, immune regulatory and suppressive cytokines 
and iNOS 
 
The analysis of the expression of different surface molecules by IL-4 DC and mature 
S-DC (Figure 8.4) was completed by the detection of specific mRNA for MHC class II 
molecules and the co-stimulatory molecules CD40, CD80 and CD86. As shown in 
Figure 8.6 specific mRNA for these molecules was proven, although IL-4 DC did not 
show a strong surface expression of these molecules in comparison to mature S-DC 
(see section 8.2.3). 
 
In addition, the expression of the immune regulatory cytokine interleukin-12 (IL-12) 
by IL-4 DC was also investigated on mRNA level. IL-12 plays an important role in 
inducing the development of particular TH cell subsets directing TH1 and TH2 
responses, respectively. As shown in Figure 8.6 IL-4 DC did not express mRNA 
specific for IL-12 in contrast to mature S-DC. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6: RT-PCR gene expression array of 
different molecules (MHC class II, CD40, CD80,
CD86, and IL-12 for IL-4 DC and S-DC. Both IL-4 
DC and mature S-DC expressed mRNA specific 
for co-stimulatory molecules CD40, CD80, CD86 
and MHC class II. IL-4 DC do not express IL-12 
molecules in comparison to mature S-DC. GAPDH 
was used as a control. The results shown are 
representative for at least four different 
experiments (see also appendix Table 12.6). 
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In addition, IL-4 DC were analysed for the presence of the immune inhibitory 
cytokines transforming growth factor-β (TGF-β) and interleukine-10 (IL-10) (Figure 
8.7). Both cytokines are potent inhibitors of T cell activation and demonstrate 
tolerizing effects on these cells. As shown in Figure 8.7 IL-4 DC expressed mRNA 
specific for TGF-β and IL-10. 
 
 
 
 
 
 
 
 
 
The enzyme nitric oxide synthase (iNOS) mediates the production of cytotoxic nitric 
oxide (NO), which is known to be involved in the killing of allogenic cells during 
destruction of organ grafts; known as transplant rejection. The presence of iNOS 
specific mRNA was proven (Figure 8.7). 
 
In addition to the qualitative analysis of gene expression by “traditional” PCR, the 
relative quantification of mRNA levels for the cell surface molecules CD80, CD86, 
CD40, and MHC class II, IL-12 and TGF-β was investigated using quantitative (“real 
time”) RT-PCR (Figure 8.8). Quantitative RT-PCR allows the detection of amplicons 
during the exponential phase of enzyme reaction, whereas traditional PCR detects 
PCR amplicons at the final phase of the PCR reaction (end-point analysis). 
Therefore, qualitative analysis of mRNA levels by “traditional” PCR is not as precise 
as relative quantitation by real time PCR in detecting differences in expression levels 
of certain mRNA. 
 
The relative quantification was done with the 2-∆∆Ct method (Livak KJ and Schmittgen 
TD, 2001); for details see appendix Table 12.7 and Figure 12.1. The results 
revealed that immature IL-4 DC demonstrate reduced levels of IL-12 and co-
stimulatory molecules CD80, CD86 and CD40. This is in accordance with the flow 
cytometric results (section 8.2.3).  
Figure 8.7: RT-PCR gene expres-
sion array of immune regulatory 
cytokines TGF-β and IL-10 and 
cytotoxic enzyme iNOS. Mature 
S-DC were used as controls. RT-
PCR analysis shows that both IL-4 
and mature S-DC do express TGF-
β, IL-10 and iNOS mRNA. The 
results shown are representative 
for at least three different 
experiments (see also appendix 
Table 12.5 and 12.6). 
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The following results are in contradiction to results revealed from flow cytometric 
analysis: the real time PCR quantification showed comparable levels of specific 
mRNA for MHC class II in mature S-DC and immature IL-4 DC (Figure 8.8 and 
appendix Table 12.7), whereas the surface expression was clearly reduced in IL-4 
DC (Figure 8.5).  
 
In addition, the real time PCR quantification demonstrated comparable levels of 
specific mRNA for TGF-β in immature IL-4 DC and mature S-DC (Figure 8.8 and 
appendix Table 12.7) which was not apparent from “traditional” PCR (Figure 8.7). 
However, expression of TGF-β specific mRNA does not necessarily imply TGF-β 
expression and secretion. The levels of secreted TGF-β by IL-4 DC and S-DC after a 
culture period of 24 hours is shown in section 8.4.2, Figure 8.19. 
 
  
 
 
 
 
 
 
 
 
 
 
8.2.5 Bone marrow-derived IL-4 DC demonstrate endocytic activity 
 
Another characteristic of immature DC is their ability to take-up antigens by a process 
called endocytosis (Quah BJC and O'Neill HC, 2005; Hotta C et al., 2006). 
Endocytosis is the process by which cells absorb molecules (such as proteins) from 
outside the cell by engulfing it with their cell membrane. In the next set of 
experiments the ability of IL-4 DC to take up antigens from outside was assessed 
using Alexa 488 conjugated Dextran. The incorporation of Dextran-Alexa 488 was 
tested by flow cytometry. Therefore, purified day 6 IL-4 DC or mature S-DC were 
incubated with Dextran-Alexa 488 for 30 min at 37°C. Incubation for 30 min at 4°C 
Figure 8.8: Real time RT-PCR quantification: 
the relative expression level of different 
target mRNA in immature IL-4 DC compared 
to mature S-DC. The relative expression level 
of certain mRNA (CD80, CD86, CD40 MHC 
class II, IL-12 and TGF-β) in immature IL-4 DC 
in comparison to mature S-DC is shown. With 
the exception of MHC class II and TGF-β
mRNA, IL-4 DC show reduced levels of m RNA 
for IL-12 and co-stimulatory molecules (CD80, 
CD86 and CD40) compared to mature S-DC.
GAPDH mRNA served as endogenous control. 
Data are presented as means ± S.D. of 3 
independent experiments (see also appendix 
Table 12.7 and Figure 12.1) 
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was used as negative control for determination of possible background staining. The 
uptake was calculated as the change in mean fluorescence (MF) between cell 
samples incubated at 37°C and 4°C. FACS analysis showed a clear up-take of 
Dextran-Alexa 488 by IL-4 DC compared to mature S-DC when mean of background 
staining is subtracted (Figure 8.9).  
 
The result of the endocytosis assay and the reduced expression of co-stimulatory 
molecules measured by flow cytometry confirm the immaturity of IL-4 DC. 
 
 
 
 
 
 
 
 
 
 
 
 
Altogether, the phenotypical characterization of IL-4 DC shows an immature 
phenotype for them. Their immaturity is confirmed by significantly reduced surface 
expression of molecules such as ICAM-1, CD40, CD45, MHC class II, CD80, CD86 
and CD25 compared to mature S-DC (Figure 8.5).  
 
This is in accordance with reduced expression levels of mRNA specific for CD80, 
CD86 and CD40 as shown by real time RT-PCR quantification (Figure 8.8). In 
addition, IL-4 DC do not express mRNA specific for IL-12 (Figure 8.6) and 
demonstrate endocytotic activity (Figure 8.9).  
 
The functional properties of these IL-4 DC are described in the following sections. 
 
 
Figure 8.9: Uptake of Dextran-
Alexa 488 by IL-4 DC versus S-
DC. IL-4 DC (open histogram, 
constant line) show increased Dex-
tran-Alexa 488 up-take compared to 
mature S-DC (closed histogram). 
The histogram shows IL-4 DC and 
mature S-DC uptake at 37°C versus 
uptake at 4°C (open histogram, 
dashed line). The results depict 
MF(37–4°C). The histogram shown 
here is representative for three dif-
ferent experiments (see also ap-
pendix Table 12.2). 
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8.3 Characterization of the IL-4 DC-mediated inhibition of T cell proliferation  
 
8.3.1 IL-4 DC are unable to activate naïve T cells  
 
The ability to activate T cells is a major feature of DC, and DC maturation increases 
this effect. Immature IL-4 DC and mature S-DC were compared for their capacity to 
induce the proliferation of naïve T cells as a sign of full T cell activation. To evaluate 
the possible stimulatory or suppressive capacity of IL-4 DC on naïve T cells, the 
mixed leukocyte culture (MLC) was used to estimate the strength of the direct 
pathway of allorecognition (see section 4.5.1.2). Thereby, strong elevated 
radioactive signals of [3H]-thymidine incorporation expressed in counts per minute 
(cpm), demonstrate a high rate of T cell proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immature IL-4 DC or mature S-DC from Lewis rats were co-cultured with naïve lymph 
node T cells isolated from Wistar Furth rats at a DC:T cell ratio of 1:10 (Figure 8.10 
A or see materials and methods). T cells cultured alone served as control. Figure 
A B 
0
10
20
30
40
50
60
T-Zellen + Milz-DC T-Zellen + BMDC T-Zellen WF
IL-4DC controlS-DC
T
T T
T
-Z
e
ll
P
ro
li
fe
ra
ti
o
n
(x
1
0
3
c
p
m
)
T
 c
e
ll
p
ro
lif
e
ra
tio
n
(x
1
0
3
cp
m
)Experimental setup 
Figure 8.10: IL-4 DC do not induce T cell 
proliferation. Naïve T cells co-cultured with 
mature S-DC showed a strong proliferation in 
contrast to T cells co-cultured with IL-4 DC. A: 
experimental setup: 104 stimulator cells (mature 
S-DC or IL-4 DC) were co-cultured with 105
responder cells (naïve T cells). Thereby, 
stimulator cells were isolated from either Lewis 
rats (B) or Wistar Furth rats (C) and responder 
cells were isolated from either Wistar Furth rats 
(B) or Lewis rats (C) to show independence of 
the rat strains used. T cells cultured alone were 
used as control. Data are presented as means ± 
S.D. of at least 3 independent experiments. 
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8.10 B shows that immature IL-4 DC did not stimulate naïve T cells in contrast to 
mature S-DC. In detail, the measured proliferation rates were 483 ± 284 cpm for IL-4 
DC and 49,620 ± 4,929 cpm for mature S-DC. The inability of IL-4 DC to activate 
naïve T cells was independent of the rat strain used for DC generation. The same 
result was observed when IL-4 DC and S-DC, isolated from Wistar Furth rats instead 
of Lewis rats, were co-cultured with naïve lymph node T cells isolated from Lewis rats 
instead of Wistar Furth rats (Figure 8.10 C). The measured proliferation rates were 
175 ± 56 cpm for IL-4 DC and 10,845 ± 1,367 cpm for mature S-DC. 
 
Immature IL-4 DC do not activate naïve T cells. The reason for this may be their 
inability to express levels of co-stimulatory molecules on their cell surface 
comparable to those of mature S-DC (see section 8.2). In consequence, they are 
unable to deliver optimal signals to naïve T cells necessary for their full activation 
(see section 4.2.3). 
 
 
8.3.2 IL-4 DC-mediated inhibition of T cell activation is associated with 
increased levels of TGF-β and reduced levels of IFN-γ and IL-2 
 
Mature DC activate naïve T cells and induce their development to certain T cell 
subsets. T cells of these subsets can be distinguished according to the cytokine 
profile produced by them (see section 4.3; Figure 4.4). As shown above, naïve T 
cells co-cultured with S-DC were fully activated and demonstrated proliferation. IL-4 
DC were unable to induce T cell proliferation. However, T cells co-cultured with IL-4 
DC that do not proliferate are not necessarily naïve T cells; they are different from 
naïve T cells. To investigate the possibility that immature IL-4 DC influence naïve T 
cells, their cytokine profile was analysed. Supernatants of T cells co-culture with S-
DC and IL-4 DC, respectively, were analysed for Interferon-γ (IFN-γ), interleukine-2 
(IL-2), TGF-β and IL-10 using ELISA assay. 
 
IL-2 is a cytokine produced by activated T cells and essential for their clonal 
expansion. IL-2 is important for T cells leaving the G1 phase and starting DNA 
synthesis. Therefore, IL-2 levels can be measured before T cells start to proliferate. 
IFN-γ is predominantly produced by TH1 (effector) cells which differentiate from naïve 
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T cells under the influence of IL-12. The immunomodulatory cytokines IL-10 and 
TGF-β inhibit the release of proinflammatory cytokines by innate immune cells. They 
are also produced by T cells with immunoregulatory properties, e.g. Treg cells. 
 
As shown in Figure 8.11, mature S-DC induced a strong differentiation of naïve T 
cells into TH1 cells. These T cells produced high levels of IFN-γ (917.3 ± 539.6 pg/ml) 
and IL-2 (228.3 ± 46.4 pg/ml). In contrast, naïve T cells cultured with immature IL-4 
DC showed a 23-fold reduced IFN-γ production (39.1 ± 6.4 pg/ml) and 2.5-fold 
reduced IL-2 levels (88.9 ± 23.1 pg/ml). These T cells demonstrated an enhanced 
production of TGF-β (225.8 ± 147.2 pg/ml) in comparison to T cells cultured with 
mature S-DC (78.7 ± 13.5 pg/ml). This indicates that naïve T cells differentiate under 
the influence of IL-4 DC into a type of T cell with possible regulatory functions1. Naïve 
T cells co-cultured with S-DC differentiated into T cells with effector functions, 
indicated by the secretion of IFN-γ. A secretion of IL-10 was not observed for T cells 
cultured with mature S-DC (37.6 ± 35.8) or immature IL-4 DC (38.4 ± 32.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.11: Naïve T cells co-cultured with IL-4 DC showed a TGF-β dominated cytokine profile. 
104 mature S-DC or 104 immature IL-4 DC were cultured with 105 naïve T cells for 3 days. The co-
culture with IL-4 DC did not influence the expression of IFN-γ by naïve T cells in contrast to T cells co-
cultured with S-DC. An IL-10 production was not observed for both T cells co-cultured with S-DC and 
IL-4 DC, respectively. Data are means ± S.D. of a minimum of 3 independent experiments. 
                                                 
1 Please note that IL-4 DC are able to produce TGF-β themselves (section 8.4.2, Figure 8.19). This observation 
is in accordance with results described by Morelli and colleagues (Morelli AE et al., 2001). 
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8.3.3 IL-4 DC-meditated inhibition of pre-activated T cell proliferation 
 
As shown in section 8.3.1, immature IL-4 DC were not able to induce the 
proliferation of naïve T cells. In the next set of experiments their capacity to further 
increase or inhibit the proliferation of activated T cells was analysed. Therefore, 
naïve T cells were incubated with JJ319 and R73 antibodies for 24 hours and these 
pre-activated T cells were cultured with immature IL-4 DC or mature S-DC. Pre-
activated T cells and non-preactivated T cells cultured without any stimulation served 
as controls. The T cell proliferation was evaluated after 72 hours. 
 
Figure 8.12 shows a significantly increased proliferation of pre-activated T cells 
compared to non-preactivated T cells (first two bars on the left side of Figure 8.12). 
The proliferation rates were 3,605 ± 632 cpm for pre-activated T cells and 444 ± 312 
cpm for non-preactivated T cells. Pre-activated T cells cultured with S-DC increased 
their proliferation up to 6-fold (20,990 ± 3,179 cpm). In contrast, pre-activated T cells 
co-cultured with IL-4 DC demonstrated with 1,480 ± 243 cpm a strongly reduced 
proliferation. This proliferation rate was significantly reduced in comparison to the 
proliferation rate of pre-activated T cells cultured without any stimulation (1,480 ± 243 
cpm versus 3,605 ± 632 cpm). This is a reduction in T cell proliferation of more than 
50%. Therefore, this result underlines that IL-4 DC are able to inhibit actively T cell 
proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.12: Activated T cells 
stopped proliferation during co-
culture with immature IL-4 DC.
Naïve T cells were pre-activated 
antigen-independent with the 
monoclonal antibodies R73 and JJ 
314 for 24 hours. Subsequently, 
these T cells were co-cultured with 
IL-4 DC and S-DC for 72 hours. S-
DC increased the proliferation of 
these pre-activated T cells, 
whereas IL-4 DC inhibited 
significantly the proliferation of 
pre-activated T cells. Untreated or 
pre-activated T cells cultured 
alone were used as controls. Data 
are means ± S.D. of three inde-
pendent experiments. Statistical 
significance is indicated using the 
paired Student t-test.  
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8.3.4 IL-4 DC-mediated inhibition of mature S-DC-induced T cell proliferation 
in co-cultures 
 
In the next set of experiments the inhibitory effect of immature IL-4 DC on T cell 
stimulation was analysed in more detail. Previous experiments showed (section 
8.3.3) that immature IL-4 DC have a suppressive effect on the proliferation of pre-
activated T cells (Figure 8.12). Here, the effect of IL-4 DC on inhibiting S-DC induced 
T cell proliferation was analysed. Since S-DC and IL-4 DC were co-cultured with 
naïve T cells, it was investigated whether IL-4 DC were able to compete with the 
stimulatory effect of mature S-DC. Different numbers of competitor IL-4 DC (103, 104 
or 105) were transferred to the proliferation assay consisting of a constant number of 
stimulator cells (104 mature S-DC) and a constant number of responder cells (105 
allogenic T cells) (Figure 8.13 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.13: Immature IL-4 DC inhibit the proliferation of naïve T cells induced by mature S-DC 
in co-cultures. A: experimental setup: Different numbers of competitor cells (103, 104 and 105 
immature IL-4 DC) were added to the assay containing 104 stimulator cells (mature S-DC) and 105 
naïve T cells. B: results: Immature IL-4 DC demonstrated a suppressive effect on mature S-DC 
induced T cell proliferation dependent on their cell number. The results observed in the competition 
assay at a ratio of 1:1 correlated with the IL-2 and IFN-γ production by naïve T cells. Allogenic T cells 
co-cultured with mature S-DC and immature IL-4 DC produced significantly lower amounts of IL-2 (C) 
and IFN-γ (D) compared to the proliferation assay without the addition of immature IL-4 DC. Data are 
presented as means ± S.D. of 3 independent experiments. The values are shown in Table 6.3. 
Statistical significance is indicated using the paired Student t-test (n.s. = not significant). 
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As shown in Figure 8.13 B, immature IL-4 DC in co-cultures with S-DC demonstrated 
a suppressive effect on S-DC induced T cell proliferation in a dose-dependent 
manner. The activation of naïve T cells in the presence of S-DC was measured as T 
cell proliferation and was 15,994 ± 1,857 cpm (Table 8.4). This proliferation was 
significantly reduced when 103, 104 or 105 immature IL-4 DC were added to the 
proliferation assay (Figure 8.13 B). Already a cell ratio of competitor to stimulator cell 
of 1:10 suppressed mature S-DC induced T cell proliferation about 5.3-fold. The most 
potent effect was observed with a competitor : stimulator cell ratio of 1:1 and 10:1 
(Figure 8.13 B and Table 8.4). 
 
In addition to measuring T cell proliferation, the cytokine profile was determined. For 
this, supernatants of the competition assays were analysed for IL-2 and IFN-γ 
secretion using ELISA assay (Figure 8.13 C and D). As shown in Figure 8.13 C and 
Table 8.4 naïve T cells co-cultured only with mature S-DC produced high levels of IL-
2 (206.2 ± 2.52 pg/ml) and IFN-γ (387.4 ± 11.78 pg/ml), whereas the addition of 
immature IL-4 DC to the proliferation assay reduced both IL-2 production (111.6 ± 
1.01 pg/ml) and IFN-γ production (31.9 ± 0.39 pg/ml). The reduction was about 49% 
and 92%, respectively, in comparison to the S-DC induced T cell proliferation. 
 
Taken together these results show that IL-4 DC suppress the S-DC induced T cell 
proliferation as well as IL-2 and IFN-γ production. This inhibition might be due to IL-4 
DC produced TGF-β (see section 8.4.2, Figure 8.19). The immunomodulatory 
cytokine TGF-β has been shown to suppress T cell receptor (TCR)-induced 
proliferation of effector T cells by inhibiting IL-2 production (Das L and Levine AD, 
2008). In addition, TGF-β has also been shown to inhibit the ability of mature DC to 
stimulate IFN-γ secretion by T cells (Kobie JJ et al., 2003). 
 
 
 
Table 8.4 (see next page) Immature IL-4 DC inhibit the proliferation of naïve T cells induced by 
mature S-DC. Different numbers of IL-4 DC ranging from 103 - 105 were added to the proliferation 
assay (104 S-DC and 105 naïve T cells). IL-4 DC inhibited the mature S-DC induced T cell proliferation 
in a dose-dependent manner. The strongest inhibition of T cell proliferation was found at a ratio 1:1 of 
stimulator cells (mature S-DC) and competitor cells (IL-4 DC) (results of T cell proliferation in cpm). 
The results observed in the competition assay at a ratio of 1:1 correlate with the production of IL-2 and 
IFN-γ (results of produced IL-2 and IFN-γ in pg/ml). The IL-2 and IFN-γ production of allogenic T cells 
in the presence of mature S-DC was significantly higher compared to the culture in which 104 IL-4 DC 
were added to 104 mature S-DC. Data are presented as means ± S.D. of 3 independent experiments. 
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 Number of IL-4 DC 103 104 105 ∅ 
 
Ratio IL-4 DC : S-DC 1:10 1:1 10:1 S-DC alone 
 
T cell proliferation (cpm) 2,971 ± 875 870 ± 240 702 ± 143 15,994 ± 1,857 
 
IL-2 (pg/ml) ---- 111.6 ± 1.0 ---- 206.2 ± 2.5 
 
IFN-γ (pg/ml) ---- 31.9 ± 0.4 ---- 387.4 ± 11.8 
(∅) = no IL-4 DC were present in the proliferation assays 
 
 
 
 
8.3.5 T cell proliferation stopped in the presence of IL-4 DC within 24 hours 
 
As described in section 8.3.4, the presence of immature IL-4 DC mediates a 
suppressive effect on the S-DC induced T cell proliferation. In order to determine the 
speed of IL-4 DC mediated suppression in more detail, they were added to the 
proliferation assays at different time points (Figure 8.14 and Table 8.5). Ten 
thousand immature IL-4 DC were added to the proliferation assay (consisting of 104 
S-DC and 105 naïve T cells) on day 0 (culture starting point), day 2 (24 hours before 
the end of culture), and day 3 (6 hours before the end of culture). Finally, the 
incorporated radioactivity was measured at the end of culture on day 3 (after 72 
hours) (Figure 8.14 A).  
 
 
 
 
Figure 8.14 (see next page): Immature IL-4 DC inhibit mature S-DC-induced T cell proliferation 
within 24 hours. A: Experimental setup: 1) T cell proliferation assay: 104 stimulator cells (mature S-
DC) were co-cultured with 105 responder cells (T cells). The cells were pulsed on day 1, day 2 and 3 
of the culture 2) Inhibition assay: 104 IL-4 DC were added to the proliferation assay (104 S-DC and 105 
naïve T cells) on day 0, day 2 and day 3 of the culture. The cells were pulsed on day 3 as described in 
"Materials and Methods". B: Results: The addition of immature IL-4 DC to the proliferation assay on 
day 0 and 2 (white and light grey bar) suppressed the increase of T cell proliferation observed in the 
uninfluenced T cell proliferation assay (black bars). Addition of immature IL-4 DC on day 3, 6 hours 
before the end of the culture, had no effect on T cell proliferation (dark gray bar Data are presented as 
means ± S.D. of 3 independent experiments. Statistical significance is indicated using the paired 
Student t-test (n.s. = not significant). The values are shown in Table 8.5.  
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In the T cell proliferation assay, the strongest increase in T cell proliferation occurred 
between day 2 and 3 of the 3-day culture. On day 1: 10,472 ± 2,534 cpm, day 2: 
17,367 ± 5,610 cpm and day 3: 27,369 ± 5,678 cpm (Table 8.5).  
 
As shown in Figure 8.14 B, the addition of immature IL-4 DC on day 2 of culture 
suppressed the strong increase in T cell proliferation between day 2 and day 3. The 
measured T cell proliferation was reduced 4-fold: 7,740 ± 467 cpm. The strongest 
inhibition of T cell proliferation (8-fold) was seen when immature IL-4 DC were added 
at the beginning of culture or, with other words, 72 hours before the end of culture. 
The addition of immature IL-4 DC 6 hours before the end of culture on day 3 had no 
effect on T cell proliferation (Figure 8.14 and Table 8.5).  
 
Altogether, the results show that immature IL-4 DC suppress the increase of T cell 
proliferation between day 2 and day 3 of the 3-day culture. The suppressive effect of 
IL-4 DC on mature S-DC induced T cell proliferation is obvious within 24 hours. The 
strength of IL-4 DC mediated suppression is dose-dependent, meaning that the 
amount of IL-4 DC added to the cultures determines the level of S-DC induced T cell 
proliferation. T cell proliferation was already strongly inhibited with low numbers 
(1x103) of immature IL-4 DC (Figure 8.13 B). 
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Table 8.5: Immature IL-4 DC inhibit mature S-DC-induced T cell proliferation within 24 hours. A: 
The proliferation rates at different time points in the T cell proliferation assay are shown. B: The effect 
of the addition of 104 immature IL-4 DC on T cell proliferation was tested in an inhibition assay. 
Immature IL-4 DC were added to the cultures on day 0 (the starting point of culture), day 2 (24 hours 
before the end of the culture) and on day 3 (6 hours before the end of culture). Subsequently, the cells 
were pulsed with [3H]-thymidine on day 3. The addition of immature IL-4 DC to the proliferation assay 
on day 0 and day 2 of the 3-day culture prevented the marked increase in the T cell proliferation that 
had been induced by mature S-DC between day 2 and day 3. Addition of immature IL-4 DC on day 3, 
6 hours before the end of culture, had no significant effect on T cell proliferation. The results (mean ± 
S.D.) of T cell proliferation in cpm of 3 different experiments. 
 
(A) Proliferation assay 
Day of pulsing 1 2 3 
 10,472 ± 2,354 17,367 ± 5,610 27,369 ± 5,678 
(B) Inhibition assay 
Day of addition of IL-4 
DC (pulsing on day 3) 
0 2 3 
 3,349 ± 526 7,740 ± 467 26,620 ± 5,471 
 
 
8.3.6 IL-4 DC are phenotypically and functionally resistant to maturation 
induced by TNF-α, LPS and CD40L 
 
One prerequisite for the clinical application of tolerogenic immature DC, for example 
after organ transplantation, is that therapeutic DC should be extensively resistant to 
different maturation stimuli. How IL-4 DC mature in vitro and acquire full DC function 
in the presence of different maturation stimuli such as replating, LPS, TNF-α and 
CD40L was investigated. 
 
IL-4 DC isolated from day 6 culture were transferred to 6-well plates and cultured in 
medium supplemented with GM-CSF (2.5 ng/ml) until day 8. On day 8 non-adherent 
cells were transferred onto new 6-well plates and stimulated with TNF-α (20 ng/ml), 
LPS (1 µg/ml) or CD40L (1 µg/ml). The cells were collected at different time points 
(day 6, day 8 and day 10) and analysed by flow cytometry. Figure 8.15 shows one 
representative flow cytometric analysis comparing the expression of different surface 
molecules on days 6, 8 and 10. Table 8.6 shows the corresponding MF values of 
antibody binding and the percentage of positive cells. Figure 8.16 shows the 
statistical significance of three independent experiments comparing the results of day 
6, day 8 and day 10 of culture. 
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Figure 8.15: Marginal phenotypic changes of immature IL-4 DC in response to maturation 
stimuli. Immature IL-4 DC were generated from a 6-day culture. The cells were replated on 6-well 
plates in 3 ml medium per well at a density of 5x105/ml supplemented with GM-CSF only (2.5 ng/ml). 
On day 8 cells were replated on new 6-well plates in 3 ml fresh medium per well at a density of 
5x105/ml supplemented with 20 ng/ml TNF-α, 1 µg/ml LPS or 1 µg/ml CD40L until day 10. Immature 
IL-4 DC were collected at different maturation stages (day 6, 8 and 10) and were analysed for different 
cell surface markers by flow cytometry. One representative example of three different experiments for 
LPS stimulation is shown (see also appendix Table 12.4). The values of mean fluorescence and 
percentage of positive cells are shown in Table 8.6. 
 
 
Table 8.6: Analysis of phenotypic changes of immature IL-4 DC in response to maturation 
stimulis (see Figure 8.15). Cells were collected on day 6, day 8 and day 10 of culture and analysed 
by flow cytometry.  Differences in the cell surface expression were quantified by mean fluorescence 
(MF) values of antibody binding. In addition, percentage of positive cells (P=Proportion) is shown. One 
representative example for LPS stimulation of at least 3 different experiments is shown. 
 Surface molecules 
 MHCII CD80 CD86 CD40 ICAM-1 
 MF P (%) MF P (%) MF P (%) MF P (%) MF P (%) 
Day 6 134 51.6 37.2 51.7 181 82.9 53 38.5 39.8 82.9 
Day 8*) 173 59.6 88 87.3 216 95.4 73.3 48.2 69.9 93 
Day 10 + LPS**) 295 63.9 139 77.8 228 92.4 207 62.9 104 75.4 
 
*) Day 8: replated on day 6 + GM-CSF; **) Day 10: replated on day 8 + LPS 
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In general, replating of IL-4 DC and subsequent addition of cytokines resulted in a 
slight up-regulation of the co-stimulatory molecules CD80, CD86 and CD40 as well 
as MHC class II and ICAM-1 on the surface of immature IL-4 DC (Figure 8.15, Table 
8.6 and Figure 8.16).  
 
Only the surface expression of ICAM-1 was significantly increased on IL-4 DC on day 
8 after replating them on day 6 and day 10 in the presence of TNF-α: MF of day 6: 
25.5 ± 10.1; MF of day 8: 58.7 ± 4.4; MF of day 10: 259.7 ± 45.9 (Figure 8.16). The 
same result was observed for the amount of cells expressing these molecules. The 
increase of positive cells was statistically insignificant (Figure 8.16). Only the amount 
of IL-4 DC expressing CD40 after exposure to LPS between days 8 and 10 was 
significantly increased: day 8: 39.2 ± 8.8%; day 10: 71.8 ± 4.9%. 
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C Figure 8.17: IL-4 DC exposed to TNF-α, LPS 
or CD40L were unable to induce T cell 
proliferation. Immature IL-4 DC isolated from a 
6-day culture were transferred to six-well plates 
in 3 ml medium per well at a density of 5x105
cells/ml supplemented with GM-CSF only (2.5 
ng/ml). On day 8, IL-4 DC were replated to new
six-well plates and cultured in 3 ml fresh medium 
per well at a density of 5x105 cells/ml supple-
mented with 20 ng/ml TNFα (A), 1 µg/ml LPS (B) 
or 1 µg/ml CD40L (C). IL-4 DC were cultured 
until day 10. At different days of culture (day 6, 8 
and 10) IL-4 DC were collected to perform a T 
cell proliferation assay with 104 IL-4 DC co-
cultured with 105 naïve T cells. 104 mature S-DC 
co-cultured with 105 naïve T cells served as a 
control. Data are presented as means ± S.D. of 3 
independent experiments. 
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The effect of different maturation stimuli on IL-4 DC maturation was measured as 
phenotypic changes by flow cytometry and as functional changes in the T cell 
proliferation assay. For this, IL-4 DC incubated with different maturation stimuli were 
isolated at different time points and tested in T cell proliferation assay to proof their 
ability to stimulate naïve T cells. Figure 8.17 shows that the stimulatory capacity of 
IL-4 DC was not increased after replating them on day 6, as well as after exposure to 
TNF-α, LPS and CD40L (Figure 8.16). 
 
It is generally accepted that DC maturation is induced by exposing them to different 
maturation stimuli, e.g. TNF-α, LPS and CD40L. In this study it was shown that 
immature IL-4 DC were resistant to maturation stimuli tested in this work, shown by 
their failure to up-regulate the co-stimulatory molecules CD80, CD86 and CD40 as 
well as MHC class II and ICAM-1. This maturation resistance has no effect on the 
inability of IL-4 DC to activate naïve T cells.  
 
 
8.4 Why IL-4 DC inhibit T cell proliferation so fast? Some experiments for 
explanation  
 
As shown in section 8.3.5 immature IL-4 DC inhibit T cell proliferation within 24 
hours (Figure 8.14). The reason for this strong effect is unclear. Therefore, in the 
next set of experiments the “origin” of this inhibitory effect was analysed on cellular 
and molecular levels in more detail. For this, immature IL-4 DC were characterized 
for possible regulatory properties such as the secretion of a soluble factor, the 
induction of T cell apoptosis and anergy and the expression of inhibitory molecules 
such as PD-L1 and PD-L2. 
 
 
8.4.1 Supernatant of IL-4 DC cultures inhibits S-DC-induced T cell proliferation 
 
Several mechanisms of suppression have been described so far, such as the 
secretion of TGF-β and TNF (Angulo I et al., 2000; Meisel R et al., 2004; Terabe M et 
al., 2003). Another candidate known for inhibiting T cell proliferation is nitric oxide or 
NO (Mazzoni A et al., 2002). To investigate the presence of a possible soluble factor 
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secreted by IL-4 DC and its effect on T cell proliferation, different volumes (25 µl, 50 
µl and 100 µl) of supernatant from cultures with immature IL-4 DC were added to the 
T cell proliferation assay (104 mature S-DC and 105 T cells). For these experiments, 
IL-4 DC isolated on day 6, were cultured for further 24 hours with a cell density of 106 
IL-4 DC in 150 µl culture medium. The supernatant of 24-hour cultured 106 mature S-
DC or T cells served as a control. The final volume was kept constant at 150 µl per 
well and the cells were pulsed with [3H]-thymidine on day 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.18: Supernatant from IL-4 DC cultures inhibits T cell proliferation in a dose-dependent 
manner. The supernatant of immature IL-4 DC had a suppressive effect on mature S-DC-induced T 
cell proliferation. Purified immature IL-4 DC from day 6 of culture were transferred to 96-well culture 
plates (106 cells/well). 24 hours later the supernatant was collected and transferred in different 
volumes (25 µl, 50 µl, and 100 µl) to the proliferation assay (105 naïve T cells cultured with 104 mature 
S-DC). The final volume was kept constant at 150 µl/well. The supernatant of mature S-DC or T cells 
served as a control (white bars). Data are presented as means ± S.D. of 3 independent experiments. 
Statistical significance is indicated using the paired Student t-test (n.s. = not significant). 
 
 
As shown in Figure 8.18 and Table 8.7, the supernatant from 106 IL-4 DC transferred 
to T cell proliferation assays was able to inhibit mature S-DC induced T cell 
proliferation in a dose-dependent manner. Interestingly, supernatant from cultures 
with only 104 IL-4 DC (instead of 106 cells) showed no suppressive effect (Table 
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12.10 appendix). The same effect was observed, when only 25 µl supernatant from 
106 IL-4 DC cultures were tested. In contrast, 50 µl supernatant reduced mature S-
DC induced T cell proliferation about 79%: from 21,341 ± 3,778 cpm for uninfluenced 
T cell proliferation to 4,456 ± 875 cpm for IL-4 DC supernatant influenced T cell 
proliferation (Table 8.7). The suppressive effect of IL-4 DC supernatant increased 
with the volume transferred. With 100 µl supernatant the T cell proliferation was 
reduced by more than 90%: from 21,341 ± 3,778 cpm for uninfluenced T cell 
proliferation to 1,962 ± 182 cpm for IL-4 supernatant influenced T cell proliferation 
(Table 8.7).  
 
One hundred µl supernatant from 106 cultured mature S-DC suppressed T cell 
proliferation, also (Figure 8.18), but the inhibitory effect of this S-DC supernatant was 
5-fold lower compared to that of IL-4-DC (Table 8.7). From these results it is possible 
to conclude the existence of a soluble factor or soluble factors responsible for the 
inhibitory effect of immature IL-4 DC on mature DC induced T cell proliferation. 
 
 
Table 8.7: Supernatant from IL-4 DC cultures inhibits T cell proliferation. The strength of 
suppressed T cell proliferation increased with increasing volume of transferred supernatant. The 
supernatant of mature S-DC or naïve T cells served as a control to exclude possible negative effects 
of day 2 supernatant. Data are presented as means ± S.D. of 3 independent experiments. 
 Volume of supernatant (µl) *) 
 25 50 100 0 
 IL-4 DC  12,586 ± 2,783**) 4,456 ± 875 1,962 ± 182 
21,341 ± 3,778  S-DC  16,387 ± 3,182 15,972 ± 3,335 10,733 ± 1770 
 T cells  17,255 ± 3,957 14,238 ± 2,910 10,625 ± 2,737 
 
*) The final volume was kept constant at 150 µl per well. 
**) Results (mean ± S.D.) of T cell proliferation in cpm. 
 
 
 
8.4.2 IL-4 DC secrete TGF-β, not IL-10 and NO 
 
Since the supernatant of 106 immature IL-4 DC inhibits the mature S-DC-induced 
activation of T cell proliferation, the presence of a soluble inhibitory factor was 
assumed. The immune inhibitory cytokines TGF-β and IL-10, as well as the cell toxic 
effector molecule nitric oxide (NO) have been implicated in the inhibition of T cell 
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Figure 8.19: IL-4 DC produce more 
TGF-β than mature S-DC. Immature 
IL-4 DC from day 6 of culture and 
purified mature S-DC were transferred 
to 96-well culture plates (106
cells/well). After 24 and 48 hours of 
culture, the supernatant was collected
and measured with specific ELISA.
Data are presented as means ± S.D.
of 3 independent experiments.
Statistical significance is indicated 
using the paired Student t-test.  
 
 
 
proliferation (Ding L and Shevach EM, 1992; Lu L et al., 1996; Bonham CA et al., 
1996; Zeller JC et al., 1999). Therefore, the presence of TGF-β, IL-10 and NO was 
investigated in the supernatant of 106 immature IL-4 DC in comparison to 106 mature 
S-DC. For these experiments, the DC were cultured for 24 and 48 hours. In contrast 
to IL-10 and NO (appendix Table 12.9), TGF-β was detected in the supernatant of 
106 immature IL-4 DC (Figure 8.19). This amount of TGF-β (24 hours: 346.77 ± 
103.05 pg/ml; 48 hours: 2,792 ± 1,292 pg/ml) was significantly increased compared 
to TGF-β in the supernatant of mature S-DC (24 hours: 105.77 ± 55.57 pg/ml; 48 
hours: 93.6 ± 38.07 pg/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altogether IL-10 and NO do not contribute to the inhibitory effect of supernatant from 
IL-4 DC cultures. TGF-β appears to be a promising candidate responsible for the IL-4 
DC mediated inhibition of T cell proliferation. This assumption can be proven with a 
TGF-β neutralising antibody. Such an antibody added to T cell proliferation assay 
neutralises the effect of TGF-β transferred with the supernatant. However, 
unfortunately, a rat TGF-β neutralising antibody is not available yet. Preleminary 
experiments, testing neutralizing monoclonal anti-TGF-β1, -β2, -β3 antibody (specific 
for bovine, mouse and human TGF-β1 and TGF-β2; R&D Systems), showed no 
effect on T cell proliferation (data not shown). At the moment it is not clear whether 
and how strong TGF-β contributes to the suppressive effect of IL-4 DC supernatant 
on mature S-DC induced T cell proliferation.  
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8.4.3 TGF-β, not IL-10, is detectable in competition assays with IL-4 DC 
 
In section 8.4.1 it was shown that the supernatant of 106 immature IL-4 DC inhibited 
the mature S-DC induced T cell proliferation and TGF-β, but not IL-10, was detected 
in these supernatant (section 8.4.2). In this section the presence of TGF-β was 
analysed in competition assays. The reason for this is, that the number of IL-4 DC 
added to the T cell proliferation assay ranged from 103 to 105 IL-4 DC and it is not 
clear whether the amount of TGF-β produced by these cell numbers is really effective 
to inhibit mature S-DC induced T cell proliferation (see section 8.3.4, Figure 8.13 B). 
Therefore, the possible presence of TGF-β and IL-10 was investigated in the 
supernatant of competition assays. In Table 8.8 the competition assay consists of 
104 S-DC and 105 naïve T cells and a constant number of IL-4 DC. 
 
 
Table 8.8: Detection of TGF-β in competition assays in the presence of IL-4 DC. 104 competitor 
cells (immature IL-4 DC) were added to the proliferation assay containing 104 stimulator cells (= 
mature S-DC) and 105 naïve T cells. The T cell proliferation assay is called competition assay when IL-
4 DC are present. The idea is that IL-4 DC compete with S-DC for the contact with T cells. T cells 
cultured alone served as a control. The detection of IL-10 served as a control. The supernatant was 
collected after 72 hours. Three different experiments are shown (each experiment in duplicate wells).  
 
  
Control 
 
Competition assay 
 
Experiment 
 
TGF-β (pg/ml) 
#1  73.2 ± 2.91  89.6 ± 6.65 
#2  82.0 ± 0.00  360.2 ± 0.04 
#3  56.6 ± 0.02  96.7 ± 0.11 
  
IL-10 (pg/ml) 
#1  3. 6 ± 0.13  4.8 ± 0.02 
#2  0.01 ± 0.01  0.02 ± 0.01 
#3          0          0 
 
 
Table 8.8 shows the results of 3 different experiments. It is possible to detect levels 
of TGF-β in the supernatant of the competition assay compared to supernatant of 
control T cells. The levels of TGF-β increased 4-fold in experiment #2. However, the 
other two experiments showed only a slight increase in TGF-β levels. These 
experiments do not show beyond a doubt that TGF-β contributes to the direct 
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inhibitory effect of IL-4 DC on mature S-DC induced T cell proliferation. Therefore, as 
mentioned in section 8.4.2, the effect of a TGF-β neutralising antibody, which is not 
available yet, needs to be tested.  
 
 
8.4.4 LPS-stimulated IL-4 DC secrete NO 
 
In section 8.4.2 it is described that untreated IL-4 DC did not synthesize cell toxic 
NO. In section 8.3.6 it is also shown that immature IL-4 DC did not mature in the 
presence of LPS, since LPS treated IL-4 DC did not show an increased expression of 
co-stimulatory molecules on their surface and they did not activate naïve T cells 
(Figures 8.15 - 8.17). However, to date it cannot be shown that LPS induced the 
secretion of different effector molecules by IL-4 DC. For cytotoxic NO it was shown 
that immature BM-DC can produce NO in response to LPS and/or IFN-γ (Lu L et al., 
1996). 
 
Therefore, in a next set of experiments it was examined whether LPS-treated IL-4 DC 
can be stimulated to synthesise inducible nitric oxide synthase (iNOS) necessary for 
the production of large amounts of NO. Therefore, 106 IL-4 DC or 106 mature S-DC 
were exposed to LPS (1 µg/ml) for 24 hours. NO production was measured as the 
accumulation of its stable end product NO2
-.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.20: LPS-stimulated IL-4 
DC synthesise iNOS and produce 
large amounts of NO. 106 immature 
IL-4 DC (harvested on day 6) and 106
mature S-DC were cultured with LPS 
with or without NMMA or with medium 
alone for 24 hours. The NO release 
was measured as the accumulation of 
the stable end product NO2
- (see 
methods and materials). Both 
immature IL-4 DC and mature S-DC 
can be stimulated to secrete NO. 
Data are presented as means ± S.D.
of 3 independent experiments.
Statistical significance is indicated 
using the paired Student t-test (n.s. = 
not significant).  
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Figure 8.21 Western blot analysis of iNOS expression 
in IL-4 DC. iNOS expression was assessed by Western 
blotting in untreated IL-4 DC and in IL-4 DC incubated with 
LPS for 24 hours. GAPDH was used as a loading control. 
The results shown are representative for at least 3 
different experiments. 
NO was strongly induced in both IL-4 DC and mature S-DC (Figure 8.20). The 
addition of the NO synthase inhibitor NMMA (250 µM) at the start of culture 
significantly inhibited the LPS-induced NO production, shown in Figure 8.20 by low 
detection of NO2
-. To confirm the induction of iNOS protein expression, LPS 
stimulated IL-4 DC were lysed and cell proteins were analysed by immunoblot using 
a rabbit anti-nitric oxide synthase II (iNOS) polyclonal antibody. As shown in Figure 
8.21, iNOS expression was confirmed in LPS stimulated IL-4 DC, but not in 
unstimulated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Altogether these results demonstrate that LPS stimulation induced the production of 
NO by IL-4 DC (Figure 8.20). In addition, the presence of iNOS was successfully 
detected in LPS-stimulated IL-4 DC (Figure 8.21). This NO production can be 
suppressed by the NO synthase inhibitor NMMA (Figure 8.20). 
 
 
 
8.4.5 Inhibition of LPS-induced NO secretion does not influence IL-4 DC 
mediated-inhibition of T cell proliferation 
 
IL-4 DC produce NO by LPS stimulation and the presence of the NO synthase 
inhibitor NMMA inhibited NO production (Figure 8.20). In this section the impact of 
NO was analysed for the IL-4 DC-mediated inhibition of both naïve T cell activation 
and mature S-DC induced T cell proliferation. Therefore, NO production was 
measured in the supernatant of T cell proliferation assays and inhibition assays (for 
more detail see Figure 8.22).  
- L
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The basal level of NO secretion was 14.4 ± 0.7 µM for IL-4 DC and 12.7 ± 2.5 µM for 
S-DC. The NO production in cultures of IL-4 DC and naïve T cells was low (10.25 ± 
2.1 µM), but in the presence of the NO synthase inhibitor NMMA NO levels were 
significantly lowered to 4.6 ± 0.8 µM (Figure 8.22 A). The same result was observed 
for supernatant of the inhibition assay (S-DC plus naïve T cells plus IL-4 DC): NO 
production did not cross the NO basal level (11.3 ± 0.8 µM) and, again, NMMA 
significantly reduced NO production (5.6 ± 0.6 µM).  
 
Although the levels of NO did not cross the basal level, nevertheless it was analysed 
whether these low NO levels may be responsible for both IL-4 DC mediated inhibition 
of T cell activation and mature S-DC induced T cell proliferation. Therefore, NMMA 
was added at the start of the culture and proliferation response was evaluated after 
72 hours. As shown in Figure 8.22 A (diagram on the right, T cell proliferation 
assay), addition of NMMA did not increase the proliferation of naïve T cells in the 
presence of IL-4 DC: without NMMA the T cell proliferation was 528.5 ± 154 cpm and 
with NMMA: 513.5 ± 57 cpm. In addition, no dramatic effect on T cell proliferation in 
the presence of NMMA was observed in the inhibition assay. In the presence of 
NMMA the IL-4 DC-mediated inhibition of S-DC-induced T cell proliferation also took 
place. The T cell proliferation increased only slightly from 635.17 ± 211 cpm to 1,918 
± 499 cpm. This T cell proliferation was still reduced 10-fold compared to mature S-
DC-induced T cell proliferation (19,454 ± 7,365 cpm).  
 
To exclude that the amount of NMMA (250 µM) used in all experiments was not 
sufficient to restore proper T cell proliferation, NMMA was added at different 
concentrations (125, 250 and 500 µM) to the T cell proliferation assay and inhibition 
assay. As shown in Figure 8.22 B, also a higher NMMA concentration (500 µM) had 
no significant effect on T cell proliferation in comparison to lower amounts of NMMA 
(250 µM).  
 
Interestingly, NO also accumulated in cultures with mature S-DC and naïve T cells 
(35.6 ± 2.6 µM) and the in presence of NMMA the NO production was reduced: 5.6 ± 
0.7 µM (streaked bar). A consequence of this reduction of NO was a dramatic 
increase in T cell proliferation from 19,454 ± 7,365 cpm without NMMA to 49,948 ± 
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7,723 cpm with NMMA. This result clearly shows that a reduction of NO production 
increases T cell proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.22: The inhibitory effect of immature IL-4 DC is not abrogated by NO inhibitor N
G
-
methyl-L-arginine acetate (NMMA). A: NO2
- accumulation in supernatant of T cell proliferation assay 
with S-DC (streaked bars; 104 S-DC and 105 naïve T cells) and IL-4 DC (white bars; 104 IL-4 DC and 
105 naïve T cells) and inhibition assay (grey bars; 104 IL-4 DC, 104 mature S-DC and 105 naïve T 
cells) with or without NMMA. IL-4 DC and mature S-DC cultured alone served as controls (=basal 
level). Mature S-DC are able to produce NO during the interaction with naïve T cells. NMMA was able 
to inhibit NO production. B: Addition of NMMA at different concentrations (125, 250 and 500 µM) to 
the culture of 104 IL-4 DC and 105 naïve T cells and inhibition assay. NMMA at a high concentration 
(500 µM) had only a marginal effect on T cell proliferation. Data are presented as means ± S.D. of 3 
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independent experiments. Statistical significance is indicated using the paired Student t-test (n.s. = not 
significant). 
 
 
 
Altogether, the results demonstrate that NO does not contribute to the IL-4 DC-
mediated inhibition of T cell activation in proliferation assays and S-DC induced T cell 
proliferation in inhibition assays (Figure 8.22 A, diagram on the right). Increased 
levels of NO are secreted by S-DC in T cell proliferation assays (Figure 8.22 A).  
 
 
 
8.4.6 IL-4 DC do not induce T cell apoptosis 
 
As demonstrated in chapter 8.4.4, LPS induces NO secretion by IL-4 DC. However, 
the results of T cell proliferation assay and inhibitory assay lead to the assumption 
that NO is not involved in the IL-4 DC-mediated inhibition of T cell proliferation 
(Figure 8.22). Therefore, the impact of NO for IL-4 DC mediated suppression of T 
cell activation was analysed in more detail. It has been shown for immature DC that 
they are able to induce T cell apoptosis (Lu L et al., 1999; Zhu M et al., 2004) and, in 
addition, NO induces apoptosis in many kinds of immune cells, including T cells 
(Fehsel K et al., 1995). Flow cytometry, a method to analyse the percentage of 
apoptotic T cells after incubation with IL-4 DC, was performed to investigate a 
possible effect of NO on T cell viability. 
 
As shown in Figure 8.23, T cells cultured with both mature S-DC or immature IL-4 
DC showed a low percentage of apoptosis (18.2% and 12.1%). The same result was 
observed for T cells cultured in the inhibition assay (13.2%). In the presence of the 
NO synthase inhibitor NMMA, the percentage of apoptotic T cells cultured with 
mature S-DC was reduced from 18.2% to 9.38% apoptotic cells (Figure 8.23). In 
contrast, the presence of NMMA in T cell cultures with IL-4 DC did not influence the 
viability of T cells (Figure 8.23).  
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Figure 8.23: T cell apoptosis is not relevant for the IL-4 DC mediated suppressive effect on T 
cell proliferation. Naïve T cells were co-cultured with 104 mature S-DC or 104 immature IL-4 DC. The 
effect on T cell apoptosis was also tested in the inhibition assay in the presence or absence of NMMA 
(250 µg/ml). Controls are T cells cultured alone. After 3 days of culture, apoptotic T cells were 
identified by double staining with anti -R73 and Annexin-V. Compared to T cell cultures with immature 
IL-4 DC, mature S-DC induced the highest T cell apoptosis, which was partially inhibited by addition of 
NMMA in both proliferation and inhibition assay. Data are representative of three separate 
experiments (see appendix Table 12.3). 
 
 
 
Altogether, the results show that IL-4 DC mediated inhibition of T cell proliferation is 
not based on induction of T cell apoptosis.  
 
 
 
8.4.7  IL-4 DC express the inhibitory molecules PD-L1 and PD-L2 
 
Despite low surface expression of MHC class II and the co-stimulatory molecules 
CD80 and CD86 on immature IL-4 DC (see section 8.2.3), immature IL-4 DC are 
able to stimulate the development of anergic Treg cells with suppressive function in 
vitro (see sections 8.5.1, 8.5.2 and 8.5.3). It is known that the balance between co-
stimulatory and co-inhibitory signals mediated by DC determines the final outcome of 
T cell activation (del Rio ML et al., 2008).  The ability of the co-stimulatory molecules 
of the B7 family CD80 and CD86 to provide co-stimulatory signals for full T cell 
activation has been well characterized. Recently, it has been shown that two 
additional B7 family members, PD-L1 and PD-L2, can deliver inhibitory signals, 
resulting in down-regulation of T cell activation (Keir ME et al., 2008). Moreover, 
blocking PD-L1 and PD-L2 on immature DC of the human system enhances T cell 
proliferation, suggesting an important role of PD-L1 and PD-L2 in induction and 
maintenance of T cell unresponsiveness (Brown JA et al., 2003). 
8 Results 
 91
In a next set of experiments, the possible expression of PD-L1 and PD-L2 on IL-4 DC 
was assessed by western blotting. For this, the IL-4 DC were cultured for 4 and 6 
days with GM-CSF and IL-4. As shown in Figure 8.24 A immature IL-4 DC 
expressed PD-L1 and PD-L2 after 4 and 6 days of culture, suggesting that GM-CSF 
and/or IL-4 induces and maintains PD-L1 and PD-L2 expression. The investigation of 
PD-L1 and PD-L2 expression after culture of progenitor cells with IL-4 only was not 
possible since progenitor cells were not able to proliferate and differentiate without 
the addition of GM-CSF (section 8.1.2, Figure 8.1).  
 
To investigate whether GM-CSF alone is sufficient to induce PD-L1 and PD-L2 
expression, bone marrow progenitor cells were cultured with GM-CSF alone instead 
of GM-CSF plus IL-4 for 4 and 6 days. Again a clear PD-L1 and PD-L2 expression 
was assessed by Western blot analysis. This leads to the conclusion that GM-CSF 
alone is sufficient to induce and maintain PD-L1 and PD-L2 expression on BM-DC. In 
addition, treatment of day 6 IL-4 DC with the maturation stimuli LPS for 24 and 48 
hours resulted in an increase of PD-L1 expression in comparison to untreated IL-4 
DC (Figure 8.28 B). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.24: Western blot analysis of PD-L1 and PD-L2 expression in immature IL-4 DC. Protein 
extracted from 1.5x106 IL-4 DC harvested on day 4 and day 6 of culture (A) and from 1.5x106 day 6 IL-
4 DC stimulated with LPS (1 µg/ml) for 24 and 48 hours (B) was loaded and separated by 
electrophoresis in 10% SDS-polyacrylamide gels. Western blot analysis was performed with 
antibodies against PD-L1 and PD-L2. GAPDH served as loading control. The results shown are 
representative for 3 different experiments. 
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Altogether the results show that immature IL-4 DC express the co-inhibitory 
molecules PD-L1 and PD-L2 on their surface and GM-CSF seems to induce and 
maintain PD-L1 and PD-L2 expression.  
 
 
 
8.4.8 PD-L1 and PD-L2 surface expression is decreased by inhibition of MEK-
pathway but does not influence IL-4 DC-mediated inhibition of T cell 
proliferation 
 
As shown in section 8.4.7, immature IL-4 DC expressed the co-inhibitory molecules 
PD-L1 and PD-L2 on their cell surface. Brown and colleagues showed that the 
blockade of PD-L1 and PD-L2 expression by human DC with monoclonal antibodies 
results in enhanced T cell activation (Brown JA et al., 2003). Therefore, the PD-L1 
and PD-L2 blockade on immature IL-4 DC should also enhance T cell proliferation. 
Unfortunately, rat monoclonal antibodies for blocking PD-L1 and PD-L2 on rat DC are 
not available yet. However, several studies with pharmacological inhibitors have 
examined signalling pathways that are required for the expression of PD-L1. The 
group of Liu showed that PD-L1 expression in cell lines is decreased when MEK1/2-
pathway is blocked by MEK inhibitor UO126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio] butadiene) (Liu J et al., 2007).   
 
In this study the importance of MEK-pathway for the expression of PD-L1 and PD-L2 
on IL-4 DC was investigated. For this, the MEK-pathway was blocked by the MEK 
inhibitor UO126 and the outcome on PD-L1 and PD-L2 expression was analysed by 
western blot.  
 
Figure 8.25 shows that the expression of PD-L1 and PD-L2 was clearly reduced in 
immature IL-4 DC when Erk1/2 phosphorylation was blocked by 10 µM UO126. This 
reduction was observed for 1 hour and 24 hours after the addition of UO126 to IL-4 
DC. 
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In the next set of experiments it was analysed whether a decreased protein 
expression of PD-L1 and PD-L2 on immature IL-4 DC could overcome the IL-4 DC-
mediated inhibition of naïve T cell activation. Therefore, 104 immature IL-4 DC were 
co-cultured with 105 naïve T cells for 72 hours with or without 10 µM UO126. Since 
UO126 was of limited stability in medium, UO126 was added to the cultures every 24 
hours.  
 
Figure 8.26 shows that reduced levels of PD-L1 and PD-L2 expression on immature 
IL-4 DC induced by MEK-inhibitor UO126 did not result in an increased T cell 
proliferation. This might be due to the fact that UO126 influence the expression of 
newly synthesized PD-L1 and PD-L2 proteins in immature IL-4 DC and not PD-L1 
and PD-L2 molecules, which are already present on the surface of immature IL-4 DC. 
In this experiment IL-4 DC were used with a clear PD-L1 and PD-L2 surface 
expression (Figure 8.24). Therefore, blocking PD-L1 and PD-L2 with monoclonal 
antibodies would be necessary. Unfortunately antibodies recognizing rat PD-L1 or 
PD-L2 are not available yet. Antibodies specific for mouse or human PD-L1 or PD-L2 
have not been tested in this study. 
 
Altogether the results show that IL-4 DC express the inhibitory molecules PD-L1 and 
PD-L2 on their cell surface. Their expression is regulated by GM-CSF induced 
MEK/ERK-pathway. The importance of PD-L1 and PD-L2 surface expression for the 
IL-4 DC-mediated inhibition of T cell activation remains unclear. 
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Figure 8.25: Blocking the ERK1/2 phosphorylation 
with UO126 reduces the expression of PD-L1 and 
PD-L2. Proteins were extracted from 1.5x106 IL-4 DC 
harvested on day 6 of culture and separated by 
electrophoresis in 10% SDS-polyacrylamide gels. 
Western blot analysis was performed with indicated 
antibodies. GAPDH served as a loading control. The 
detection of Erk1/2 phosphorylation was also analysed in 
IL-4 DC harvested on day 6 of culture. IL-4 DC were 
replated on 6-well plates (1.5x106/well) and incubated
with 10 µM UO126 at different time points. Western blot 
analysis was performed with indicated antibodies. 
Unphosphorylated p43/44 served as a loading control.
The results shown are representative for 3 different 
experiments. 
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Figure 8.26: Impact of MEK inhibitor UO126 
on T cell proliferation in co-cultures with 
immature IL-4 DC. 104 immature IL-4 DC were 
co-cultured with 105 naïve T cells for 72 hours,
with or without the addition of 10 µM UO126
every 24 hours to the culture. Proliferation assay 
(104 S-DC co-cultured with 105 naïve T cells) 
served as a control. Data are presented as 
means ± S.D. of 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5 Immature IL-4 DC induce T cells with regulatory properties and Treg cell-
like phenotype 
 
8.5.1 IL-4 DC-induced expansion of naturally occurring Treg cells  
 
Initially, it was believed that immature DC induced T cell unresponsiveness because 
of the absence of both inflammatory signals and low expression of co-stimulatory 
molecules on their surface. However, to date, a growing body of evidence indicates 
that immature DC induce T cell unresponsiveness by induction and / or stimulation of 
Treg cells (Morelli AE and Thomson AW, 2003).  
 
The ability of immature IL-4 DC to generate Treg cells was investigated in a next set of 
experiments. For this, lymph node cells were co-cultured with immature IL-4 DC or 
mature S-DC. Lymph node cells cultured alone served as control. On day 3, DC were 
depleted from the cultures and DC-free lymph node cells, dominated by T cells, were 
analysed by flow cytometry with monoclonal antibodies representing Treg cell-specific 
marker consisting of CD4, CD25, MHC class II, and Foxp3. Figure 8.27 shows one 
representative example of flow cytometric analsyis. Figure 8.28 summarises the 
results of 3 independent experiments.  
 
The percentage of so-called naturally occurring CD4posFoxp3pos Treg cells within 
unpurified total lymph node cells ranged between 5 and 7% (Figure 8.27). Their 
amount increased after co-culture with mature S-DC to 11% and after co-culture with 
IL-4 DC to 16%.  
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In 2006 the group of Baecher-Allan et al. demonstrated that MHC class II expression 
by human CD4posCD25high T cells indicates a functionally distinct population of mature 
Treg cells inhibiting T cell proliferation
 and cytokine production via an early contact-
dependent mechanism associated with induction of Foxp3 (Baecher-Allan C et al., 
2006). Based on these observations the MHC class II expression of rat Treg cells was 
analysed. As shown in Figure 8.27 all Foxp3pos T cells were also positive for MHC 
class II molecules. Therefore, MHC class II surface expression may also be a useful 
marker for the identification of rat Treg cells. 
 
The number of Treg cells increased during the co-culture of unpurified lymph node 
cells with IL-4 DC. Treg cells can be induced from naïve CD4
posCD25neg T cells (Groux 
H et al., 1997; Kemper C et al., 2003) or expanded from naturally occurring 
CD4posCD25posFoxp3pos Treg cells (Marguti I et al., 2008).  
 
The induction of Treg cells from naïve CD4
posCD25neg T cells was analysed by the 
following experiment: naturally occurring CD4posFoxp3pos Treg cells were depleted 
from total lymph node cells and the Treg cell-free lymph node cells, most of them 
naïve T cells, were cultured with IL-4 DC for 3 days (Figure 8.27, middle panel). 
Corresponding T cell co-culture experiments were done with mature S-DC. Flow 
cytometric analysis revealed that the number of Treg cells increased slightly (up to 
8%) during the co-culture with IL-4 DC. Since the naïve T cells were contaminated 
with approximately 3% Treg cells, it is not clear whether this increase was actually 
caused by naïve T cells or by the remaining Treg cells.  
 
In further experiments the naturally occurring CD4posFoxp3pos Treg cells within lymph 
node cells were enriched (Figure 8.27, lower panel) and subsequently co-cultured 
with immature IL-4 DC. The Treg cell enrichment provided a Treg cell population 
contaminated with naïve T cells but the flow cytometric analysis revealed that 
enriched CD4posCD25posFoxp3pos Treg cells were expanded intensively by both S-DC 
and IL-4 DC.  
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Figure 8.27: Naturally occurring Treg cells are expanded by IL-4 DC and S-DC in vitro. 10
4 
immature IL-4 DC or mature S-DC were co-cultured with 105 total lymph node T cells (upper panel), 
105 naïve T cells depleted of CD4posCD25pos T cells (middle panel) or with purified 105 CD4posCD25pos 
T cells (lower panel). After 3 days the cells were collected and, after depletion of DC, labelled with 
fluorescent antibodies for CD4, CD25 and Foxp3. All cells are gated on CD4pos cells. One 
representative example of at least 3 different experiments is shown (see appendix Table 12.8). 
 
 
These results show that immature IL-4 DC as well as mature S-DC are able to induce 
the proliferation of CD4posCD25posFoxp3pos Treg cells to nearly the same extent. They 
are not able to induce the generation of CD4posCD25posFoxp3pos Treg cells from naïve 
T cells. Since Treg cells demonstrate a low rate of proliferation, the expansion of Treg 
cells by IL-4 DC might correspond to the very low T cell proliferation by IL-4 DC 
(Figure 8.10 B). In contrast, activation and proliferation of effector T cells was not 
observed in the presence of IL-4 DC (Figure 8.10 B and Figure 8.11, section 8.32). 
High T cell proliferation observed in the proliferation assay (T cells + S-DC, Figure 
8.10 B) might be due more to the preferential activation / expansion of effector T cells 
than to the activation/expansion of Treg cells. 
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Figure 8.28: IL-4 DC and S-DC induce 
the expansion of Treg cells in vitro. 10
4
immature IL-4 DC or mature S-DC were 
co-cultured with 105 total lymph node T 
cells (white bars), 105 naïve T cells 
depleted of naturally occurring Treg cells
(CD4posCD25neg T cells) or with enriched 
105 naturally occurring Treg cells (CD4
pos
CD25pos T cells) for 3 days.
Subsequently, DC-depleted cells were
labelled with fluorescent antibodies for 
CD4, CD25 and Foxp3. The fold increase 
of CD4pos CD25posFoxp3pos T cells after 
co-culture with S-DC or IL-4 DC over the 
T cell control was analysed. Data are 
presented as means ± S.D. of 3 
independent experiments. Statistical 
significance is indicated using the paired 
Student t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5.2 IL-4 DC-mediated induction of anergic T cells 
 
In 2000 Jonuleit et al. showed that repetitive stimulation of naïve cord blood–derived 
T cells with allogenic immature DC resulted in the induction of suppressive, 
nonexpanding (anergic), IL-10-producing Treg-like cells (Jonuleit H et al., 2000). 
Anergy appears when co-stimulatory signals are absent and describes a state of 
functional unresponsiveness of T cells that are unable to initiate a productive 
response to secondary stimulation, even if this includes full co-stimulation (Sebille F 
et al., 2003; Wekerle T et al., 2002). In addition, anergy is characterized by an 
inhibition of IL-2 secretion (Lechler R et al., 2001). 
 
To determine whether immature IL-4 DC are able to induce an anergic state in naïve 
T cells, 1x105 naïve T cells were incubated with 1x104 immature IL-4 DC. T cells 
cultured alone or together with mature S-DC served as control. At the end of culture, 
IL-4 DC or S-DC were depleted with the antibody Ox-42 and magnetic-beads. The 
resulting T cells of the first culture were transferred to the second culture consisting 
of 1x104 fresh mature S-DC per well (Figure 8.29 A). Finally, the incorporated 
radioactivity was measured at the end of the second culture on day 3 (Figure 8.29 
B). 
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Figure 8.29: IL-4 DC induce anergic T cells. A: Experimental setup: 105 naïve T cells were pre-
incubated for 3 days with 104 immature IL-4 DC. T cells cultured alone or with mature S-DC served as 
control. After depletion of dendritic cells, T cells were transferred to mature S-DC. 72 hours later the T 
cell proliferation was determined. B: Results: Mature S-DC are not able to induce a restimulation of T 
cells pre-incubated with IL-4 DC. The suppressed capacity of T cell proliferation could be restored by 
addition of exogenous IL-2 (266 ng/ml). The data shown are represented as means ± S.D. and 
represent the results from representative experiments repeated three times.  
 
 
 
As shown in Figure 8.29 B, S-DC activated T cells from the first co-culture could 
expand in the presence of fresh, isolated S-DC during the second culture: 20,324 ± 
2,761 cpm. In contrast, T cells co-cultured with IL-4 DC during the first culture could 
not expand in the presence of mature S-DC during the second culture: 1,503 ± 335 
cpm. This unresponsiveness, however, could be abolished by adding of 266 ng/ml 
exogenous IL-2. The measured proliferation was then 15,952 ± 467 cpm (Figure 
8.29 B). 
A 
1. Culture 
2. Culture 
B 
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Naïve T cells cultured without S-DC (and therefore without proliferation signals) 
during the first culture could be activated during the second culture with S-DC: 
13,352 ± 2,437 cpm. This result shows that most of the naïve T cells survived without 
proliferation signals during the first culture period. Therefore, immature IL-4 DC 
induce a reversible state of functional unresponsiveness in co-cultured T cells and 
these T cells show features of anergic T cells (Figure 8.29).  
 
 
8.5.3 IL-4 DC-induced anergic T cells demonstrate immune inhibitory proper-
ties 
 
The regulatory effect of anergic T cells is well known. For humans and mice, several 
groups have demonstrated that T cells generated in co-culture with immature DC are 
able to inhibit T cell responses in vitro (Bashuda H et al., 2005; Cools N et al., 2008; 
Gad M et al., 2004; Jonuleit H et al., 2003; Kubsch S et al., 2003; Kuwana M, 2002). 
 
In this study we further analysed the function of T cells pre-incubated with immature 
IL-4 DC. These T cells were tested for their ability to suppress mature S-DC induced 
T cell proliferation. The possible suppressor T cells were recovered from the first co-
culture with IL-4 DC and transferred to the second assay containing fresh isolated 
naïve “indicator” T cells and mature S-DC. T cells incubated with S-DC during the 
first culture were used as control cells. The viability of “indicator” T cells was tested in 
a control proliferation assay. After 3 days the [3H]- thymidine incorporation was 
measured (Figure 8.30 A).  
 
The results show that T cells co-cultured with IL-4 DC reduced the S-DC induced 
proliferation of “indicator” T cells in the second culture about 92% from 22,494 ± 469 
cpm to 1,768 ± 325 cpm (Figure 8.30 B).  
 
T cells activated by S-DC during the first culture were tested in the second culture. 
These activated T cells were not able to inhibit the S-DC induced proliferation of 
“indicator” T cells, although proliferation was reduced in comparison to the control 
proliferation assay. The reason for this is the different number of cells. For the control 
proliferation assay 104 S-DC und 105 naïve “indicator” T cells were co-cultured. The 
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inhibitory effect of T cells cultured with IL-4 DC or S-DC was shown in a second 
proliferation assay consisting of 104 S-DC und 105 naïve “indicator” T cells and 105 T 
cells transferred from the first culture with IL-4 DC or S-DC (Figure 8.30). 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                  
 
 
 
 
 
 
 
 
 
 
                        
 
 
 
 
 
Figure 8.30: IL-4 DC-induced anergic T cells inhibit S-DC induced T cell proliferation. A: 
Experimental setup: 105 naïve T cells were pre-incubated for 3 days with 104 immature IL-4 DC. Naïve 
T cells cultured with mature S-DC served as control. After depletion of dendritic cells, T cells were 
transferred to a second T cell proliferation assay containing fresh mature S-DC and naïve T cells. 72 
hours later the T cell proliferation was determined. B: Results: T cells pre-incubated with immature IL-
4 DC inhibit mature S-DC induced T cell proliferation. The data shown are represented as means ± 
S.D. and represent the results from representative experiments repeated three times.  
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The results of Figure 8.30 demonstrate that naïve T cells co-cultured with immature 
IL-4 DC demonstrate immune inhibitory effects and a phenotyp characteristic for Treg 
cells (Figure 8.27).  
 
S-DC primarily induce a population of effector T cells that is unable to inhibit the 
activation of “indicator” T cells. In addition, S-DC are also able to restimulate Treg 
cells (Figure 8.27).  
 
Altogether IL-4 DC, phenotypically characterized by reduced surface expression of 
MHC class II and co-stimulatroy molecules, are unable to activate naïve T cells or 
suppress proliferation of activated T cells. The characterization of IL-4 DC does not 
lead to the identification of one mechanism that fully explain all features of IL-4 DC, 
but evidence was found that TGF-β as soluble factor may be strongly involved in IL-4 
DC-mediated inhibition of T cell proliferation. Two exciting properties of the IL-4 DC 
are their inability to mature and the induction of anergic T cells with regulatory 
features.  
 
IL-4 DC are characterized by the following properties: 
♦ Growth in cell clusters (Figure 8.1, 8.2) 
♦ Low surface expression of co-stimulatory molecules and MHC II (Figure 8.3) 
♦ Deficient production of IL-12 (Figure 8.6, 8.8) 
♦ Endocytosis (Figure 8.9) 
♦ Resistance to different maturation stimuli (Figure 8.15, 8.17)  
♦ Expression of inhibitory molecules PD-L1 and PD-L2 (Figure 8.24-8.26) 
 
IL-4 DC demonstrate the following effects: 
♦ Inability to activate naïve T cells (Figure 8.10) 
♦ Inhibition of S-DC induced T cell proliferation (Figure 8.13, 8.29) 
♦ Inhibition of antibody induced T cell proliferation (Figure 8.12) 
♦ Inhibition effect within 24 hours (Figure 8.14) 
♦ Secretion of soluble factors suppressing T cell proliferation (Figure 8.18) 
♦ Secretion of TGF-β was successfully proofed (Figure 8.19) 
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♦ Expression of iNOS and secretion of NO; probably not involved in IL-4 DC-
mediated inhibition of T cell proliferation (Figure 8.20-8.22)  
 
T cells co-cultured with IL-4 DC are characterized by: 
♦ TGF-β dominated cytokine profile (Figure 8.11) 
♦ Inhibition of S-DC-induced T cell proliferation (Figure 8.29) 
♦ Reduced ability to respond to full activation by S-DC (Figure 8.30) 
♦ A phenotype typical for Treg cells (Figure 8.27) 
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9 Discussion 
 
DC are the main key regulators of the immune system. They are known as inducers 
of destructive immune responses but they can also exert tolerogenic functions 
(Steinman RM et al., 2003). The ability to induce tolerance makes them interesting 
for clinical applications to inhibit excessive immune responses in autoimmune 
disorders and transplant rejection (Tarbell KV et al., 2004; Zhang X et al., 2008). This 
characteristic is the reason why DC have been the focus of numerous studies over 
the last years investigating their clinical relevance to modulate the outcome of 
unwanted immune responses (van Duivenvoorde LM et al., 2006; Steinman RM and 
Banchereau J, 2007).   
 
It has become obvious over the past years that not a single type of tolerogenic DC is 
able to control the diversity of mechanisms involved in T cell tolerance. Therefore, it 
is important to generate and select the optimal cell type suitable for DC-based 
therapies. However, the differences existing between humans and the most popular 
small animal models mice and rat, makes it difficult to develop a common protocol 
suitable for the generation of immature DC for the 3 species. In vitro characterization 
of DC mechanisms underlying their suppressive effect has mainly been focused on 
humans and mice and less on rat. Since the rat is widely used as an experimental 
animal model in a variety of scientific areas such as immune responses to patho-
gens, tumors, self-antigens, or allografts, the present study analyses the importance 
of rat tolerogenic immature DC and their interaction with immunoregulatory Treg cells.  
 
 
 
9.1 The outcome of a specific IL-4 DC population depends on the 
combination of the cytokines GM-CSF and IL-4 
 
The immune regulatory functions of DC seem to be mainly related to an immature 
developmental stage. Mature DC can efficiently induce the development of effector T 
cells, whereas immature DC are involved in maintenance of peripheral tolerance 
(Mahnke K et al., 2002; Mahnke K et al., 2003). The low number of DC found in 
tissues or in circulation (1-3%) limited their characterization (Banchereau J and 
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Steinman R, 1998; Jenkins DE et al., 1998), since for this purpose large numbers of 
isolated DC are necessary (Freudenthal PS and Steinman RM, 1990; O'Doherty U et 
al., 1993; O'Doherty U et al., 1994). In contrast to tissues or blood, large numbers of 
DC can be generated from bone marrow precursor cells, when cultured with 
appropriate cytokines (Inaba K et al., 1992; Romani N et al., 1994; Szabolcs P et al., 
1997; Lutz MB et al., 1999).  
 
One of the first protocols for the generation of rat immmature DC was published by 
Kliniker et al. (Klinkert WE et al., 1982). They cultured low density bone marrow 
progenitor cells with supernatant from ConA-treated spleen cells. In 1986 a protocol 
followed that described DC expansion from rat bone marrow progenitor cells in a 
serum-free medium (Bowers WE and Berkowitz MR, 1986). Both protocols revealed 
a cell yield of about 1% or less of the starting bone marrow cultures. Thereafter, 
Inaba K et al. was one of the first using purified GM-CSF for the generation of mice 
DC from bone marrow cells. They showed that GM-CSF improves the cell yield of rat 
BMDC, but the numbers were still low (Inaba K et al., 1992). Ten years later the 
group of Bai L et al. published their experiences in generating human DC in the 
presence of GM-CSF (Bai L et al., 2002). Further cytokines, like IL-4 or TNF-α, 
combined with GM-CSF have been shown to be necessary for the induction of high 
cell numbers of DC (Szabolcs P et al. 1995; Romani N et al. 1996; Talmor M et al., 
1998; Young JW, 1999; Labeur MS et al., 1999; Lu L et al., 1999). 
 
In this study the optimal growth conditions required for the generation of large 
numbers of immature rat IL-4 DC from bone marrow cells was systematically 
evaluated; only few studies have been done on this. The cultivation protocols of 
these studies differ concerning cytokine concentration, end point of culture and the 
type of bone marrow progenitor cells (Talmor M et al., 1998; Grauer O et al., 2002). 
Bone marrow is an extremly complex mixture of different cell types; it also contains 
three types of stem cells: hematopoietic stem cells, mesenchymal stem cells and 
endothelial stem cells. Most of these cells adhere to plastic surfaces and are used for 
the generation of immature DC (Xiao BG et al., 2001; Muthana M et al., 2004). 
During culture some cells loose their adherence and move into the supernatant. 
These non-adherent cells also can be used for the generation of immature DC as 
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well (Chen-Woan M et al., 1995; Lutz MB et al., 1999; Grauer O et al., 2002; Powell 
TJ et al., 2003; Muthana M et al., 2004; Berger TG et al., 2009).  
 
The influence of GM-CSF alone and in combination with IL-4 to induce immature rat 
DC was analysed. It was found that GM-CSF was a key factor in promoting both DC 
proliferation and differentiation in vitro (Table 8.1, Figure 8.1) but resulted in a poor 
DC yield (Table 8.1, Figure 8.1). This observation, which is in accordance with the 
results of other studies, seems to be unique for the generation of rat DC (Chen-Woan 
M et al., 1995; Talmor M et al., 1998; Grauer O et al., 2000; Muthana M et al., 2004). 
The presence of GM-CSF alone is sufficient for the generation of mice and human 
bone marrow-derived DC (Romani N et al. 1994; Lutz MB et al., 1999). In this study it 
is shown, that IL-4 in combination with increasing concentrations of GM-CSF further 
increases the cell yields (Table 8.1, Figure 8.1). However, the percentage of cell 
yield peaked at a concentration of 5 ng/ml of GM-CSF, with or without IL-4, but only 
under the influence of IL-4 did bone marrow progenitor cells develop loosely 
adherent cell clusters which increased the cell yield (Table 8.1, Figure 8.1). The 
formation of cell clusters indicates the development of bone marrow progenitor cells 
along the LC pathway (Riedl E et al., 2000). Cellular aggregates were formed 
between day 2 and day 4 in the present study (Figure 8.2).  
 
Rat IL-4 DC recovered from cultures revealed the surface expression of the rat DC 
marker Ox-62 and MHC class II, confirming the development of immature DC. Ox-62 
recognizes the rat homolog of the 150 kDa integrin-αE2 subunit and was originally 
described as being a useful marker for rat veiled cells (Brenan M and Puklavec M, 
1992). High surface expression of MHC class II can be considered as an indicator for 
mature DC (Santambrogio L et al., 2006). In this study, the flow cytometric analysis 
clearly demonstrated more than 85% Ox-62-positive cells, regardless of the cytokine 
combination used (Table 8.1). These results differ from those shown by Brisette-
Starkus et al. and Muthana et al. The authors did not observe such high levels of Ox-
62-positive cells generated in the presence of GM-CSF and IL-4 (Brisette-Starkus CS 
et al., 2002; Muthana M et al., 2004). The reason for this is not clear, since both 
publications used GM-CSF and IL-4 concentrations investigated in this study. The 
protocol of Brisette-Starkus et al. only differs in that they removed and discarded non-
adherent cells on day 4 of culture. Previous studies have employed different 
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treatments to improve the purity of BM-DC precursors for the outcome of highly pure 
DC populations. These protocols include the removal of contaminating non-DC 
progenitors (Inaba K et al., 1992; Talmor M et al., 1998 and Grauer O et al., 2002). 
However, these depletion steps may also remove vital and expanding DC precursor 
subsets (Maroof A, 2001; Hart DN, 1997). For this reason the culture protocol 
described in this study avoids procedures such as removing non-adherent precursor 
cells during culture (section 7.1).  
 
Literature on the generation of immature DC is heterogeneous and often 
controversial. Thereby, it is not always clear how different cytokine combinations 
influence DC maturation. For example, GM-CSF at a concentration of 1 ng/ml 
combined with IL-4 generates phenotypically immature DC in rats (Garrovillo M et al., 
2001), whereas the same cytokine combination induces the generation of 
phenotypically mature BM-DC in mice (Lutz MB et al., 2000). All these aspects e.g. 
different progenitor cell populations, cytokine combination as well as different species 
need to be taken into consideration for the final outcome of phenotypic and functional 
characteristics of DC (Table 9.1). 
 
In the present study, DC growth conditions were optimised to increase the yield of 
immature (MHC class IIlow) Ox-62 positive DC from bone marrow progenitor cells. A 
cytokine combination of 5 ng/ml GM-CSF plus 5 ng/ml IL-4 produces one of the best 
results concerning cell yield of Ox-62 positive IL-4 DC, cluster formation, and 
expression of MHC class II (Table 8.1). The results show that GM-CSF is an 
essential key factor for the generation / proliferation of bone marrow-derived DC. IL-4 
seems to play a secondary / accessory role as an “enhancer” for the generation of 
cell clusters with proliferating DC demonstrating an immature phenotype (MHC class 
IIlow). 
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(1) Grauer O et al., Histochem Cell Biol 2002; 117 (4): 351-362 ; (2) Powell TJ et al., Immunology 2003; 109 (2): 197-208; (3) 
Lutz MB et al., Journal of Immunological  Methods 1999; 223 (1): 77-92; (4) Tang L et al., J Zhejiang  Univ SCIENCE B 2005; 
6(12): 1176-1181 
 
 
 
9.2  Immature IL-4 DC are resistant to different maturation stimuli  
 
Immature DC are able to take up antigen, but they are unable to present antigens, 
whereas mature DC are professional antigen presenting cells with a low capacity of 
endocytosis (Quah BJC and O'Neill HC, 2005; Hotta C et al., 2006). The immature 
phenotype of IL-4 DC was demonstrated by a very low expression of co-stimulatory 
molecules CD80, CD86 and CD40 as well as significantly reduced levels of CD45, 
MHC class II, CD25 and adhesion molecule ICAM-1 compared to that of mature S-
DC (Figure 8.5). In addition, their immature phenotype was confirmed by their 
pronounced endocytic activity, demonstrated by measuring the uptake of Dextran-
Alexa 488 (Figure 8.9). Furthermore, the immaturity of IL-4 DC was confirmed by 
their inability to activate naïve T cells (Figure 8.10). It is well known that according to 
the “two-signal” hypothesis naïve T cells need engagement of the T cell receptor with 
MHC molecule (signal 1) in addition to a second stimulus through co-stimulation by 
CD80 and CD86 (signal two) to become fully activated (Libscomb MF and Matsen 
BJ, 2002). This hypothesis may explain the inability of IL-4 DC to activate naïve T 
cells because they demonstrate a low surface expression of both MHC class II as 
well as co-stimulatory molecules (Figure 8.5). It is also possible to inhibit T cell 
proliferation by blocking the co-stimulation with e.g. the CTLA-4Ig fusion protein 
(Balzevic V et al., 2001). 
 
IL-4 DC also demonstrate low expression of ICAM-1, CD25 and CD45 compared to 
mature S-DC (Figure 8.5). Different studies suggest that adhesion molecules such as 
ICAM-1 on the DC surface are required for optimal activation of T cells through 
interaction of LFA-1 on T cells with ICAM-1 (Van Seventer GA et al., 1990; 
Ybarrondo B et al., 1994). It has been shown that blocking ICAM-1 with a monoclonal 
antibody prolonged skin and heart allografts (Isobe M et al., 1992; Isobe M et al., 
1996). CD45 molecule has been shown to help regulation of T cell proliferation and 
differentiation (Montoya M et al., 2006; Pricket TCR and Hart DN et al., 1990). 
Several studies demonstrated that a monoclonal antibody specific for the CD45RB 
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isoform is a potent immunomodulator that prolongs allograft survival in several 
murine transplantation models (Lazarovits AI et al., 1996; Auersvald LA et al., 1997; 
Gregori S et al., 2005). CD25 expression by human and pig DC is described and it is 
suggested they have an important role in driving the immune response towards a TH1 
response (Mnasria K et al., 2008; Pilon C et al., 2009). The immune inhibitory effect 
caused by blocking CD25 with an anti-CD25 antibody was confirmed by in vitro 
experiments (Mnasria K et al., 2008). Presently, anti-CD25 monoclonal antibodies 
are widely used in clinical transplantation to prevent acute allograft rejection (Vincenti 
F et al., 1998; Ter Meulen CG et al., 2004).  
 
Mature DC are required for full activation of naïve T cells (Quah BJC and O´Neill HC, 
2005). DC maturation can be triggered by a response to microbial components such 
as LPS, double-stranded RNA, or CpG-DNA, or by inflammatory cytokines such as 
CD40L and TNF-α (de Smedt T et al., 1996; Sparwasser T et al., 1998; Ridge JP et 
al., 1998; Caux C et al., 1992). However, maturation-resistance of tolerogenic DC is 
one prerequisite for a possible clinical application. To our knowledge the maturation-
resistance of rat IL-4 DC has not been described yet. In this study we show that low-
adherent immature rat IL-4 DC did not respond to maturation stimuli such as LPS, 
TNF-α or CD40L. These treated IL-4 DC still expressed low levels of MHC class II 
and co-stimulatory molecules (Table 8.6) compared to the higher surface expression 
of these molecules on mature S-DC (Table 8.3). However, several studies exist 
showing that rat BM-DC cultured at either low or high GM-CSF concentration are 
able to mature in response to different maturation stimuli (Brissette-Storkus CS et al., 
2002; Grauer O et al., 2002; DePaz HA et al., 2003; Janelidze S et al., 2005). In 
contrast, Muthana and colleagues showed that LPS had no effect on CD80 and MHC 
class II expression on adherent rat BM-DC (Muthana M et al., 2004). 
 
The maturation-resistance of immature IL-4 DC reflects their inability to stimulate T 
cells (Figure 8.17). These results are in contrast to other studies on rat (Grauer O et 
al., 2002) and murine bone marrow-derived DC (Lutz MB et al., 1999), although the 
phenomenon of maturation-resistance of mice DC has also been shown by Lutz and 
colleagues (Lutz MB et al., 2000). They reported that mice bone marrow cells 
cultured with low doses of GM-CSF generate immature DC that do not respond to 
maturation stimuli. However, the presence of IL-4 abrogated the maturation-resistant 
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phenotype of these BM-DC. The same effect of IL-4 on DC maturation was observed 
for human DC (Berger TG et al., 2009). The reason for numerous conflicting results 
may be the use of different DC populations, such as adherent and non-adherent cells 
(Powell TJ et al., 2001; Powell TJ et al., 2002), the use of DC at different maturation 
stages and/or different treatments of the DC cultures, such as different cytokine 
combinations and/or concentrations, time point of cell harvesting and re-plating (Lutz 
MB et al., 1999).  
 
The generation of maturation-resistant rat IL-4 DC for tolerance induction in vivo 
might be a better strategy than the generation of maturation-sensitive immature DC. 
The important goal, however, is to indentify such maturation-resistant immature DC 
for humans. 
 
 
 
9.3 Implication for a soluble factor responsible for the IL-4 DC-mediated 
suppressive effect 
 
Inhibition of T cell responses by DC secreted inhibitory molecules is possible (Guillot 
C et al., 2003). IL-4 DC demonstrate a suppressive effect on mature S-DC-induced T 
cell proliferation in a dose-dependent manner (Figure 8.13). Similar results have been 
observed by Powell and colleagues (Powell TJ et al., 2003). They reported that 
immature BM-DC, separated by expression of the Fc receptor, inhibited T cell 
proliferation. In addition, we were able to show that the suppressive effect of 
immature IL-4 DC was detectable within 24 hours after the addition of IL-4 DC on day 
2 to the culture with naïve T cells and mature S-DC (Figure 8.14). To our knowledge 
this is the first description of the time course immature BM-DC needed to suppress T 
cell proliferation. The suppressive effect of IL-4 DC on mature S-DC-induced T cell 
proliferation seems to be mediated by their ability to inhibit IL-2 and IFN-γ production 
and to induce TGF-β production (Figure 8.11 and 8.13).  
 
IL-4 DC are able to produce TGF-β themselves (Figure 8.19). This has also been 
demonstrated by Morelli and colleagues (Morelli AE et al., 2001). They detected high 
levels of TGF-β in the supernatant of immature CD11cposCD86neg but not in the 
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supernatant of mature CD11cposCD86pos DC cultured for 24 hours. Supernatant of IL-
4 DC demonstrated a dose-dependent inhibitory effect on mature S-DC-induced T 
cell proliferation (Figure 8.18). TGF-β is a potent immunoregulatory cytokine known 
to have potent effects on inhibiting the differentiation and proliferation of both CD4pos 
and CD8pos T cells (Li MO et al., 2006). Das and Levine, for example, showed that 
TGF-β suppresses TCR-induced proliferation of effector T cells by inhibiting IL-2 
production (Das L and Levine AD, 2008). In addition, it has also been shown that 
TGF-β inhibits the ability of mature DC to stimulate IFN-γ secretion by T cells (Kobie 
JJ et al., 2003). Zang et al. demonstrated that prolongation of graft survival is TGF-β 
dependent and associated with the generation of TGF-β secreting Treg cells (Zang W 
et al., 2008). In addition, Treg mediated TGF-β production was suggested as an 
important mechanism of suppression (Kariminia A et al., 2005; McGeachy MJ et al., 
2007). IL-4 DC producing TGF-β were able to expand Treg cells with inhibitory 
functions. The presence of Treg cells after co-culture with immature IL-4 DC may 
account for increased TGF-β levels (Figure 8.11). In addition to TGF-β produced by 
IL-4 DC themselves (Figure 8.19), it is known that Treg cells can also produce TGF-β 
(Simon JC et al., 2002; Wan YY et al., 2007). However, whether T cells incubated 
with IL-4 DC really produce TGF-β producing cells has not been analysed so far and 
will be the focus of a future study.  
 
Mature S-DC induced the activation of TH1 cells secreting IFN-γ and IL-2, whereas 
IL-4 DC favoured the development of T cells producing low levels of IFN-γ and IL-2, 
and significantly increased levels of TGF-β (Figure 8.11). Secretion of IL-10 was not 
detected in either situation. Different studies have shown that Tr1 cells, a subtype of 
Treg cells, are characterized by a unique pattern of cytokine production distinct from 
that of TH1 and TH2 cells. They produce high levels of IL-10 and/or TGF-β, and low 
amounts of IL-2 (Asseman C et al., 1999; Jonuleit H et al., 2000; Powrie F et al., 
1996).  
 
In addition to TGF-β, toxic NO has been reported to act as a suppressive mediator of 
DC (Bonham CA et al., 1996; Yamamoto K et al., 1998; Powell TJ et al., 2003; 
Rößner S et al., 2005). Elevated NO levels have also been implicated in rejection of 
organ or tissue allografts (Krulová M et al., 2002; Holán V et al., 2006; Matuschek A 
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et al., 2009). In contrast, the inhibition of NO production promotes graft acceptance 
(Winlaw DS et al., 1995). Immature IL-4 DC have been shown to produce NO after 
appropriate stimulation with LPS (Figure 8.20). Induction of iNOS protein expression 
in immature IL-4 DC could be confirmed by western blotting (Figure 8.21). It has 
been shown that NO production of DC results from the induction of iNOS enzyme by 
LPS, proinflammatory cytokines such as exogenous IFN- γ produced in interaction 
with allogenic T cells (Lu L et al., 1996). A clear association between NO production 
and the presence of mature S-DC, but not immature IL-4 DC, was observed in the 
present study. The presence of the NO inhibitor NMMA increased the S-DC-induced 
T cell proliferation from 19,454 ± 7,365 cpm to 49,948 ± 7,723 cpm (Figure 8.22). 
The high levels of NO detectable in S-DC-induced T cell proliferation might be due to 
IFN-γ produced by activated T cells (Nadeau KC et al., 1995; Melter M et al., 1999; 
Rocha PN et al., 2003) (Figure 8.11). IFN-γ is mainly produced by activated T cells 
and stimulates the NO production by DC and others (Lu L et al., 1996). The presence 
of NMMA had little effect on the IL-4 DC-mediated inhibition of S-DC-induced T cell 
proliferation (Figure 8.22) and no evidence was found for NO-mediated T cell 
apoptosis (Figure 8.23). 
 
Altogether, the results of this study demonstrate that immature IL-4 DC are very 
potent inhibitors of the activation of naïve T cells. The main reason for their inhibitory 
effect may be the low expression of co-stimulatory molecules on their cell surface. 
However, other mechanisms such as the secretion of soluble immune inhibitory 
cytokines such as TGF-β may also be involved. Therefore, the detection of TGF-β in 
the supernatant of immature IL-4 DC described in this study is an interesting finding 
that needs to be further investigated to clarify its role in the inhibition of T cell 
proliferation. 
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9.4 PDL-1 and PD-L2 signalling on IL-4 DC: a possible role in tolerance 
induction? 
 
The ability of co-stimulatory molecules of the B7 family, such as CD80 and CD86, to 
provide co-stimulatory signals for full T cell activation has been well characterized. 
Recently, two additional B7 family members, PD-L1 and PD-L2, have been shown to 
deliver inhibitory signals resulting in down-regulation of T cell activation (Keir ME et 
al., 2008); thereby playing an essential role in peripheral tolerance (Keir ME et al., 
2006; Habicht A et al., 2007).  
 
To our knowledge PD-L1 and PD-L2 expression on rat DC and its role in T cell 
tolerance has not been previously investigated. Therefore, in the present study, the 
expression of PD-L1 and PD-L2 by immature IL-4 DC was examined. Both PD-L1 
and PD-L2 protein are expressed in immature IL-4 DC via a MEK/ERK-dependent 
pathway, possibly induced by GM-CSF (Figure 8.24 A). Thereby, LPS was able to 
up-regulate PD-L1 expression (Figure 8.24 B; PD-L2 antibody was not available at 
this time). PD-L1 expression on plasma cells from multiple myeloma patients via a 
MEK-dependent pathway has been reported by Lui and colleagues (Liu J et al., 
2007). The role of IL-4 in induction of PD-L1 and/or PD-L2 on immature IL-4 DC 
remains to be investigated. A study by Yamazaki et al. showed that PD-L1 is further 
up-regulated on macrophages by LPS, IFN-γ, GM-CSF and IL-4, whereas PD-L2 is 
induced on macrophages by IFN-γ, GM-CSF and IL-4 (Yamazaki T et al., 2002). 
However, it is not clear whether and to what extent the expression of PD-L1 and/or 
PD-L2 on the surface of immature IL-4 DC contributes to their ability to inhibit S-DC-
induced T cell proliferation.  
 
In this study UO126, an inhibitor of MEK-pathway, was tested to investigate the role 
of PD-L1 and PD-L2 on immature IL-4 DC interacting with T cells. Indeed, we 
observed reduced protein levels of both PD-L1 and PD-L2 protein expression. 
However, UO126 had no effect on the low capacity of IL-4 DC to stimulate naïve T 
cells (Figure 8.26). This might be due to the fact that UO126 only decreases the 
expression of both molecules on the protein level. However, previous studies 
revealed that PD-L1 and PD-L2 are already present on the surface of immature IL-4 
DC on day 4 and day 6 of DC culture. To better understand the function of both 
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molecules in the system of the present study one would have to develop anti-rat PD-
L1 and PD-L2 monoclonal antibodies (both are not commercially available) which 
block engagement with PD-1. Both anti-PD-L1 and PD-L1 antibody have been shown 
to enhance the capacity of human immature DC to stimulate T cell activation and 
cytokine production (Brown JA et al., 2003).  
 
The study by Brown and colleagues showed that in addition to immature DC, PD-L1 
and PD-L2 are also expressed on mature DC. This study did not investigate the 
expression of both molecules on the surface of mature S-DC. A possible expression 
of PD-L1 on mature DC might appear questionable at first glance, since these cells 
are able to induce full T cell proliferation rather than T cell inhibition. But high levels 
of co-stimulatory molecules and MHC class II might provide strong stimulatory 
signals to overcome the negative signals delivered via PD-L1:PD-1 pathway, 
resulting in full T cell activation. Recently, the group of Wang et al. provided evidence 
that signaling through PD-L1 expressed on DC is required for the induction of Treg 
cells (Wang L et al., 2008). The extent of PD-L1 and/or PD-L2 expression for the 
expansion of Treg cells by immature IL-4 DC and mature S-DC is presently not clear.  
 
 
 
9.5 IL-4 DC are able to induce anergic T cells with immune inhibitory 
properties: implications for the generation of Treg cells 
 
Immunological tolerance is the ultimate goal for the treatment of different 
immunological diseases such as autoimmunity and transplant rejection. DC, with 
their well-known immunostimulatory properties, have been found to play a crucial role 
in induction/maintenance of peripheral T-cell tolerance (Steinman RM et al., 2003). 
There is growing evidence that interactions between DC and T cells play an 
important role in the balance between immunity and tolerance. Various mechanisms 
causing T cell tolerance include induction of T cell apoptosis, anergy and the 
generation of Treg cells (Abbas AK et al., 2004). It is generally believed that T cell 
tolerance induced by immature DC is caused by “intermediate” levels of MHC class II 
and the absence or low expression levels of co-stimulatory molecules on immature 
DC (Lutz MB et al., 2000; Schwartz RH et al., 2003). Therefore, low expression of co-
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stimulatory molecules on immature IL-4 DC (Figure 8.5) may allow and contribute to 
the induction of T cell anergy by immature IL-4 DC.  
 
Several recent studies indicate that immature DC can also promote peripheral T cell 
tolerance by the induction of regulatory T cell populations (Jonuleit H et al., 2000; 
Jonuleit H et al., 2001; Min WP et al., 2003; Yamazaki S et al., 2003; Trabell KV et 
al., 2006; Zhang X et al., 2008). In the present study, the capacity of IL-4 DC to 
generate or expand Treg cells with the phenotype CD4
posCD25posFoxp3pos in vitro was 
investigated. IL-4 DC are able to induce the proliferation and therefore the expansion 
of occurring Treg cells (Figure 8.27 and Figure 8.28), but are unable to generate Treg 
cells from naïve T cells. This observation is in accordance with results published by 
Marguti et al. showing that an increase in Treg cells by immature DC is mainly 
attributable to the expansion of naturally occurring Treg cells in lymph nodes (Marguti I 
et al., 2008). 
 
In addition to DC it is well known that MHC class II is also expressed on activated T 
cells, enabling them to present peptide antigens to other T cells (Holling TM et al., 
2002). This T-T cell interaction results in tolerance (LaSalle JM et al., 1992). In 2006, 
Baecher-Allan et al. demonstrated that MHC class II expression by human 
CD4posCD25high T cells identifies a functionally distinct population of mature Treg cells. 
These cells inhibit T cell proliferation and cytokine production via an early contact-
dependent mechanism that is associated with induction of Foxp3 (Baecher-Allan C et 
al., 2006). In contrast, MHC-IInegCD4posCD25high T cells did not induce early contact-
dependent suppression. Based on these observations the MHC class II expression of 
Treg cells induced by immature IL-4 DC was examined. This study clearly 
demonstrates that naturally occurring Treg cells are positive for MHC class II molecule 
(Figure 8.27). Therefore, the MHC class II molecule might be a useful marker for the 
identification and selection of rat Treg cells inducing early contact-dependent 
suppression. 
 
There is accumulating evidence that DC maturation can no longer be used to 
distinguish tolerogenic and immunogenic DC, since the ability of mature DC to 
expand Treg cells in human and mice has already been demonstrated in several 
studies (Banerjee DK et al., 2006; Marguti I et al., 2008; Verhasselt V et al., 2004; 
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Yamazaki S et al., 2003; Yamazaki S et al., 2006). In this study it was also shown 
that the expansion of Treg cells occurred independently, regardless of the maturation 
state of rat DC. Both immature IL-4 DC as well as mature S-DC are able to expand 
Treg cells from naturally occurring Treg cells (Figure 8.27; Figure 8.28). It seems that 
co-stimulatory molecules such as CD80, CD86 and CD40 might not be involved in 
the expansion of Treg cells. Therefore other factors, possibly soluble factors, might be 
involved. Yamazaki et al. suggested that the ability of mature BM-DC to expand Treg 
cells by induction of proliferation is dependent on exogenous IL-2 (Yamazaki S et al., 
2003). In the periphery, IL-2 signalling seems to be critical for maintaining the 
survival of Treg cells (Fontenot JD et al., 2005). The results of this study show that the 
expansion of Treg cells occurs independently of the presence of exogenous IL-2. This 
has also been observed by Marguti and colleagues (Marguti I et al., 2008). In 
addition, T cells co-cultured with IL-4 DC secreted reduced levels of IL-2 (Figure 
8.11). The extent to which IL-2 contributes to the expansion of Treg cells was not 
analysed in this study and still needs to be investigated.  
 
Purified T cells collected from cultures with immature IL-4 DC were not able to fully 
respond to stimulatory signals of mature S-DC, whereas T cells isolated from co-
cultures with mature S-DC were able to expand in response to mature S-DC (Figure 
8.29 B). This unresponsiveness of T cells pre-incubated with immature IL-4 DC, 
however, could be reversed by external addition of IL-2 (Figure 8.29 B). These 
results allow the assumption that immature IL-4 DC induce a reversible state of 
functional T cell unresponsiveness (T cell anergy). Indeed, Sakaguchi et al. reported 
that the anergic state of Treg cells can be abrogated by IL-2 (Sakaguchi S et al., 
2001). DC treated with IL-10 have also been shown to induce anergy in CD4 and 
CD8 T cells (Steinbrinck K et al., 1999; Jonuleit H et al., 2000).  
 
It has been shown that Treg cells are non-proliferative (anergic) and are able to 
suppress the activation/proliferation of other T cells when they are co-cultured with 
antigen presenting cells (Sakaguchi S et al., 2001). For humans and mice, several 
groups have demonstrated that T cells generated in co-culture with immature DC are 
able to inhibit T cell responses in vitro (Bashuda H et al., 2005; Cools N et al., 2008; 
Gad M et al., 2004; Jonuleit H et al., 2003; Kubsch S et al., 2003; Kuwana M, 2002). 
Thereby, the suppressor effector function of Treg cells seems to be antigen non-
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specific (Thornton AM and Shevach EM, 2000). No information was found in 
literature that rat immature DC are able to induce anergic T cells with suppressive 
functions. Therefore, in the present study, the effect of immature IL-4 DC on naive T 
cells was analysed in more detail. Naive T cells were incubated with immature IL-4 
DC for 3 days. Afterwards, the purified T cells were transferred to the proliferation 
assay consisting of mature S-DC and naïve T cells. T cells pre-incubated with IL-4 
DC were able to inhibit mature S-DC-induced T cell proliferation (Figure 8.30). In 
contrast, T cells pre-incubated with mature S-DC inhibited slightly T cell proliferation. 
This is not unexpected since mature S-DC are able to expand Treg cells; also shown 
in this study. However, Treg cells expanded by S-DC are not as suppressive as Treg 
cells expanded by IL-4 DC. 
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10 Conclusions 
 
The usage of in vitro generated autologous DC for immunomodulation is one of the 
most promising approaches to initiating peripheral tolerance, especially after organ 
transplantation. In the present study rat bone marrow-derived immature IL-4 DC were 
generated in the presence of GM-CSF plus IL-4, displaying suppressive properties 
(inhibition of T cell activation) and tolerogenic functions (expansion of Treg cells). IL-4 
DC demonstrate an immature phenotype (MHC class IIlow, CD80low/CD86low, IL-12neg) 
and characteristic effects, e.g. inhibition of S-DC-induced T cell proliferation and 
expansion of Treg cells (Table 10.1). 
 
Table 10.1: Comparison of phenotype and properties of tolerogenic immature IL-4 DC with 
mature S-DC. 
 
 
DC properties 
 
IL-4 DC 
 
S-DC 
Immature phenotype   
MHCIIlow, CD80/86low, ICAM-1low, IL-12neg Yes No 
Endocytic activity Yes No 
In vitro functions   
Activation of naïve T cells No Yes 
Inhibition of proliferation of pre-activated T cells  Yes No 
Inhibition of S-DC induced T cell proliferation Yes No 
Maturation resistant Yes No 
Soluble factor(s) with inhibitory properties (TGF-β; NO) Yes
1) Yes2) 
Expansion of Treg cells Yes Yes 
Induction of T cell anergy  Yes No 
Induction of T cells with regulatory properties Yes No 
Expression of inhibitory molecules (PD-L1, PD-L2) Yes No data 
In vivo functions *)   
Prevention of allograft rejection Yes No 
 
1) presumably TGF-β; 2) partially NO; *) Tiurbe GC et al., 2009 
 
 
IL-4 DC may mediate these functions by a passive process, e.g. low expression of 
co-stimulatory molecules, and/or through an active process such as inhibitory 
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signalling (e.g. through PD-L1 and/or PD-L2), and/or secretion of immune inhibitory 
cytokine TGF-β. 
 
The results of the present study provide answers to the following questions: 
 
 
(A) What is the optimal culture condition required for the generation of 
immature IL-4 DC? 
 
The prerequisite for phenotypic and functional characterization was the high yield 
generation of IL-4 DC from bone marrow progenitors in the presence of GM-CSF and 
IL-4. Testing the influence of different cytokine combinations on the yield of Ox-62 
positive cells at the end of a 6-day culture period reveals that the addition of 5 ng/ml 
GM-CSF and 5 ng/ml IL-4 produced the best result with an accept amount of 
cytokines (Table 8.1; Figure 8.2). The results showed that GM-CSF is absolutely 
necessary for the generation of DC from progenitor cells. However, GM-CSF alone 
was not able to induce the formation of high cell numbers. The addition of IL-4 to the 
culture was the key factor for the development of high cell yields and cluster 
formation. Under the influence of 5 ng/ml GM-CSF and 5 ng/ml IL-4 bone marrow 
cells started to proliferate and to form cell clusters within 48 hours. On day 6, the end 
of the culture, the cells developed large clusters loosely attached to the plate. These 
cells were identified as a homogenous cell population of IL-4 DC (Figure 8.2). 
 
 
(B) What are the main phenotypic characteristics of IL-4 DC? 
 
IL-4 DC demonstrate a phenotype different from that of mature S-DC. At different 
developmental stages (day 0, 2, 4 and 6) an up-regulation of co-stimulatory 
molecules CD80, CD86 and CD40, MHC class II and OX62 could be seen (Figure 
8.3), in addition to an expression of CD45 and CD25 on day 6 (Figure 8.4). However, 
the expression of all investigated molecules was significantly lower compared to their 
expression on mature S-DC (Figure 8.4 and Figure 8.5). The reduced expression of 
CD80, CD86 and CD40 was confirmed by real time RT-PCR (Figure 8.8). In addition, 
IL-4 DC did not express mRNA specific for IL-12 and demonstrated endocytic activity 
(Figure 8.6 and Figure 8.9). In summary, these results confirm an immature 
phenotype of IL-4 DC on day 6 of the culture. 
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(C) What is the effect of IL-4 DC on naïve T cells in vitro? 
 
The present study shows that immature IL-4 DC were not able to activate naïve T 
cells (Figure 8.10). This induction of hyporesponsiveness was associated with 
increased levels of secreted TGF-β and reduced levels of IFN-γ and IL-2 (Figure 
8.11). Immature IL-4 DC were able to inhibit S-DC-induced T cell proliferation 
dependent on the number of IL-4 DC added to the proliferation assay (Figure 8.13). 
This strong inhibitory effect was mediated within 24 hours (Figure 8.14). The 
inhibition of mature S-DC-induced T cell proliferation by immature IL-4 DC might be 
partly caused by soluble factors (Table 8.8; Figure 8.22), since the supernatant of 
immature IL-4 DC showed a clear suppressive effect (Figure 8.18). The presence of 
the immune regulatory cytokine TGF-β was proofed in these supernatants (Figure 
8.19).  
 
Naïve T cells pre-incubated with immature IL-4 DC were not able to proliferate in the 
presence of mature S-DC (induction of an anergic state). This anergic state was 
reversible by the addition of exogenous IL-2 (Figure 8.29). In addition, T cells pre-
incubated with IL-4 DC inhibited the mature S-DC induced T cell proliferation, 
demonstrating that immature IL-4 DC are able to induce T cells with immune 
inhibitory functions (Figure 8.30). 
 
 
(D) Do IL-4 DC exhibit a stable immature phenotype? 
 
To achieve full activation of T cells, DC need to undergo a process of functional 
maturation. DC maturation can be triggered by LPS, CD40L and TNF-α, for example. 
In this study immature IL-4 DC were found to be resistant to maturation. They kept 
their inability to activate naïve T cells (Figure 8.17) and failed to up-regulate the co-
stimulatory molecules CD80, CD86 and CD40, MHC class II and ICAM-1 (Figure 
8.15 and 8.16).  
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(E) Are IL-4 DC able to generate Treg cells from naïve T cells in vitro? 
 
Immature IL-4 DC were able to increase the percentage of Treg cells with the 
phenotype CD4posCD25posFoxp3pos (Figure 8.27). This increase came from the 
expansion of naturally occurring Treg cells rather than from the generation of naïve T 
cells. In addition, immature IL-4 DC induced an anergic state in T cells that could be 
reversed by adding exogenous IL-2 (Figure 8.29). Furthermore, these T cells were 
able to inhibit S-DC-induced T cell proliferation in vitro, demonstrating a regulatory 
effect of IL-4 DC on naïve T cells during co-culture (Figure 8.30). 
 
In this study we demonstrated that not only immature IL-4 DC but also mature S-DC 
are able to expand Treg cells in vitro. Based on these results, we conclude that the 
induction of tolerance and immunity can no longer be distinguished by the phenotype 
of DC. 
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12  Appendix 
 
 
Table 12.1: Increase of different surface antigens over time. Cells were collected at different 
developmental stages (day 0, 2, 4 and 6). Differences in the cell surface expression were quantified by 
mean fluorescence (MF) values of antibody binding. In addition, percentage (%) of positive cells (P= 
Proportion) is shown. Data of three different experiments are shown. (x) not analysed. 
Antigen day 0 day 2 day 4 day 6 
#1 MF P (%) MF P (%) MF P (%) MF P (%) 
MHC II 1.39 1.34 11.1 10.3 43.3 40.4 119 84.6 
OX62 8.23 2.74 29.7 23.4 60.7 51.8 119 73.4 
CD80 5.89 12.0 11.6 12.8 53.9 48.6 114 70.7 
CD86 7.14 5.22 10.2 11.5 39.2 45.5 133 77.7 
CD40 28.1 10.9 68 10.7 190 37.5 172 61.9 
 
Antigen day 0 day 2 day 4 day 6 
#2 MF P (%) MF P (%) MF P (%) MF P (%) 
MHC II 1.76 0.31 31.7 13.2 49.6 39.6 115 79.7 
OX62 20.3 5.68 23.9 15 51.4 45.4 212 85.3 
CD80 4.61 0.69 18.8 19.7 93.8 57.3 156 77.5 
CD86 6.42 1.92 21 18.9 59.7 46.5 129 81.5 
CD40 27.7 2.45 97 16.8 157 42.3 188 66.8 
 
Antigen day 0 day 2 day 4 day 6 
#3 MF P (%) MF P (%) MF P (%) MF P (%) 
MHC II 1.21 0.47 18.2 15 57.6 60.9 123 73.1 
OX62 30.5 2.49 110 23.5 237 72.6 X X 
CD80 3.51 4.45 20.6 20.8 98 63.1 126 56.7 
CD86 4.58 2.62 10.9 14.9 66.4 52.3 108 54.1 
CD40 8.13 3.21 65.6 13.1 196 47.6 231 52.8 
 
 
 
 
Table 12.2: IL-4 DC demonstrate endocytic activity. IL-4 DC show increased Dextran-Alexa 488 
up-take compared to mature S-DC. The uptake at 37 °C versus uptake at °4 C (control). The results 
depict MF(37 – 4°C). Data of three different experiments are shown. 
 
IL-4 DC S-DC control 
MF(37°C) MF (37°C-4°C) MF(37°C) MF (37°C-4°C) MF(4°C) 
351 314 37 6.4 30.6 
212 194.9 14.4 -2.7 17.1 
101 92.8 11.8 3.61 8.19 
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Table 12.3: Analysis of T cell apoptosis by staining with Annexin V. T cells cultured with mature 
S-DC alone showed the highest rate of apoptosis. Data of three different experiments are shown. 
 
 
 
 
T cells 
alone 
 
T cells 
+ 
S-DC 
 
T cells 
+ 
S-DC 
+ 
NMMA 
 
T cells 
+ 
IL-4 DC 
 
T cells 
+ 
IL-4 DC 
+ 
NMMA 
 
 cells 
+ 
S-DC 
+ 
IL-4 DC 
 
T cells 
+ 
S-DC 
+ 
IL-4 DC 
+ 
NMMA 
 
 
apoptotic  
T cells (%) 
 
9.14 
 
18.2 
 
9.38 
 
12.1 
 
1.7 
 
13.2 
 
9.83 
3.6 8.26 6.06 5.72 4.93 6.23 4.82 
8.44 14.3 11.6 10.8 7.38 13.6 7.75 
 
 
 
 
Table 12.4: Phenotypic changes of IL-4 DC after stimulation with LPS, TNF-α or CD40L. IL-4 DC 
were collected at different developmental stages [day 6, day 8 and day 10 (with addition of TNF-α, 
LPS or CD40L on day 8)]. Differences in the cell surface expression were quantified by mean 
fluorescence (MF) values of antibody binding. In addition percentage (%) of positive cells (P= 
Proportion) is shown. Data of three different experiments for each cytokine are shown. 
 
Developmental 
stage 
MHCII CD80 CD86 CD40 ICAM-1 
MF P(%) MF P(%) MF P(%) MF P(%) MF P(%) 
Day 6 
#1 315 26 22.5 21.7 159 66.1 108 64.9 15.5 15.8 
#2 82.1 54.4 63.1 81.8 278 93.5 22.1 6.38 35.6 36.3 
#3 - - - - - - - - - - 
Day 8 *) 
#1 135 51 75.6 48.5 274 80.3 80.9 20.6 50 59.7 
#2 327 79.7 103 65.6 129 85.5 97.5 70.6 63.6 95.2 
#3 182 51 131 43.7 250 80.5 255 55.7 62.7 75.8 
Day 10 **) 
(+TNF-α) 
#1 888 59.8 122 68.4 292 81.6 215 47.4 341 84.3 
#2 568 88.6 103 86.5 123 97.2 206 80.4 256 95 
#3 288 70.5 253 65.9 366 85.7 315 73.7 182 79.5 
Day 6 
#1 147 33.8 22.1 57.8 108 91.9 6.03 7.02 24 81.2 
#2 134 51.6 37.2 51.7 181 82.9 53 38.5 39.8 82.9 
#3 407 87 93.3 79.5 250 91.5 74.5 61 63.8 85.9 
Day 8 
#1 97.5 34.1 45.6 73.9 214 94.5 17.3 21.6 29.9 75.4 
#2 173 59.6 88 87.3 216 95.4 73.6 48.2 69.9 93 
#3 254 77.1 126 54 479 90.7 84.6 47.8 67.7 87.7 
Day 10 
(+LPS) 
#1 158 33.7 78.7 31.4 144 68.3 259 72.8 68.7 54.7 
#2 295 63.9 139 77.8 248 92.4 207 62.9 104 75.4 
#3 227 51.7 446 47.4 715 62 73.6 79.8 168 68.1 
Day 6 
#1 280 65.6 28.9 61.4 148 80.6 9.98 17.5 25.8 74.5 
#2 67 38.6 22.3 58.6 99.1 79.8 28.9 11.6 24.7 69.8 
#3 220 78.7 69 59 127 72.5 54.9 48.6 58.7 78.8 
Day 8 
#1 153 47.4 158 85.6 39.2 51.6 142 46.4 38.8 69.8 
#2 111 40.2 28.2 59.6 187 93.4 68.9 41.4 37 72.2 
#3 303 84.9 110 66.4 171 73.1 101 55.1 65.5 87 
Day 10 
(+CD40L) 
#1 486 80.5 195 23.5 224 30.8 47.3 48.2 69.2 91.2 
#2 161 45.9 62.8 22.3 170 64.2 86.1 27.4 52 56.3 
#3 363 79.3 233 70 321 81.5 73.7 42.4 89.6 80.6 
 
*)   IL-4 DC were replated on day 6 and cultured until day 8 in the presence of 2.5 ng/ml GM-CSF (see materials and methods) 
**)  IL-4 DC were replated on day 8 and cultured until day 10 in the presence of TNF-α (20 ng/ml), LPS (1µg/ml) or CD40L 
(1µg/ml) (see materials and methods).  
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Figure 12.1: Calculation of the relative expression level of CD80 in immature IL-4 DC compared 
to mature S-DC: an example for calculation of relative expression levels by using the 2
-∆∆Ct 
method. Calculation steps: ∆Ct = Ct(CD80) - Ct(GAPDH), ∆∆Ct = ∆Ct(IL-4 DC) - ∆Ct(S-DC), relative 
expression level = 2-∆∆Ct. Expression level of CD80 mRNA is 2.3-fold reduced compared to expression 
level of CD80 mRNA in mature S-DC. 
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Table 12.5: RT-PCR analysis of IL-4 DC. As shown in Figure 8.6 specific mRNA for of co-stimulatory molecules CD40, CD80 and CD86 and MHC class 
II was proved by agarose gel analysis. (+) Signal; (–) No signal; (+/-) low signal; (x) not analysed. 
 
 
*) RT-PCR of different cell preparations was performed on the same day 
 
XXXXX+/-+X++/-+/-+/-+29.08.07IL-4 DC
XXXXX+/-+XX+/-–++17.08.07IL-4 DC
+/-XXX–+X–XXXX+13.08.07IL-4 DC
+XXX+/-+/-X–XXXX+06.08.07IL-4 DC
+XXX+/-++X++–++12.07.07IL-4 DC
X++/-+/-XXXXXXXX+03.07.07IL-4 DC
XXXXXXX–+++/-++28.06.07IL-4 DC
XXXXXXX–+++++17.04.07IL-4 DC
XXXXXXXX+++++09.11.06IL-4 DC
XXXXXXXX+++++07.11.06IL-4 DC
XXXXXXXX+++++12.10.06 *)IL-4 DC
XXXXXXXX+++++12.10.06 *)IL-4 DC
XXXXXXXX+++++21.09.06 *)IL-4 DC
XXXXXXXX+++++21.09.06 *)IL-4 DC
XXXXXXXX–++/-++28.08.06IL-4 DC
XXXXXXXX++–++16.08.06IL-4 DC
XXXXXXXX+––++06.06.06IL-4 DC
IL-18TLR-4TNF-αIL-6iNOSIL-10TGF-βIL-12MHC IICD86CD80CD40GAPDHRT-PCR
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type
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+/-XXXXX+X+++X+15.11.07S-DC
XXXXX–+X+++/-+/-+29.08.07S-DC
XXXXX–+/-XX+–++17.08.07S-DC
+/-XXX+–X+XXXX+14.08.07S-DC
+/-XXX+/-+/-+++++++08.08.07S-DC
X+++XXXXXXXX+
03.07.07 
*)S-DC
X++/-+XXXXXXXX+
03.07.07 
*)S-DC
X+/-++XXXXXXXX+
03.07.07 
*)S-DC
XXXXXXX+/-++–++
28.06.07 
*)S-DC
XXXXXXX+/-+++++
28.06.07 
*)S-DC
XXXXXXX+/-+/-++/-++
28.06.07 
*)S-DC
XXXXXXX+/-+++/-++
28.06.07 
*)S-DC
XXXXXXX+/-++/-+/-++19.04.07S-DC
XXXXXXXX+/-++++04.1006S-DC
XXXXXXXX+++++21.09.06S-DC
XXXXXXXX+++/-++21.08.06S-DC
XXXXXXXX+++++01.08.06S-DC
IL-18TLR-4TNF-αIL-6iNOSIL-10TGF-βIL-12MHC IICD86CD80CD40GAPDHRT-PCR
Cell 
type
Table 12.6: RT-PCR analysis of S-DC. As shown in Figure 8.6 specific mRNA for of co-stimulatory molecules CD40, CD80 and CD86 and MHC class II 
was proved by agarose gel analysis. (+) Signal; (–) No signal; (+/-) low signal; (x) not analysed. 
 
*) RT-PCR of different cell preparations was performed on the same day 
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ix
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0.431.2310.6512.889.0710.0013.6222.9813.4226.5032.0523.41IL-4 DC
1---9.4110.009.428.8315.6617.3715.2825.6626.7924.11S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
CD80CD80CD80CD80GAPDHCD80
0.133.004.978.31---1.6313.6222.9813.4221.93---15.05IL-4 DC
1---1.973.014.43-1.5415.6617.3715.2818.6721.8013.748S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
CD86CD86CD86CD86GAPDHCD86
0.142.796.766.287.306.6813.6222.9813.4219.9030.2820.10IL-4 DC
1---3.973.274.524.1315.6617.3715.2818.9221.8919.41S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
CD40CD40CD40CD40GAPDHCD40
1.02-0.0034.873.4310.510.6813.6222.9813.4217.0533.4914.10IL-4 DC
1---4.906.405.882.4215.6617.3715.2822.0623.2517.70S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
MHC IIMHC IIMHC IIMHC IIGAPDHMHC II
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1
5
2
 
0.0093.5014.9010.5716.6217.5022.5415.0414.2133.1131.6731.71IL-4 DC
1---11.4010.1512.6411.4116.5417.2916.2926.6829.9327.71S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
IL-12IL-12IL-12IL-12GAPDHIL-12
1,06-0.093.092.704.951.9913.6222.9813.4216.3227.5715.41IL-4 DC
1---3.183.563.942.0515.6617.3715.2819.2221.3117.33S-DC
relative 
expression 
level
ΔΔCtmean Δ CtΔCtCtCt
TGF-βTGF-βTGF-βTGF-βTGF-βTGF-β
 
Table 12.7 (see also next page): The real time RT-PCR quantification of MHC class II, IL-12, TGF-β and co-stimulatory molecules CD80, CD86 
and CD40. Total RNA, cDNA, and Real-Time PCR amplification were performed as described in methods and materials. Relative expression level of 
target mRNA in immature IL-4 DC was compared to that of mature S-DC. Shown are the Ct values (of three different experiments), the ∆ Ct values, the 
mean of the ∆Ct values, the ∆∆Ct values and the relative expression level (2-∆∆Ct). GAPDH mRNA served as endogenous control. For calculation details 
see also Figure 12.1. 
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Table 12.8: Expansion of CD4
pos
CD25
pos
Foxp3
pos
 T cells after co-culture with DC. Upper rows: T 
cell populations before and after depletion or purification of CD4posCD25pos T cells are shown. Lower 
rows: 104 immature IL-4 DC or mature S-DC were co-cultured with 105 total lymph node T cells, 105 
naïve T cells depleted of CD4posCD25pos T cells  or with purified 105 CD4posCD25pos T cells. After 3 
days the cells were collected and after depletion of DC labelled with fluorescent antibodies for CD4, 
CD25 and Foxp3. All cells are gated on CD4pos cells. 3 different experiments are shown. 
 
 
*)  repetition of three independent experiments 
**)  CellectionTM Pan Mouse IgG Kit (see methods and materials) 
***) depletion and purification by FACS sorting (see methods and materials) 
 
 
 
 
Table 12.9: Release of NO and IL-10 into the supernatant of mature S-DC and immature IL-4 DC. 
Immature IL-4 DC from day 6 of culture and purified mature S-DC were transferred to 96-well culture 
plates (106 cells/well). The supernatant was collected 24 and 48 hours later. Data are presented as 
means ± S.D. of 3 independent experiments. 
 
 S-DC IL-4 DC 
NO (NO2-)
*) 24hr 48hr 24hr 48hr 
concentration (µM) 3.09 ± 1.98 3.80 ± 2.30 1.55 ± 1.05 5.32 ± 4.67 
IL-10 24hr 48hr 24hr 48hr 
concentration (pg/ml) 10.37 ± 6.03 9.39 ± 8.61 2.17 ± 1.98 4.18 ± 3.23 
 
*) The NO release was measured as the accumulation of the stable end product NO2- (see methods and materials). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 T cells cultured with DC 
 
Total lymph node cells 
 
CD4posCD25neg 
 
(after depletion of 
CD4posCD25pos T cells) 
CD4posCD25pos 
 
(after purification of 
CD4posCD25pos T cells)  
Experiment No.*) 1**) 2***) 3**) 1 2 3 1 2 3 
CD4posCD25pos (%) 6.02 5.6 9.87 1.3 2.91 5.08 35.3 36.7 62.3 
CD4posCD25neg (%) 38.9 38.6 56.8 39.5 81.3 49 51.2 28 33 
MLR condition CD4posCD25posFoxp3pos T cells (%) 
T cells alone (control) 7.84 6.02 7.02 5.22 5.41 5.33 17.2 31.7 35.8 
T cells + S-DC 10.7 10.8 12.9 6.46 6.71 5.68 26 51.1 62.5 
T cells + IL-4 DC 17.6 15.8 16.5 7.26 7.87 7.08 34.1 55.2 63.1 
12 Appendix 
 154
Table 12.10: The supernatant from 10
4
 IL-4 DC does not inhibit T cell proliferation in the 
proliferation assay. Different volumes (25 µl, 50 µl and 100 µl) the supernatant of 24 hour cultured  
IL-4 DC (104) had no effect on mature S-DC induced T cell proliferation. The supernatant of mature S-
DC or media cultured without DC served as a control to exclude possible negative effects of day 2 
supernatant. Data are presented as means ± S.D. of 3 independent experiments. 
 
 
 Volume of supernatant (µl) *) 
 25 50 100 0 
 IL-4 DC  39,172 ± 3977 **) 41,872 ± 3572 34,667 ± 3507 
42,984 ± 4,991  S-DC  - - 36,353 ± 7476 
 media***)  - - 43,754 ± 5551 
 
*) The final volume was kept constant at 150 µl per well. 
**) Results (mean ± S.D.) of T cell proliferation in cpm. 
***) media cultured for 24 hours without the addition of DC. 
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Figure 8.7:  RT-PCR gene expression array of immune regulatory cytokines 
TGF-β and IL-10 and cytotoxic enzyme iNOS.  
 
 65 
Figure 8.8:  Real time RT-PCR quantification: the relative expression level of 
different target mRNA in immature IL-4 DC compared to mature S-
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Figure 8.9: Uptake of Dextran-Alexa 488 by IL-4 DC versus S-DC. 
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Figure 8.10:  IL-4 DC do not induce T cell proliferation. 
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Figure 8.11:  Naïve T cells co-cultured with IL-4 DC showed a TGF-β dominated 
cytokine profile.  
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Figure 8.12:  Activated T cells stopped proliferation during co-culture with 
immature IL-4 DC.  
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Figure 8.13:  Immature IL-4 DC inhibit the proliferation of naïve T cells induced by 
mature S-DC in co-cultures.  
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Figure 8.14:  Immature IL-4 DC inhibit mature S-DC-induced T cell proliferation 
within 24 hours. 
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Figure 8.15:  Marginal phenotypic changes of immature IL-4 DC in response to 
maturation stimuli. 
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Figure 8.16:  Marginal phenotypic changes of immature IL-4 DC after stimulation 
with TNF-α, LPS or CD40L.  
 78 
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Figure 8.17:  
 
IL-4 DC exposed to TNF-α, LPS or CD40L were unable to induce T 
cell proliferation. 
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Figure 8.18:  
 
Supernatant from IL-4 DC cultures inhibits T cell proliferation in a 
dose-dependent manner.  
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Figure 8.19: IL-4 DC produce more TGF-β than mature S-DC.  
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Figure 8.20:  LPS-stimulated IL-4 DC synthesise iNOS and produce large 
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Figure 8.21: Western blot analysis of iNOS expression in IL-4 DC. 
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-methyl-L-arginine acetate (NMMA). 
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Figure 8.23: T cell apoptosis is not relevant for the IL-4 DC mediated suppressive 
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Figure 8.24: Western blot analysis of PD-L1 and PD-L2 expression in immature 
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Figure 8.25: Blocking the ERK1/2 phosphorylation with UO126 reduces the 
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